Stevens–Johnson syndrome and toxic epidermal necrolysis in Hong Kong

Hong Kong Med J 2024 Apr;30(2):102–9 | Epub 26 Mar 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Stevens–Johnson syndrome and toxic epidermal necrolysis in Hong Kong
Christina MT Cheung, MB, ChB, MRCP1; Mimi M Chang, MB, ChB, FRCP1; Joshua JX Li, MB, ChB, FHKCPath2; Agnes WS Chan, MB, ChB, MRCP1
1 Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
2 Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China
 
Corresponding author: Dr Agnes WS Chan (agneswschan@cuhk.edu.hk)
 
 Full paper in PDF
 
Abstract
Introduction: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [hereafter, SJS/TEN] are uncommon but severe mucocutaneous reactions. Although they have been described in many populations worldwide, data from Hong Kong are limited. Here, we explored the epidemiology, disease characteristics, aetiology, morbidity, and mortality of SJS/TEN in Hong Kong.
 
Methods: This retrospective cohort study included all hospitalised patients who had been diagnosed with SJS/TEN in Prince of Wales Hospital from 1 January 2004 to 31 December 2020.
 
Results: There were 125 cases of SJS/TEN during the 17-year study period. The annual incidence was 5.07 cases per million. The mean age at onset was 51.4 years. The mean maximal body surface area of epidermal detachment was 23%. Overall, patients in 32% of cases required burns unit or intensive care unit admission. Half of the cases involved concomitant sepsis, and 23.2% of cases resulted in multiorgan failure or disseminated intravascular coagulation. The mean length of stay was 23.9 days. The cause of SJS/TEN was attributed to a drug in 91.9% of cases, including 84.2% that involved anticonvulsants, allopurinol, antibiotics, or analgesics. In most cases, patients received treatment comprising either best supportive care alone (35.2%) or combined with intravenous immunoglobulin (43.2%). The in-hospital mortality rate was 21.6%. Major causes of death were multiorgan failure and/or fulminant sepsis (81.5%).
 
Conclusion: This study showed that SJS/TEN are uncommon in Hong Kong but can cause substantial morbidity and mortality. Early recognition, prompt withdrawal of offending agents, and multidisciplinary supportive management are essential for improving clinical outcomes.
 
 
New knowledge added by this study
  • Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions in Hong Kong, with a combined annual incidence of 5.07 cases per million.
  • Stevens–Johnson syndrome and TEN cause considerable burdens on the Hong Kong healthcare system due to their prolonged length of stay, high demand for intensive care, and substantial mortality.
Implications for clinical practice or policy
  • Clinicians should be aware of the early signs and symptoms of SJS and TEN to enable rapid recognition of the disease and prompt withdrawal of culprit drugs.
  • Dedicated multidisciplinary teams should be established in tertiary centres to optimise patient outcomes.
 
 
Introduction
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are uncommon but potentially life-threatening severe mucocutaneous reactions characterised by extensive epidermal necrosis and detachment. Both entities are considered variants of a single disease continuum and are classified according to the percentage of body surface area (BSA) with epidermal detachment.1 2 Although SJS and TEN (hereafter, SJS/TEN) have been described in all ethnicities worldwide,3 studies of these reactions in Hong Kong have been limited.4 5 The incidence, clinical characteristics, aetiology, treatment regimen, morbidity, and mortality in the territory are largely unknown. This pilot study aimed to review cases of SJS/TEN over a 17-year period at a tertiary referral centre in Hong Kong, and to aid future research in Hong Kong focused on severe cutaneous adverse reactions.
 
Methods
This retrospective cohort study included all hospitalised patients who had been diagnosed with SJS/TEN and were treated in Prince of Wales Hospital (PWH), a major regional hospital under the New Territories East Cluster (NTEC), from 1 January 2004 to 31 December 2020.
 
Patient identification
Patients with clinical and histological diagnoses of SJS/TEN were identified from the Hospital Authority database using International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes and the database of the Department of Anatomical and Cellular Pathology of PWH, respectively.
 
Inclusion criteria
Diagnoses of SJS/TEN were based on consensus guidelines.1 Patients were diagnosed with SJS, SJS/TEN overlap, and TEN when they exhibited epidermal detachment levels of <10%, 10% to 30%, and >30%, respectively, with consistent histological features (if skin biopsy was performed). Consistent histological features were regarded as partial- to full-thickness epidermal necrosis.
 
Exclusion criteria
Patients were excluded if they had an alternative diagnosis, such as severe cutaneous adverse reactions other than SJS/TEN (eg, drug reaction with eosinophilia and systemic symptoms syndrome/acute generalised exanthematous pustulosis/generalised bullous fixed drug eruption), erythema multiforme major, autoimmune blistering disease, acute graft-versus-host disease, and infections such as staphylococcal scalded skin syndrome.
 
Data collection and statistical analysis
Clinical characteristics were collected from electronic records and, when available, hospital case notes. The following clinical characteristics were recorded and analysed: age at onset, sex, ethnicity, maximal BSA of detached or detachable skin, SCORTEN (Severity-of-Illness Score for Toxic Epidermal Necrolysis) prognostic score,6 mucosa involved, histology results if available, causative drugs, time from exposure to onset, time from onset to admission and treatment, treatment regimen, disease complications, mortality and its cause, and length of stay. Efforts to identify causative drugs were guided by the ALDEN (algorithm of drug causality for epidermal necrolysis) score,7 which was retrospectively calculated by two independent investigators. All clinical data were expressed as percentages or means ± standard deviations unless otherwise specified.
 
This article was written in compliance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guidelines.
 
Results
Using the International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for SJS/TEN, 164 potential patients with 166 cases of SJS/TEN during the period from January 2004 to December 2020 were initially identified. Six additional patients with SJS/TEN were identified from the database of the Department of Anatomical and Cellular Pathology of PWH. Forty-seven patients were excluded due to alternative diagnoses. In total, 123 patients with 125 cases of SJS/TEN were included in the study (Fig).
 

Figure. Flowchart of patient identification and exclusion
 
Demographic characteristics and disease classification
Among the 123 patients with SJS/TEN, 53 were men and 70 were women; the female-to-male ratio was 1.32:1 (Table 1). The mean age at onset was 51.4 years, and most patients were Chinese. Of the 125 cases, 59 were SJS, 27 were SJS-TEN overlap, and 39 were TEN. A small number of patients (n=18, 14.4%) were admitted for other medical issues but developed SJS/TEN after hospitalisation.
 

Table 1. Demographic characteristics of patients (n=123) and disease classification in each case (n=125)
 
Clinical characteristics and clinical course
The mean time from disease onset to hospitalisation was 4.9 days (Table 2). Fever was present on admission in 88 cases (70.4%). The mean maximal BSA of epidermal detachment was 23%. Mucosal involvement was common; only five cases (4.0%) lacked mucosal involvement. Skin biopsy was performed in 87 cases (69.6%) and the mean SCORTEN prognostic score was 2.17.
 

Table 2. Clinical characteristics and clinical course (n=125)
 
Burns unit or intensive care unit admission was required in 40 cases (32.0%) and half of these cases required invasive mechanical ventilation. In total, 63 cases (50.4%) involved concomitant infection from various sources. Multiorgan failure or disseminated intravascular coagulation occurred in 29 cases (23.2%). The mean length of stay in the hospital was 23.9 days (Table 2).
 
Aetiology
Stevens–Johnson syndrome and TEN onset was attributed to a drug in 114 of 124 cases (91.9%); one patient developed a second case of SJS/TEN upon accidental re-exposure to the same culprit drug (paracetamol). Four cases (3.2%) were caused by infection, and no cause was identified in six cases (4.8%). The identified culprit drugs are shown in Table 3. The mean time from initiation of the culprit drug to onset of SJS/TEN was 20.5 ± 16.7 days (range, 1-87; median, 15.5).
 

Table 3. Culprit drugs for Stevens–Johnson syndrome and toxic epidermal necrolysis identified (n=114)
 
Treatment
All patients received the best supportive medical care available. In some cases, patients received additional treatment. The numbers and proportions of cases treated with different regimens are shown in Table 4. The mean time between disease onset and active treatment initiation was 7.4 ± 6.1 days (range, 1-34; median, 6).
 

Table 4. Treatment regimens (n=125)
 
Intravenous immunoglobulin (IVIG) was administered in 54 cases. The mean total dose of IVIG was 3.2 g/kg (range, 1.5-6; administered over 2-6 days). High-dose IVIG, defined as ≥3 g/kg, was administered in 40 cases. Systemic steroid regimens considerably varied, with daily doses of prednisolone ranging from 20 to 120 mg (or an equivalent dose). The cyclosporine regimen was 3 mg/kg/day, tapered over 20 to 30 days.
 
Mortality
There were 27 deaths in the study cohort, and the overall mortality rate was 21.6%. The mean time from SJS/TEN onset to death was 23.6 ± 19.0 days (range, 5-76). Most patients died from multiorgan failure and/or fulminant sepsis (n=22, 81.5%); other causes of death were acute coronary syndrome (n=2), liver failure (n=1), and sudden cardiac arrest (n=2).
 
The observed mortality rates were 16.9%, 22.2%, and 28.2% for SJS, SJS-TEN overlap, and TEN, respectively. The SCORTEN-based predicted mortality rates were 14.1%, 28.5%, and 36.9% for SJS, SJS-TEN overlap, and TEN, respectively. Inpatient-onset SJS/TEN had a high mortality rate of 77.8%: 14 deaths among 18 patients who developed SJS/TEN after admission.
 
Discussion
Epidemiology
Stevens–Johnson syndrome and TEN are recognised worldwide, with several epidemiological studies conducted in Europe and the US. In the 1990s, Roujeau et al8 reported that the annual incidence of TEN in France was 1.2 cases per million; during the same period, the estimated overall annual incidences of SJS/TEN were 1.89 cases per million in Germany9 and 4.2 cases per million in the US.10 In the past decade, two large epidemiological studies in the US11 and United Kingdom12 revealed that the overall annual incidences of SJS/TEN were 12.7 and 5.76 cases per million, respectively. In contrast, the epidemiology of SJS/TEN in Asia is not well-documented.13 In Singapore, based on a small retrospective hospital-based study of 20 patients with TEN, the estimated annual incidence of TEN was 1.4 cases per million14; in Korea, a large population-based study indicated that the overall annual incidence of SJS/TEN was 4.9 to 6.5 cases per million.15 In the present study, there were 125 cases of SJS/TEN during the 17-year study period. Notably, 13 of these cases were transferred from hospitals outside of the NTEC: one was SJS, three were SJS/TEN overlap, and nine were TEN. The NTEC serves a population of 1.3 million.16 The estimated annual incidence of TEN alone and combined annual incidence of SJS, SJS-TEN overlap, and TEN were 1.36 and 5.07 cases per million, respectively; these incidences are comparable with findings from studies in other countries.
 
Stevens–Johnson syndrome is approximately threefold more common than TEN.15 17 However, in the current study, fewer than half of the cases (47.2%) were SJS, whereas 31.2% were TEN. This may be related to referral bias, whereby more severe cases were transferred to the study hospitals, whereas ‘milder’ cases were managed in regional hospitals where the patients were initially admitted. Prince of Wales Hospital is a tertiary referral centre and one of the few hospitals in Hong Kong with both on-site dermatologists and burns unit support. In our cohort, 31 cases (24.8%) were transferred from peripheral hospitals: 18 (14.4%) arrived from hospitals within the NTEC, whereas 13 (10.4%) arrived from hospitals outside of the NTEC.
 
Aetiology
Stevens–Johnson syndrome and TEN are most often drug-induced, and a culprit drug is identified in approximately 85% of cases.7 18 The reactions usually occur between 7 days and 8 weeks after drug ingestion.19 However, upon rechallenge with the culprit drug, SJS/TEN can develop within hours.17 19 Efforts to identify causative drugs were guided by the ALDEN score.7 In cases of SJS/TEN, the most commonly implicated high-risk medications are anticonvulsants, allopurinol, antimicrobials, and oxicam non-steroidal anti-inflammatory drugs.19 20 In the present study, SJS/TEN onset was attributed to a drug in 114 of 124 cases (91.9%). The mean time between drug initiation and SJS/TEN onset was 20.5 days. Among these 114 cases, 81.6% were caused by the high-risk medications listed above. These findings are comparable with previous reports.
 
Mortality
Stevens–Johnson syndrome and TEN are associated with high mortality rates, with 1% to 5% in cases of SJS and 25% to 30% in cases of TEN. Survival analyses in multinational European studies (EuroSCAR [European Study of Severe Cutaneous Adverse Reactions] and RegiSCAR [Registry of Severe Cutaneous Adverse Reactions]) have indicated that the overall mortality rate in cases of SJS/TEN is approximately 22% to 23%.18 20 21 22 23 In Asia, reported overall mortality rates vary from 12.3% to 25%.24 25 26 27 Sepsis leading to multiorgan failure is the most common cause of death.21 Despite the substantial mortality, there currently is no therapeutic regimen with a clear benefit for patients with SJS/TEN.18 21 Considering the rarity of these diseases, it is difficult to conduct randomised trials. Early recognition, rapid withdrawal of offending agents, and best supportive care remain the primary components of clinical management.
 
In the current study, the overall mortality rate was 21.6%; in 81.5% of these cases, the patient died of fulminant sepsis or multiorgan failure. These findings are consistent with existing literature. However, the mortality rate in cases of SJS was much higher in the present study than in previous studies. In the 59 cases of SJS, there were 10 deaths; the mortality rate was 16.9%. Among the 10 patients who died, six experienced complete skin re-epithelisation before death from other medical conditions, which include massive duodenal ulcer bleeding, acute coronary syndrome, metastatic lung cancer, acute liver and renal failure due to herbs, aspiration pneumonia, and sudden cardiac arrest. The remaining four patients had inpatient-onset SJS; they were initially admitted for traumatic intracranial haemorrhage, post-hepatectomy liver failure, convulsions caused by metastatic lung cancer, and post-stroke seizure, respectively. These patients exhibited skin-specific improvements but soon died of aspiration pneumonia and acute renal failure, liver failure, metastatic lung cancer with respiratory failure and liver failure, and sudden cardiac arrest, respectively. The high mortality rate among patients with SJS in the present study could be related to referral bias (as noted in the Epidemiology subsection above); specifically, more severe cases of SJS with co-morbidities and/or complications may have been transferred to our tertiary centre for medical care, whereas less severe cases of SJS might have been managed in regional hospitals where the patients were initially admitted. Indeed, the predicted mortality rate (based on the SCORTEN prognostic score) among cases of SJS in our cohort was 14%; this rate was similar to the observed mortality rate.
 
In the present study, inpatient-onset SJS/TEN had a high mortality rate (77.8%). Although high mortality of inpatient-onset SJS/TEN was not previously described in the literature, we speculate that this high mortality was related to the underlying medical conditions for which patients were initially admitted. The clinical characteristics of the 14 patients who died are presented in Table 5.
 

Table 5. Subgroup analysis of patients with inpatient-onset Stevens–Johnson syndrome and toxic epidermal necrolysis
 
In addition to high mortality, SJS/TEN were associated with high rates of burns unit/intensive care unit admission (32%) and prolonged length of stay (mean=23.9 days) [Table 2], placing a considerable burden on the public healthcare system.
 
Limitations and strengths
As a retrospective cohort study, the present study had some intrinsic limitations. Some hospital case notes (ie, from earlier in the study period) were no longer retrievable. Clinical characteristics such as the exact date of disease onset, precise total BSA involved, and detailed drug history (including over-the-counter medications/medications prescribed by private doctors) might not have been available for some of these older cases. Skin biopsies were performed in 70% of cases and might have been omitted in cases of terminal illness. Many patients with milder cases were lost to follow-up after discharge; thus, long-term sequelae were not well-documented.
 
Additionally, referral bias may have been present because PWH is a tertiary referral centre. Such bias could have led to underestimation of the true incidence of SJS and overestimation of the incidence of TEN; milder cases of SJS might have been managed in regional hospitals, whereas more severe cases of TEN were transferred to our centre for better care. Similarly, there may have been overestimation of various outcome measures including length of stay, complications, and mortality.
 
Nonetheless, this study had several strengths. To our knowledge, this is one of the largest single-centre studies regarding SJS/TEN in Asia; it included a homogenous group of predominantly Chinese patients. The patients were managed by the same dermatology team with a consistent diagnostic and therapeutic approach throughout the study period. Data collection was adequate, and exhaustive evaluation of drug history was feasible for cases with access to both electronic records and hospital case notes. To ensure accurate identification of causative drugs, the ALDEN score was retrospectively evaluated by two independent dermatology doctors during the study.
 
Conclusion
This is the first large study in Hong Kong to provide data regarding the epidemiology, disease characteristics and clinical course, aetiology, treatment regimen, and mortality of SJS/TEN. Although uncommon, SJS/TEN is associated with substantial morbidity and mortality. Therefore, in addition to increasing awareness of SJS/TEN among patients and clinicians, efforts should be made to optimise inpatient care among public hospitals in Hong Kong by establishing dedicated multidisciplinary teams that are experienced in the management of SJS/TEN.
 
Author contributions
Concept or design: CMT Cheung, MM Chang.
Acquisition of data: All authors.
Analysis or interpretation of data: All authors.
Drafting of the manuscript: CMT Cheung, AWS Chan.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
This research was approved by the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (Ref No.: 2017.424). The requirement for informed consent was waived by the Committee due to the retrospective nature of the research.
 
References
1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6. Crossref
2. Roujeau JC. Stevens–Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997;24:726-9. Crossref
3. Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-58. Crossref
4. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001;27:372-5. Crossref
5. Yeung CK. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis [dissertation]. Queen Mary Hospital, The University of Hong Kong; 2004.
6. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149-53. Crossref
7. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens–Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8. Crossref
8. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Fléchet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42. Crossref
9. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-73. Crossref
10. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-7. Crossref
11. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and mortality of Stevens–Johnson syndrome and toxic epidermal necrolysis in United States adults. J Invest Dermatol 2016;136:138797. Crossref
12. Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol 2017;137:1240-7. Crossref
13. Lee HY, Martanto W, Thirumoorthy T. Epidemiology of Stevens–Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. Dermatologica Sinica 2013;31:217-20. Crossref
14. Chan HL. Toxic epidermal necrolysis in Singapore, 1989 through 1993: incidence and antecedent drug exposure. Arch Dermatol 1995;131:1212-3. Crossref
15. Yang MS, Lee JY, Kim J, et al. Incidence of Stevens–Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national health insurance database in Korea. PLoS One 2016;11:e0165933. Crossref
16. Hospital Authority, Hong Kong SAR Government. New Territories East Cluster biennial report 2018-2020. Available from: https://www3.ha.org.hk/ntec/clusterreport/clusterreport2018-20/index.html. Accessed 8 Feb 2024.
17. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013;69:173. e1-13; quiz 185-6. Crossref
18. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg 2016;69:e119-53. Crossref
19. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7. Crossref
20. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. J Invest Dermatol 2008;128:35-44. Crossref
21. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013;69:187.e1-16; quiz 203-4. Crossref
22. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85. Crossref
23. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens–Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 2013;133:1197-204. Crossref
24. Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med 2011;57:115-9. Crossref
25. Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in Stevens–Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract 2014;2014:237821. Crossref
26. Suwarsa O, Yuwita W, Dharmadji HP, Sutedja E. Stevens–Johnson syndrome and toxic epidermal necrolysis in Dr Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013. Asia Pac Allergy 2016;6:43-7. Crossref
27. Lee HY, Fook-Chong S, Koh HY, Thirumoorthy T, Pang SM. Cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center. J Am Acad Dermatol 2017;76:106-13. Crossref

Impact of a novel pre-hospital stroke notification programme on acute stroke care key performance indicators in Hong Kong: a multicentre prospective cohort study with historical controls

Hong Kong Med J 2024 Apr;30(2):94-101 | Epub 5 Apr 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE  CME
Impact of a novel pre-hospital stroke notification programme on acute stroke care key performance indicators in Hong Kong: a multicentre prospective cohort study with historical controls
KY Cheng, FHKCEM, FHKAM (Emergency Medicine)1; Ellen LM Yu, BSc, MSc (Epi/Biostat)2; Tafu Yamamoto, MB, ChB1; Julie CL Kwong, BHS, MBA3; YK Ho, MB, BS, FHKAM (Emergency Medicine)4; HK Ngan, MB, BS, FHKAM (Emergency Medicine)1; WH Lin, MB, BS1; Jessica MT Lau, FHKCEM, FHKAM (Emergency Medicine)5; CH Cheung, MB, ChB, MRCP (UK)6; Gordon PC Lee, FHKCEM, FHKAM (Emergency Medicine)4; LH Siu, FHKAM (Medicine), FHKCP3; Bun Sheng, MSc, MB, ChB6; Winnie WY Wong, FHKAM (Medicine), FRCP3; WY Man, BNurs, MSc6; Cathy CC Cheung, BNurs, MSc5; CT Tse, MB, BS, FHKAM (Medicine)6
1 Department of Accident and Emergency, Yan Chai Hospital, Hong Kong SAR, China
2 Clinical Research Centre, Kowloon West Cluster, Hospital Authority, Hong Kong SAR, China
3 Division of Neurology, Department of Medicine and Geriatrics, Caritas Medical Centre, Hong Kong SAR, China
4 Department of Accident and Emergency, Caritas Medical Centre, Hong Kong SAR, China
5 Department of Accident and Emergency, North Lantau Hospital, Hong Kong SAR, China
6 Division of Neurology, Department of Medicine and Geriatrics, Princess Margaret Hospital, Hong Kong SAR, China
 
Corresponding author: Dr KY Cheng (pkycheng31@fellow.hkam.hk)
 
 Full paper in PDF
 
Abstract
Introduction: Early identification and initiation of reperfusion therapy is essential for suspected acute ischaemic stroke. A pre-hospital stroke notification (PSN) protocol using FASE (facial drooping, arm weakness, speech difficulties, and eye palsy) was implemented to improve key performance indicators (KPIs) in acute stroke care delivery. We assessed KPIs and clinical outcomes before and after PSN implementation in Hong Kong.
 
Methods: This prospective cohort study with historical controls was conducted in the Accident and Emergency Departments of four public hospitals in Hong Kong. Patients were screened using the PSN protocol between August 2021 and February 2022. Suspected stroke patients between August 2020 and February 2021 were included as historical controls. Door-to-needle (DTN) and door-to–computed tomography (DTC) times before and after PSN implementation were compared. Clinical outcomes including National Institutes of Health Stroke Scale score at 24 hours and modified Rankin Scale score at 3 months after intravenous recombinant tissue-type plasminogen activator (IV-rtPA) were also assessed.
 
Results: Among the 715 patients (266 PSN and 449 non-PSN) included, 50.8% of PSN patients and 37.7% of non-PSN patients had a DTC time within 25 minutes (P<0.001). For the 58 PSN and 134 non-PSN patients given IV-rtPA, median DTN times were 67 and 75.5 minutes, respectively (P=0.007). The percentage of patients with a DTN time within 60 minutes was higher in the PSN group than in the non-PSN group (37.9% vs 21.6%; P=0.019). No statistically significant differences in clinical outcomes were observed.
 
Conclusion: Although the PSN protocol shortened DTC and DTN times, clinical outcomes did not significantly differ.
 
 
New knowledge added by this study
  • This study validates findings from a previous study that pre-hospital stroke notification (PSN) improves key performance indicators among stroke patients in Hong Kong.
  • It is unclear whether PSN improves overall clinical outcomes among stroke patients.
Implications for clinical practice or policy
  • Further research is warranted to assess whether PSN improves patient outcomes and other acute care parameters.
  • Considering the resource-intensive nature of PSN, its cost-effectiveness requires additional investigation.
 
 
Introduction
In Hong Kong, approximately 3000 stroke-related deaths occur annually; stroke is among the top three reasons for hospital admission.1 Strokes lead to prolonged hospital stays, and affected patients are likely to require long-term residential care.2 Early accurate identification of acute ischaemic stroke and initiation of reperfusion therapy have been associated with significant improvements in functional outcomes and a lower likelihood of hospital mortality.3 4 Therefore, efforts to shorten any steps within the stroke onset-to-treatment cascade can enhance outcomes for these patients.
 
The 2019 update to the American Stroke Association (ASA) 2018 guidelines for the management of acute ischaemic stroke recommends early stroke recognition and notification during initial medical contact using validated screening tools in suspected stroke patients.5 Pre-hospital notification to the receiving hospital allows early resource mobilisation prior to arrival of the suspected stroke patient, ensuring timely management. In Hong Kong, a recent study demonstrated improvements in several major benchmarks for acute stroke care.6 In August 2021, a pre-hospital stroke notification (PSN) protocol using the FASE protocol (facial drooping, arm weakness, speech difficulties, and eye palsy) was implemented across the Kowloon West Cluster, the largest service cluster in Hong Kong, which serves nearly 2 million residents.7 The inclusion of eye palsy in FASE aims to detect often-missed cases of posterior stroke8 9 and aid the identification of large vessel occlusion (LVO).10 In this study, we aimed to assess key performance indicators (KPIs) and clinical outcomes before and after the implementation of PSN.
 
Methods
Study design
This multicentre prospective cohort study with historical controls involved four Accident and Emergency Departments (AEDs) in the Kowloon West Cluster, namely, Princess Margaret Hospital, North Lantau Hospital, Caritas Medical Centre and Yan Chai Hospital, and their respective neurology divisions. Prior to implementation of the PSN FASE protocol, there was no established emergency medical services (EMS) ambulance protocol for pre-hospital notification of suspected stroke patients. The non-PSN FAST protocol (facial drooping, arm weakness, speech difficulty, and time) was used at the AED to screen suspected stroke patients. In this study, all suspected stroke patients between August 2021 and February 2022 were screened using the PSN FASE protocol and included in the PSN group; similar patients between August 2020 and February 2021 served as historical controls in the non-PSN group. Data were collected from each hospital’s neurology division and clinical data system; accuracy was confirmed by two independent authors. Suspected LVO was defined as the presence of clinical signs and symptoms compatible with internal carotid artery, middle cerebral artery, or basilar artery infarcts, along with radiological evidence from computed tomography (CT) brain scans, as reviewed by a neurologist. Confirmed LVO was defined as the presence of LVO on computed tomography angiography (CTA).
 
Patients
The PSN FASE protocol was implemented during initial contact by EMS personnel during ambulance transfer. This protocol specifies that the patient must be aged ≥18 years and exhibits acute stroke symptoms of facial weakness, unilateral arm and/or leg weakness, speech disturbance, or eye palsy within 4 hours. Protocol exclusion criteria included symptoms with suspected trauma aetiology, Glasgow Coma Scale score ≤8, systolic blood pressure <100 mm Hg, previous medical history of seizure/epilepsy, or long-term chairbound or bedbound status. If a patient meets inclusion criteria with no exclusion criteria, EMS personnel activate the PSN protocol by informing the closest AED to prepare for the incoming stroke patient. In the present study, patients transported with this protocol constituted suspected stroke patients in the PSN group.
 
In contrast, the non-PSN FAST protocol is activated by a physician in the AED. This protocol requires the patient to display acute stroke symptoms of facial asymmetry, limb weakness, or speech disturbance, while meeting all of the following criteria: (1) age ≥18 years; (2) onset of stroke symptoms within 3.5 hours before the request for intravenous recombinant tissue-type plasminogen activator (IV-rtPA) administration; (3) signs and symptoms compatible with acute stroke; and (4) reasonable premorbid functional status (at least not bedbound). Protocol exclusion criteria included active internal bleeding, recent severe head trauma or intracranial/spinal surgery within the preceding 3 months, clinical presentation suggestive of subarachnoid haemorrhage or aortic dissection, acute stroke symptoms in the context of infective endocarditis, intra-axial intracranial neoplasm, coagulopathy (platelet count <100 × 109/L or international normalised ratio >1.7), or ongoing use of anticoagulant medication.
 
FASE protocol of pre-hospital stroke notification
In the PSN FASE protocol, EMS personnel are trained to screen potentially IV-rtPA–eligible stroke patients and to notify the receiving AED about patients with thrombolytic eligibility. An AED physician and a nursing team are prepared for immediate assessment upon patient arrival; an experienced on-duty stroke nurse is notified prior to arrival. The AED physician immediately determines whether the patient should be considered for thrombolytic therapy. If the thrombolytic therapy criteria are met, the patient undergoes a plain CT brain scan and assessment by an on-call neurologist for intravenous thrombolytic therapy. If IV-rtPA treatment is approved by the on-call neurologist, IV-rtPA is administered to the patient; this administration was similar for both historical and prospective groups.
 
Outcomes measurement
The primary outcome in this study was door-to-needle (DTN) time, which the ASA recommends to be within 60 minutes. The secondary outcomes were onset-to-door (OTD) and door-to-CT (DTC) times. The recommended DTC time is within 25 minutes, but no specific recommendation exists for OTD time.11 The National Institutes of Health Stroke Scale (NIHSS) score at 24 hours post-rtPA and modified Rankin Scale (mRS) score at 3 months post-rtPA were also recorded. A good clinical outcome was defined as a reduction of ≥4 in NIHSS score at 24 hours post-rtPA or an mRS score of 0 to 1 at 3 months post-rtPA.
 
Statistical analysis
Baseline characteristics, KPIs, and clinical outcomes were presented as count (%), mean ± standard deviation, or median (interquartile range). The Pearson Chi squared test, Fisher’s exact test, Mann-Whitney U test, and independent t test were used to compare the PSN and non-PSN groups. Further comparisons between the two groups were performed after one-to-one matching based on hospital, sex, age-group (≤80 years and >80 years), and NIHSS score at onset. Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV), along with 95% confidence intervals, were computed for the PSN group using the FAS protocol (facial drooping, arm weakness, and speech difficulties) with or without eye palsy, as well as eye palsy alone. The PPVs of the protocols were compared using relative predictive values in a paired study design, as proposed by Moskowitz and Pepe.12 Statistical analyses were performed using SPSS software (Windows version 26.0; IBM Corp, Armonk [NY], United States) and the DTComPair package in R software (version 3.6.1). P values <0.05 were considered statistically significant.
 
Results
In total, 715 suspected stroke patients were included, with 449 in the non-PSN group and 266 in the PSN group. Intravenous recombinant tissue-type plasminogen activator was administered to 134 (29.8%) patients and 58 (21.8%) patients in the non-PSN and PSN groups, respectively (P=0.019) [Table 1]. Among the remaining 208 patients (78.2%) not given IV-rtPA in the PSN group, 43 patients were beyond the IV-rtPA window, and 46 patients had alternative unknown diagnoses at AED attendance. Twenty-one patients had symptoms that resolved or improved by the time of AED attendance (Fig).
 

Table 1. Comparison of baseline characteristics and key performance indicators of suspected stroke patients between pre-hospital stroke notification (PSN) and non-PSN groups
 

Figure. Summary of stroke patients screened using the pre-hospital stroke notification protocol
 
Comparison in all suspected stroke patients
Demographic characteristics were compared between the non-PSN and PSN groups, as shown in Table 1. Age and hyperlipidaemia significantly differed between the two groups. The median ages were 69.7 years in the non-PSN group and 72.4 years in the PSN group (P=0.022). The percentages of patients with hyperlipidaemia were 53.9% in the non-PSN group and 43.9% in the PSN group (P=0.010). Door-to-CT time was significantly shorter in the PSN group than in the non-PSN group (24.5 vs 31 minutes; P<0.001). The percentage of patients achieving the DCT time goal of 25 minutes was greater in the PSN group than in the non-PSN group (50.8% vs 37.7%; P<0.001). However, the median OTD time was longer in the PSN group than in the non-PSN group (97 vs 85.5 minutes; P=0.003).
 
Comparison in patients given intravenous recombinant tissue-type plasminogen activator
Among stroke patients given IV-rtPA, sex, hypertension, and hyperlipidaemia significantly differed between the two groups, as illustrated in Table 2. In the non-PSN group, 53.7% of patients were men, compared with 69.0% in the PSN group (P=0.049). Regarding key risk factors for ischaemic stroke, the respective prevalences of hypertension and hyperlipidaemia were 74.6% and 61.9% in the non-PSN group, whereas they were 53.4% and 44.8% in the PSN group. The NIHSS scores at symptom onset were similar between the non-PSN and PSN groups. The percentages of patients with suspected LVO were also similar between the PSN and non-PSN groups (40.4% vs 37.3%; P=0.759), as were the percentages of patients with CTA-confirmed LVO (52.6% vs 60.0%; P=1.000).
 

Table 2. Comparison of baseline characteristics and key performance indicators of stroke patients given intravenous recombinant tissue-type plasminogen activator between pre-hospital stroke notification (PSN) and non-PSN groups
 
The DTN time was shorter in the PSN group than in the non-PSN group (67 vs 75.5 minutes; P=0.007). Additionally, the percentage of patients achieving the DTN time goal of 60 minutes was greater in the PSN group (37.9% vs 21.6%; P=0.019). However, there were no differences in median DTC time and percentage of patients achieving the DTC time goal of 25 minutes (Table 2). As shown in Table 3, the percentages of patients with good clinical outcomes after IV-rtPA were similar between non-PSN and PSN groups, as indicated by a reduction of ≥4 in NIHSS score at 24 hours (50.8% vs 49.0%; P=0.829) and an mRS score of 0 to 1 at 90 days (43.3% vs 35.4%; P=0.342).
 

Table 3. Comparison of short-term and long-term clinical outcomes of stroke patients given intravenous recombinant tissue-type plasminogen activator between pre-hospital stroke notification (PSN) and non-PSN group
 
Matched comparison of patients given intravenous recombinant tissue-type plasminogen activator
The non-PSN and PSN groups were matched based on hospital, sex, age-group, and NIHSS score at onset. After matching, the percentage of patients achieving the DTC time goal of 25 minutes was greater in the PSN group than in the non-PSN group (64.0% vs 44.0%; P=0.045). The median DTN time was also shorter in the PSN group (65.5 vs 76.5 minutes; P=0.003). Moreover, the percentage of patients achieving the DTN time goal of 60 minutes was greater in the PSN group than in the non-PSN group (42.0% vs 18.0%; P=0.009) [Table 2]. Finally, the percentages of patients with good clinical outcomes after IV-rtPA were similar between non-PSN and PSN groups, as evidenced by a reduction of ≥4 in NIHSS score at 24 hours (47.7% vs 48.9%; P=0.913) and an mRS score of 0 to 1 at 90 days (36.0% vs 33.3%; P=0.789) [Table 3].
 
Predictive value of eye palsy assessment in the pre-hospital stroke notification protocol
Among the 22 patients with eye palsy in the PSN group, 18 patients had either facial drooping, arm weakness or speech difficulties; seven patients were administered IV-rtPA. In the PSN group, the PPVs for using FAS, eye palsy alone, and FAS with eye palsy to identify stroke patients eligible for IV-rtPA were 22.14%, 31.82%, and 38.89%, respectively (Table 4). Compared with the PPV of FAS, the PPV of FAS with eye palsy was significantly higher (P=0.046), whereas the PPV of eye palsy alone did not significantly differ (P=0.223).
 

Table 4. Eye palsy as a predictive factor for intravenous recombinant tissue-type plasminogen activator among suspected stroke patients in pre-hospital stroke notification group only (n=266)
 
Discussion
The AHA and ASA recommend specific time goals for KPIs in stroke patients, such as OTD, DTC, and DTN times. Early recognition of stroke and utilisation of PSN for these patients are emphasised in the recent ASA guidelines as recommendations that can facilitate achievement of these goals. The recent adoption of a PSN protocol by the public hospital system in Hong Kong is intended to improve these KPIs and, ultimately, clinical outcomes among stroke patients.
 
In the present study, the PSN FASE protocol resulted in shorter DTC and DTN times, compared with the non-PSN protocol. A shorter DTN is associated with improved patient outcomes3 4 and enables more patients to receive IV-rtPA within the therapeutic window.13 However, the onset-to-needle time did not differ between the two groups (144.5 vs 159 minutes; P=0.525) [Table 2], which may be explained by the longer OTD time in the PSN group than in the non-PSN group (97 vs 85.5 minutes; P=0.003) [Table 1]. To control for potential confounding factors, we matched the non-PSN and PSN stroke patients based on multiple variables; the results confirmed that DTC and DTN times were shorter in the PSN group.
 
However, these improvements in KPIs did not lead to statistically significant improvements in clinical outcomes, as evidenced by a reduction of ≥4 in NIHSS score at 24 hours post-rtPA (50.8% vs 49.0%; P=0.829) and an mRS score of 0 to 1 at 90 days (43.3% vs 35.4%; P=0.342) [Table 3]. The results of previous studies have suggested favourable mRS score outcomes in 33% to 41% of stroke patients given IV-rtPA12 14; the absence of favourable neurological outcomes in the present study may be attributed to the higher baseline level of neurological improvement in the non-PSN group. Moreover, the relatively small sample sizes in the PSN and non-PSN groups (58 vs 134; P=0.019) [Table 1] may explain the lack of statistically significant clinical benefit in this study; future studies with larger sample sizes may provide further insights. The longer OTD time in the PSN group compared with the non-PSN group suggests that patients in the PSN group were administered IV-rtPA later than patients in the non-PSN group, potentially resulting in worse clinical outcomes. Finally, the lack of statistically significant improvements in clinical outcomes may be explained by the higher NIHSS score at onset in the PSN group (15 vs 11; P=0.573) [Table 2]; regardless of matching to control for potential confounding factors, we did not observe any statistically significant improvement in clinical outcomes.
 
A higher percentage of stroke patients received IV-rtPA in the non-PSN group compared with the PSN group, which may differ from the findings in some recent studies.6 15 This discrepancy may be attributed to the learning curve associated with the new FASE protocol in the PSN group; EMS personnel may have engaged in ‘over-activation’ for borderline suspected stroke patients during early implementation. Additionally, because screening in the PSN group was performed by EMS personnel, it may have been less accurate than screening by physicians (ie, in the non-PSN group). The longer OTD time in the PSN group suggested that patients in the PSN group presented to the AED later than patients in the non-PSN group, increasing the likelihood that they would miss the 4-hour window for IV-rtPA administration.
 
The inclusion of eye palsy in the FASE protocol is intended to identify potential cases of posterior stroke8 9 and aid the identification of LVO.10 Although we found that the FASE protocol had a higher PPV (compared with the FAST protocol) for identifying stroke patients eligible for IV-rtPA, we did not assess whether the FASE protocol reliably identified patients with posterior strokes. Future studies validating the FASE protocol would provide additional insights. Considering the role of conjugate eye deviation in identifying LVO strokes,16 17 research exploring the ability of the FASE protocol to identify these patients would be valuable. Investigations of EMS personnel accuracy in eye palsy recognition may also be useful.
 
Limitations
Possible limitations of this study include the potential for experimenter bias, considering that most investigators were also clinicians involved in patient management. However, it may be difficult to address this bias due to staffing constraints in peripheral acute hospitals, where researchers also serve as clinicians. Furthermore, the findings in this study are consistent with the results of other studies regarding pre-hospital notification protocols for suspected stroke patients.
 
We also included the percentage of stroke patients with CTA-confirmed LVO to provide a more comprehensive analysis, considering that LVO strokes have been linked to worse clinical outcomes compared with non-LVO strokes.18 We observed no statistically significant differences in the percentages of suspected LVO and CTA-confirmed LVO strokes between the two study groups. However, because logistical considerations and resource limitations hindered our ability to perform diagnostic CTA for all patients, the true number of CTA-confirmed LVO strokes may be underestimated. Finally, the relatively small sample size may restrict our capacity to draw definitive conclusions.
 
Conclusion
This study validated the previous finding that a PSN protocol improves multiple stroke KPIs in Hong Kong. It also improves the understanding of whether a PSN protocol directly improves overall clinical outcomes among stroke patients, an area with limited evidence in current literature.19 The implementation of a PSN protocol using the new FASE assessment guideline shortened DTN and DTC times compared with a non-PSN protocol. However, this study did not reveal any statistically significant improvement in overall clinical neurological outcomes between these two protocols. Further research may be warranted to assess whether PSN improves patient outcomes and other acute care parameters.
 
Author contributions
Concept or design: KY Cheng, ELM Yu.
Acquisition of data: KY Cheng, T Yamamoto.
Analysis or interpretation of data: KY Cheng, ELM Yu.
Drafting of the manuscript: KY Cheng, ELM Yu.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Acknowledgement
The authors thank Mr Kin-wah Tam from North Lantau Hospital for data retrieval at the Hospital.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
This research was approved by the Kowloon West Cluster Research Ethics Committee of Hospital Authority, Hong Kong [Ref No.: KW/EX-21-134(163-12)]. A waiver of patient consent was granted by the Committee since the data had been collected prior to this research and the risk of identification is minimal, and no new additional data was required for the research.
 
References
1. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Physical activity: a major strategy for stroke prevention. Non-communicable diseases watch. October 2022. Available from: https://www.chp.gov.hk/files/pdf/ncd_watch_oct_2022.pdf. Accessed 28 Mar 2024.
2. Woo J, Ho SC, Goggins W, Chau PH, Lo SV. Stroke incidence and mortality trends in Hong Kong: implications for public health education efforts and health resource utilisation. Hong Kong Med J 2014;20(3 Suppl 3):S24-9.
3. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309:2480-8. Crossref
4. Man S, Xian Y, Holmes DN, et al. Association between thrombolytic door-to-needle time and 1-year mortality and readmission in patients with acute ischemic stroke. JAMA 2020;323:2170-84. Crossref
5. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49:e46-110. Crossref
6. Leung WC, Teo KC, Kwok WM, et al. Pre-hospital stroke screening and notification of patients with reperfusion-eligible acute ischaemic stroke using modified Face Arm Speech Time test. Hong Kong Med J 2020;26:479-85. Crossref
8. Kleindorfer DO, Miller R, Moomaw CJ, et al. Designing a message for public education regarding stroke: does FAST capture enough stroke? Stroke 2017;38:2864-8. Crossref
9. Aroor S, Singh R, Goldstein LB. BE-FAST (Balance, Eyes, Face, Arm, Speech, Time): reducing the proportion of strokes missed using the FAST mnemonic. Stroke 2017;48:479-81. Crossref
10. Beume L, Hieber M, Kaller CP, et al. Large vessel occlusion in acute stroke. Stroke 2018;49:2323-9. Crossref
11. Matsuo R, Yamaguchi Y, Matsushita T, et al. Association between onset-to-door time and clinical outcomes after ischemic stroke. Stroke 2017;48:3049-56. Crossref
12. Moskowitz CS, Pepe MS. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs. Clin Trials 2006;3:272-9. Crossref
13. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-72. Crossref
14. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-35. Crossref
15. Hsieh MJ, Tang SC, Chiang WC, et al. Effect of prehospital notification on acute stroke care: a multicenter study. Scand J Trauma Resusc Emerg Med 2016;24:57. Crossref
16. Ollikainen JP, Janhunen HV, Tynkkynen JA, et al. The Finnish Prehospital Stroke Scale detects thrombectomy and thrombolysis candidates—a propensity score–matched study. J Stroke Cerebrovasc Dis 2018;27:771-7. Crossref
17. Keenan KJ, Kircher C, McMullan JT. Prehospital prediction of large vessel occlusion in suspected stroke patients. Curr Atheroscler Rep 2018;20:34. Crossref
18. Malhotra K, Gornbein J, Saver JL. Ischemic strokes due to large-vessel occlusions contribute disproportionately to stroke-related dependence and death: a review. Front Neurol 2017;8:651. Crossref
19. Sangari A, Akhoundzadeh K, Vahedian M, Sharifipour E. Effect of pre-hospital notification on delays and neurological outcomes in acute ischemic stroke. Australas Emerg Care 2022;25:172-5. Crossref

Prediction of hospital mortality among critically ill patients in a single centre in Asia: comparison of artificial neural networks and logistic regression–based model

Hong Kong Med J 2024 Apr;30(2):130-8 | Epub 28 Mar 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Prediction of hospital mortality among critically ill patients in a single centre in Asia: comparison of artificial neural networks and logistic regression–based model
Swan Lau, BSc, MB, BS1; HP Shum, MD, FRCP2; Carol CY Chan, FHKCA, FHKAM (Anaesthesiology)2; MY Man, MRCP (UK), FHKAM (Medicine)2; KB Tang, FHKCA, FHKAM (Anaesthesiology)2; Kenny KC Chan, MStat, FHKAM (Anaesthesiology)3; Anne KH Leung, FHKCA (IC), FCICM4; WW Yan, FRCP, FHKAM (Medicine)2
1 Department of Anaesthesia, Pain and Perioperative Medicine, Queen Mary Hospital, Hong Kong SAR, China
2 Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China
3 Department of Anaesthesia and Intensive Care, Tuen Mun Hospital, Hong Kong SAR, China
4 Department of Intensive Care, Queen Elizabeth Hospital, Hong Kong SAR, China
 
Corresponding author: Dr Swan Lau (ls037@ha.org.hk)
 
 Full paper in PDF
 
Abstract
Introduction: This study compared the performance of the artificial neural network (ANN) model with the Acute Physiologic and Chronic Health Evaluation (APACHE) II and IV models for predicting hospital mortality among critically ill patients in Hong Kong.
 
Methods: This retrospective analysis included all patients admitted to the intensive care unit of Pamela Youde Nethersole Eastern Hospital from January 2010 to December 2019. The ANN model was constructed using parameters identical to the APACHE IV model. Discrimination performance was assessed using area under the receiver operating characteristic curve (AUROC); calibration performance was evaluated using the Brier score and Hosmer–Lemeshow statistic.
 
Results: In total, 14 503 patients were included, with 10% in the validation set and 90% in the ANN model development set. The ANN model (AUROC=0.88, 95% confidence interval [CI]=0.86-0.90, Brier score=0.10; P in Hosmer–Lemeshow test=0.37) outperformed the APACHE II model (AUROC=0.85, 95% CI=0.80-0.85, Brier score=0.14; P<0.001 for both comparisons of AUROCs and Brier scores) but showed performance similar to the APACHE IV model (AUROC=0.87, 95% CI=0.85-0.89, Brier score=0.11; P=0.34 for comparison of AUROCs, and P=0.05 for comparison of Brier scores). The ANN model demonstrated better calibration than the APACHE II and APACHE IV models.
 
Conclusion: Our ANN model outperformed the APACHE II model but was similar to the APACHE IV model in terms of predicting hospital mortality in Hong Kong. Artificial neural networks are valuable tools that can enhance real-time prognostic prediction.
 
 
New knowledge added by this study
  • An artificial neural network model outperformed the Acute Physiologic and Chronic Health Evaluation (APACHE) II model but was similar to the APACHE IV model in terms of predicting hospital mortality.
  • The three most important predictor variables were the highest sodium level, highest bilirubin level, and lowest white cell count within 24 hours of intensive care unit admission.
  • External validation studies using data from other hospitals are recommended to confirm these findings.
Implications for clinical practice or policy
  • Prediction of mortality among critically patients is challenging.
  • Artificial neural networks, along with other machine learning techniques, are valuable tools that can enhance real-time prognostic prediction.
 
 
Introduction
Intensive care treatments are primarily intended to improve patient outcomes. Considering the high operating costs of intensive care units (ICUs), a reliable, decision-supporting, risk stratification system is needed to predict patient outcomes and facilitate cost-effective use of ICU beds. Several disease severity scoring systems, such as the Acute Physiology and Chronic Health Evaluation (APACHE) system and the Simplified Acute Physiology Score system, are currently used to objectively assess outcomes and recovery potential in this complex and diverse group of patients.1 2
 
The APACHE system, one of the most commonly used benchmark severity scoring systems worldwide, can measure disease severity and predict hospital mortality among ICU patients. In the 40 years since its initial development, the APACHE system has undergone multiple revisions to improve statistical power and discrimination performance by modifying the numbers and weights of included variables.3 4 5 6 The underlying statistical principle is multivariable logistic regression based on data from an American population. The results are easy to interpret and allow robust outcome prediction for individuals with characteristics similar to the original population. However, the APACHE system has limited capacity to manage non-linear relationships between predictor and outcome variables, interactions between variables, and missing data. Although the value of the APACHE system for mortality prediction has been established, especially in Western countries, its discrimination performance and calibration are inconsistent when applied outside of the US.7 8 9 10 Since 2008, the Hospital Authority in Hong Kong has utilised the APACHE IV model to assess outcomes in critically ill patients. Nevertheless, the APACHE II model remains the most extensively validated version; it is widely used for research and reference purposes.11
 
In the early 1990s, artificial neural networks (ANNs), a type of machine learning algorithm, were proposed as alternative statistical techniques to logistic regression–based method. Similar to the organisation and data processing configurations in human brains, these networks consist of input and output layers with at least one or more intermediate (hidden) layers for pattern recognition. Each layer contains several ‘artificial neurons’, known as nodes, for data extraction; these nodes are connected with each other through variable ‘weights’.12 Artificial neural networks identify representative patterns from input data and observed output data within a training set, then fine-tune the variable weights; thus, they can predict outcomes when provided novel information. This method has considerable advantages in terms of managing non-linear relationships and multivariable interactions.13
 
A review of 28 studies comparing ANN and regression-based models showed that ANN outperformed regression-based models in 10 studies (36%), was outperformed by regression-based models in four studies (14%), and had similar performance in the remaining 14 studies (50%).14 Multiple recent studies also demonstrated that the integration of machine learning with electronic health records provided more accurate and reliable predictive performance compared with conventional prognostic models.15 16
 
This study was conducted to compare ANN performance with the performances of extensively validated and benchmark scoring systems—APACHE II and APACHE IV—in terms of predicting hospital mortality among critically ill patients in Hong Kong.
 
Methods
This retrospective analysis included all patients aged ≥18 years with first-time admissions to the ICU of Pamela Youde Nethersole Eastern Hospital between 1 January 2010 and 31 December 2019. The hospital is a 2000-bed tertiary care regional hospital that provides comprehensive services except for cardiothoracic surgery, transplant surgery, and burn management. The ICU is a 24-bed, closed, mixed medical-surgical unit with an average of 1600 patients admitted annually.
 
Demographic characteristics and hospital mortality data were retrospectively recorded. The worst value of each physiological parameter during the first 24 hours after ICU admission was used to generate an APACHE score. The predicted mortality risk was calculated based on published methods.3 5 Included parameters were age, sex, systolic and diastolic blood pressures, temperature, heart rate, respiratory rate, glucose level, blood urea nitrogen level, serum sodium level, creatinine level, haematocrit level, white cell count, albumin level, bilirubin level, pH, fraction of inspired oxygen, partial pressures of carbon dioxide and oxygen, bicarbonate, and urine output during the first 24 hours after ICU admission. For patients who had multiple ICU admissions during a single hospital stay, only the first admission was included. Patients were excluded if they died or were discharged from the ICU within 4 hours after admission.
 
Instances of incomplete data were resolved by multiple imputation using the Markov chain Monte Carlo algorithm (ie, fully conditional specification). This method fits a univariate (single dependent variable) model using all other available variables in the model as predictors, then imputes missing values for the dependent variable. The method continues until the maximum number of iterations is reached; the resulting imputed values are saved to the imputed dataset.
 
Neural network models were constructed with SPSS software (Windows version 25.0; IBM Corp, Armonk [NY], US) using the same parameters as in the APACHE IV model (online supplementary Fig); SPSS software was also used to examine model precision. The multilayer perceptron procedure, a class of feed-forward learning model, consists of ≥3 layers of nodes: input, hidden, and output.17 Automatic architecture building, which computes the best number of units in a hidden layer, was performed with SPSS software. Each hidden unit is an activation function of the weighted sum of the inputs; the values of the weights are determined by an estimation algorithm. In this study, the hidden layer consisted of 12 units (nodes). A hyperbolic tangent activation function was also employed for the hidden layers. Softmax activation and cross-entropy error functions were used for the output layer. The multilayer perceptron procedure utilised a backpropagation technique for supervised training. Learning occurred in the recognition phase for each piece of data via changes to connection weights based on the amount of error in the output compared with the expected result (gradient descent method).18
 
The training process was terminated when no further decreases in calculated error were observed. Subsequently, network weights were identified and used to compute test values. The importance of an independent variable was regarded as a measure of the extent to which network model–predicted values differed from observed values. Normalised importance, expressed as a percentage, constituted the ratio between the importance of each predictor variable and the largest importance value. Model stability was assessed by tenfold cross-validation. Oversampling of minority classes was performed via duplication to manage imbalances in outcome data.
 
Categorical and continuous variables were expressed as numbers (percentages) and medians (interquartile ranges). The Chi squared test or Fisher’s exact test was used for comparisons of categorical data; the Mann-Whitney U test was used for comparisons of continuous data. The performances of ANN, APACHE II, and APACHE IV models were evaluated in terms of discrimination and calibration power. Discrimination, which constitutes the ability of a predictive model to separate data into classes (eg, death or survival), was evaluated using the area under the receiver operating characteristic curve (AUROC). The AUROCs of the models were compared using the DeLong test. Calibration, which represents the closeness of model probability to the underlying probability of the study population, was evaluated using the Brier score, Hosmer–Lemeshow statistic, and calibration curves.19 All P values were two-sided, and values < 0.05 were considered statistically significant. All analyses were performed with SPSS software and MedCalc statistical software (version 19.6.1).
 
Results
In total, 14 503 patients were included. The demographic characteristics and hospital mortality data of the study cohort were shown in Table 1, while the physiological and laboratory parameters required to generate an APACHE score were presented in Table 2. Among the recruited patients, 4.93% had at least one missing data point, and the overall rate of missing data was 0.48%. Furthermore, 1400 (9.7%) of the recruited patients were randomly assigned to the validation set; the remaining patients (n=13 103, 90.3%) were assigned to the model development set. With respect to the ANN model, 70% and 30% of the development set were used for training and testing purposes, respectively. The median age was 67 years (interquartile range [IQR]=54-78), median APACHE II score was 18 (IQR=13-25), and median APACHE IV score was 66 (IQR=46-91). The overall hospital and ICU mortality rates were 19.3% (n=2799) and 9.6% (n=1392), respectively.
 

Table 1. Patient characteristics and outcome parameters
 

Table 2. Physiological and laboratory parameters during the first 24 hours after admission to the intensive care unit
 
The baseline co-morbidities, source of admission, disease category, APACHE II score, and APACHE IV score were similar in the test and validation sets (Table 1). More patients in the validation set received continuous renal replacement therapy (18.3% vs 16.1%; P=0.04). Concerning the worst physiological and laboratory parameters within the first 24 hours (Table 2), there were almost no significant differences between the development and validation sets; notably, the haemoglobin level was lower in the validation set (11.3 g/dL vs 11.5 g/dL; P=0.02).
 
In the development set, the ANN model (AUROC=0.89, 95% confidence interval [CI]=0.88-0.92, Brier score=0.10; P in Hosmer–Lemeshow test=0.34) outperformed the APACHE II model (AUROC=0.80, 95% CI=0.79-0.81, Brier score=0.15; P<0.001) and APACHE IV model (AUROC=0.84, 95% CI=0.83-0.85, Brier score=0.12; P<0.001) for prediction of hospital mortality. The cross-validation accuracy ranged from 0.98 to 1 (mean=0.99), indicating that our ANN model had good stability. There was no statistically significant difference between our ANN model and an ANN model created by oversampling of minority classes (AUROC=0.89, 95% CI=0.89-0.90; P=0.103).
 
In the validation set, the ANN model (AUROC=0.88, 95% CI=0.86-0.90, Brier score=0.10, P in Hosmer–Lemeshow test=0.37) was superior to the APACHE II model (AUROC=0.85, 95% CI=0.80-0.85, Brier score=0.14; P<0.001 for both comparisons of AUROCs and Brier scores) but similar to the APACHE IV model (AUROC=0.87, 95% CI=0.85-0.89, Brier score=0.11; P=0.34 for comparison of AUROCs, and P=0.05 for comparison of Brier scores) [Fig 1].
 

Figure 1. Receiver operating characteristic curves for different models (validation set)
 
The calibration curve for the validation set showed that the ANN model (Fig 2a) outperformed the APACHE IV model (Fig 2b) and the APACHE II model (Fig 2c).
 

Figure 2. Calibration curves for different models (validation set). (a) Artificial neural network model. (b) Acute Physiology and Chronic Health Evaluation (APACHE) IV model. (c) APACHE II model
 
The importances of the predictor variables in predictions of hospital mortality using the ANN model were evaluated. Within 24 hours of ICU admission, the highest sodium level was the most important variable, followed by the highest bilirubin level and the lowest white cell count. Details regarding the normalised importance of each covariate are presented in online supplementary Tables 1 and 2.
 
Discussion
To our knowledge, this is the first study in Asia to assess the performance of ANN and compare it with the performances of two extensively validated and benchmark scoring systems—APACHE II and APACHE IV—in terms of predicting hospital mortality among critically ill patients. We found that the ANN model provided better discrimination and calibration compared with the APACHE II model. However, the difference between the ANN and APACHE IV models was less prominent. Calibration was slightly better with the ANN model, but discrimination was similar between the ANN and APACHE IV models.
 
Conventional logistic regression–based APACHE systems often lose calibration over time and require regular updates to maintain performance.6 11 20 21 22 The original APACHE II model was developed over 30 years ago using data from 13 different hospitals in the US; it was validated in the country before clinical application.2 Studies in Hong Kong7 and Singapore23 have shown that the APACHE II model has good discrimination but poor calibration for ICU patients in Asia. Calibration remained suboptimal regardless of customisation as demonstrated by Lew et al,23 indicating the need for a new prognostic prediction model. Wong and Young24 showed that the APACHE II model had equivalent performance status compared with an ANN model that had been trained and validated using the original APACHE II data. In a medicalneurological ICU in India, an ANN model trained on an Indian population (with or without redundant variables) demonstrated better calibration compared with the APACHE II model.25 The authors speculated that this finding was partly related to differences in standards of care and resources between American and Indian ICUs.25 Overall, differences in case mix, advances in medical technology, and the use of more recent data may explain the superiority of our ANN model compared with the APACHE II model.
 
Compared with ICU patients in the US, it is fivefold more common for Hong Kong ICU patients to begin renal replacement therapy.26 More than 50% of critically ill patients in Hong Kong require mechanical ventilation, compared with 28% in the US.26 27 A recent population-based study of all patients admitted to adult ICUs in Hong Kong between 2008 and 2018 showed that the APACHE IV standardised mortality ratio decreased from 0.81 to 0.65 during the study period, implying a gradual decline in the performance of the APACHE IV model.26 This model, which was established using data derived from >100 000 ICU patients in 45 US hospitals between 2002 and 2003,5 also tends to overestimate hospital mortality among ICU patients in Hong Kong. In contrast to our study population, where Asian ethnicities were most common, 70% of the patients in APACHE IV reference population were Caucasian.5 The subtle differences in performance between our ANN model and the APACHE IV model could be related to differences in timing during the development of the models. Nevertheless, our ANN model trained on a Hong Kong population was better calibrated for prediction in such a population, compared with the APACHE IV model. This improved calibration could be related to differences in target population (Asian vs Caucasian), epidemiology, and disease profile.
 
The selection of appropriate variables is a key aspect of model development. The inclusion of additional predictor variables does not necessarily improve a model’s overall performance. Redundant variables may result in overfitting and produce a complicated predictive model without additional benefits. A recently published large national cohort study from Sweden showed that a simplified ANN model with eight parameters outperformed the Simplified Acute Physiology Score III model in terms of discrimination and calibration.28 Among the eight parameters, age and leukocyte count were the most and least important variables, respectively. Notably, leukocyte count was the most important variable in terms of predicting mortality among patients on continuous renal replacement therapy.29 Similar to the present study, Kang et al29 found that age was the 12th most important variable. The overall performance of an ANN model trained with APACHE II parameters in an Indian population could be maintained with the 15 highest information gain variables, including serum sodium level and leukocyte count.25
 
Among the 53 parameters in our ANN model, the highest sodium level, highest bilirubin level, and lowest white cell count within 24 hours of ICU admission were the top three most important predictor variables (online supplementary Table 1). The association between acquired hypernatraemia and increased hospital mortality among critically patients has consistently been demonstrated in multiple studies.30 31 Hyperbilirubinaemia, another complication in patients with sepsis, was associated with the onset of acute respiratory distress syndrome.32 Sepsis and gastrointestinal/hepatobiliary diseases caused ICU admission in approximately 40% of our patients, possibly explaining the importance of hyperbilirubinaemia in our ANN model. Although the importance of leukocyte count has been demonstrated in other mortality prediction models, the previous models did not specify whether the count was high or low.25 28 29 In the present study, the lowest white cell count was more important than the highest white cell count. Another intriguing observation was that age constituted the 11th most important predictor in our ANN model (online supplementary Table 1). Age is a predictor of survival in many prognostic models.3 5 28 Increasing biological age is often associated with multiple co-morbidities and a progressive decline in physiological reserve, leading to increased mortality. However, a recently published systematic review of 129 studies showed large variations in ICU and hospital mortality rates among older ICU patients, ranging from 1% to 51% in single-centre retrospective studies and 6% to 28% in multicentre retrospective studies.33 These results could be related to differences in admission policies, premorbid functional status, and the intensity of provided to older critically ill patients.
 
Our ANN model was trained and internally validated on a large number of representative data samples that included most patients admitted to a tertiary ICU in Hong Kong over the past decade. This approach addressed the small sample size limitation that was common in previous studies.24 25 34 All data were automatically collected by a computer system, eliminating the risk of human error during data extraction. Healthcare system digitalisation and advances in information technology have enabled effortless generation of abundant clinical data (eg, physiological parameters, laboratory results, and radiological findings), which can facilitate data collection and development of a new risk prediction model via machine learning.35 36 We hope that generalisability to other ICUs in Asia can be achieved through external validation studies.
 
Limitations
This study had some limitations. Although the sample size was large, all data were collected from a single centre; in contrast, data for the APACHE scoring system were derived from multiple large centres. Because the primary objective of the present study was comparison of performance between our ANN model and the APACHE II and APACHE IV models using identical parameters, we did not attempt to determine the optimal subset of parameters that would maintain high ANN performance.25 28 Furthermore, our ANN model may not be applicable to other centres with different case mixes and medical approaches. The lack of external validation may lead to concerns about overfitting, which is a common challenge in ANN model development. Because mortality prediction among ICU patients is a dynamic process, other limitations include the use of static data and the lack of a fixed time point for mortality assessment.
 
Conclusion
Mortality prediction among critically patients is a challenging endeavour. Our ANN model, which was trained with representative data from a Hong Kong population, outperformed the internationally validated APACHE II model with respect to critically ill patients in Hong Kong. In contrast to the APACHE IV model, our ANN model demonstrated better calibration but similar discrimination performance. External validation studies using data from other hospitals are recommended to confirm our findings. Future studies should explore the feasibility of reducing the number of variables while preserving the discrimination and calibration power of the ANN model. The widespread use of computerised information systems, rather than paper records, in ICU and general ward settings has led to increased data availability. Artificial neural networks, along with other machine learning techniques, are valuable tools that can enhance real-time prognostic prediction.
 
Author contributions
Concept or design: S Lau, HP Shum, CCY Chan.
Acquisition of data: S Lau, HP Shum, CCY Chan.
Analysis or interpretation of data: S Lau, HP Shum, CCY Chan.
Drafting of the manuscript: S Lau.
Critical revision of the manuscript for important intellectual content: MY Man, KB Tang, KKC Chan, AKH Leung, WW Yan.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interests.
 
Declaration
Part of the research was presented at the 34th Annual Congress of the European Society of Intensive Care Medicine (3-6 October 2021, virtual) and the Annual Scientific Meeting 2021 of Hong Kong Society of Critical Care Medicine (12 December 2021, virtual).
 
Funding/support
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
 
Ethics approval
The study protocol complies with the Declaration of Helsinki and was approved by the Hong Kong East Cluster Research Ethics Committee of Hospital Authority, Hong Kong (Ref No.: HKECREC-2021-024). The requirement for patient consent was waived by the Committee due to the retrospective nature of the study.
 
Supplementary material
The supplementary material was provided by the authors and some information may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by the Hong Kong Academy of Medicine and the Hong Kong Medical Association. The Hong Kong Academy of Medicine and the Hong Kong Medical Association disclaim all liability and responsibility arising from any reliance placed on the content.
 
References
1. Keegan MT, Gajic O, Afessa B. Severity of illness scoring systems in the intensive care unit. Crit Care Med 2011;39:163-9. Crossref
2. Breslow MJ, Badawi O. Severity scoring in the critically ill: part 1—interpretation and accuracy of outcome prediction scoring systems. Chest 2012;141:245-52. Crossref
3. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. Crossref
4. APACHE III study design: analytic plan for evaluation of severity and outcome [editorial]. Crit Care Med 1989;17:S169-221.
5. Zimmerman JE, Kramer AA, McNair DS, Malila FM, Shaffer VL. Intensive care unit length of stay: benchmarking based on Acute Physiology and Chronic Health Evaluation (APACHE) IV. Crit Care Med 2006;34:2517-29. Crossref
6. Zimmerman JE, Kramer AA. Outcome prediction in critical care: the Acute Physiology and Chronic Health Evaluation models. Curr Opin Crit Care 2008;14:491-7. Crossref
7. Tan IK. APACHE II and SAPS II are poorly calibrated in a Hong Kong intensive care unit. Ann Acad Med Singap 1998;27:318-22.
8. Gupta R, Arora VK. Performance evaluation of APACHE II score for an Indian patient with respiratory problems. Indian J Med Res 2004;119:273-82.
9. Choi JW, Park YS, Lee YS, et al. The ability of the Acute Physiology and Chronic Health Evaluation (APACHE) IV score to predict mortality in a single tertiary hospital. Korean J Crit Care Med 2017;32:275-83. Crossref
10. Ghorbani M, Ghaem H, Rezaianzadeh A, Shayan Z, Zand F, Nikandish R. A study on the efficacy of APACHEIV for predicting mortality and length of stay in an intensive care unit in Iran. F1000Res 2017;6:2032. Crossref
11. Ko M, Shim M, Lee SM, Kim Y, Yoon S. Performance of APACHE IV in medical intensive care unit patients: comparisons with APACHE II, SAPS 3, and MPM0 III. Acute Crit Care 2018;33:216-21. Crossref
12. Xie J, Su B, Li C, et al. A review of modeling methods for predicting in-hospital mortality of patients in intensive care unit. J Emerg Crit Care Med 2017;1:18. Crossref
13. Tu JV. Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. J Clin Epidemiol 1996;49:1225-31. Crossref
14. Sargent DJ. Comparison of artificial neural networks with other statistical approaches: results from medical data sets. Cancer 2001;91(8 Suppl):1636-42. Crossref
15. Meiring C, Dixit A, Harris S, et al. Optimal intensive care outcome prediction over time using machine learning. PLoS One 2018;13:e0206862. Crossref
16. Rajkomar A, Oren E, Chen K, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med 2018;1:18. Crossref
17. Norgaard M, Ravn O, Poulsen NK, Hansen LK. Neural Networks for Modelling and Control of Dynamic Systems: A Practitioner’s Handbook. London: Springer; 2000.
18. Ludermir TB, Yamazaki A, Zanchettin C. An optimization methodology for neural network weights and architectures. IEEE Trans Neural Netw 2006;17:1452-9. Crossref
19. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010;21:128-38. Crossref
20. Lam KW, Lai KY. Evaluation of outcome and performance of an intensive care unit in Hong Kong by APACHE IV model: 2007-2014. J Emerg Crit Care Med 2017;1:16. Crossref
21. Paul E, Bailey M, Van Lint A, Pilcher V. Performance of APACHE III over time in Australia and New Zealand: a retrospective cohort study. Anaesth Intensive Care 2012;40:980-94. Crossref
22. Mann SL, Marshall MR, Holt A, Woodford B, Williams AB. Illness severity scoring for intensive care at Middlemore Hospital, New Zealand: past and future. N Z Med J 2010;123:47-65.
23. Lew CC, Wong GJ, Tan CK, Miller M. Performance of the Acute Physiology and Chronic Health Evaluation II (APACHE II) in the prediction of hospital mortality in a mixed ICU in Singapore. Proc Singapore Healthc 2019;28:147-52. Crossref
24. Wong LS, Young JD. A comparison of ICU mortality prediction using the APACHE II scoring system and artificial neural networks. Anaesthesia 1999;54:1048-54. Crossref
25. Nimgaonkar A, Karnad DR, Sudarshan S, Ohno-Machado L, Kohane I. Prediction of mortality in an Indian intensive care unit. Comparison between APACHE II and artificial neural networks. Intensive Care Med 2004;30:248-53. Crossref
26. Ling L, Ho CM, Ng PY, et al. Characteristics and outcomes of patients admitted to adult intensive care units in Hong Kong: a population retrospective cohort study from 2008 to 2018. J Intensive Care 2021;9:2. Crossref
27. Wunsch H, Angus DC, Harrison DA, Linde-Zwirble WT, Rowan KM. Comparison of medical admissions to intensive care units in the United States and United Kingdom. Am J Respir Crit Care Med 2011;183:1666-73. Crossref
28. Holmgren G, Andersson P, Jakobsson A, Frigyesi A. Artificial neural networks improve and simplify intensive care mortality prognostication: a national cohort study of 217,289 first-time intensive care unit admissions. J Intensive Care 2019;7:44. Crossref
29. Kang MW, Kim J, Kim DK, et al. Machine learning algorithm to predict mortality in patients undergoing continuous renal replacement therapy. Crit Care 2020;24:42. Crossref
30. O’Donoghue SD, Dulhunty JM, Bandeshe HK, Senthuran S, Gowardman JR. Acquired hypernatraemia is an independent predictor of mortality in critically ill patients. Anaesthesia 2009;64:514-20. Crossref
31. Olsen MH, Møller M, Romano S, et al. Association between ICU-acquired hypernatremia and in-hospital mortality: data from the medical information mart for intensive care III and the electronic ICU collaborative research database. Crit Care Explor 2020;2:e0304. Crossref
32. Zhai R, Sheu CC, Su L, et al. Serum bilirubin levels on ICU admission are associated with ARDS development and mortality in sepsis. Thorax 2009;64:784-90. Crossref
33. Vallet H, Schwarz GL, Flaatten H, de Lange DW, Guidet B, Dechartres A. Mortality of older patients admitted to an ICU: a systematic review. Crit Care Med 2021;49:324-34. Crossref
34. Clermont G, Angus DC, DiRusso SM, Griffin M, Linde-Zwirble WT. Predicting hospital mortality for patients in the intensive care unit: a comparison of artificial neural networks with logistic regression models. Crit Care Med 2001;29:291-6. Crossref
35. Kim S, Kim W, Park RW. A comparison of intensive care unit mortality prediction models through the use of data mining techniques. Healthc Inform Res 2011;17:232-43. Crossref
36. Bulgarelli L, Deliberato RO, Johnson AE. Prediction on critically ill patients: the role of “big data”. J Crit Care 2020;60:64-8. Crossref

The Omicron variant of COVID-19 and its association with croup in children: a single-centre study in Hong Kong

Hong Kong Med J 2024 Feb;30(1):44–55 | Epub 8 Feb 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
The Omicron variant of COVID-19 and its association with croup in children: a single-centre study in Hong Kong
Michelle CY Lam, MB, ChB, MRCPCH; David SY Lam, MB, BS, FHKAM (Paediatrics)
Department of Paediatrics and Adolescent Medicine, Tuen Mun Hospital, Hong Kong SAR, China
 
Corresponding author: Dr Michelle CY Lam (lcy766@ha.org.hk)
 
 Full paper in PDF
 
Abstract
Introduction: The fifth wave of the coronavirus disease 2019 (COVID-19) pandemic in Hong Kong was dominated by the Omicron variant, which may cause more upper airway involvement in children. This study was performed to identify any associations between the Omicron variant of COVID-19 and croup in children.
 
Methods: This retrospective study reviewed the electronic medical records of patients admitted to Tuen Mun Hospital in Hong Kong from 1 January 2018 to 31 March 2022 under the diagnostic code for croup (J05.0 in the International Classification of Diseases 10th Edition). Patients were categorised into three groups according to their admission periods, namely, non–COVID-19, COVID-19–pre-Omicron, and COVID-19–Omicron groups. Disease associations and severity were compared according to incidence, Westley Croup Score, length of hospital stay, medication use, respiratory support, and intensive care unit admissions.
 
Results: The COVID-19 incidence among patients with croup was significantly higher in the COVID-19–Omicron group than in the COVID-19–pre-Omicron group (90.0% vs 2.0%; P<0.001). Compared with patients in the COVID-19–pre-Omicron and non–COVID-19 groups, patients in the COVID-19–Omicron group also had a higher Westley score (moderate and severe disease in the COVID-19–Omicron group: 56.7%; COVID-19–pre-Omicron group: 22.0%, P=0.004; non–COVID-19 group: 24.8%, P<0.001), longer median hospital stay (COVID-19–Omicron group: 3.00 days; COVID-19–pre-Omicron group: 2.00 days, P<0.001; non–COVID-19 group: 2.00 days, P=0.034), and higher mean dexamethasone requirement (COVID-19–Omicron group: 0.78 mg/kg; COVID-19–pre-Omicron group: 0.49 mg/kg, P<0.001; non–COVID-19 group: 0.58 mg/kg, P=0.001).
 
Conclusion: The Omicron variant of COVID-19 is associated with croup and can cause more severe disease in Hong Kong children.
 
 
New knowledge added by this study
  • The Omicron variant is associated with higher risk of croup than previously circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • The presence of croup in a patient infected with the Omicron variant of SARS-CoV-2 could lead to a more prolonged and severe disease course.
  • Omicron-associated croup may require more doses and a larger total amount of dexamethasone, as well as a longer hospital stay.
Implications for clinical practice or policy
  • Paediatricians should be aware of the potential for prolonged courses of croup during the Omicron era of the coronavirus disease 2019 (COVID-19) pandemic.
  • More healthcare resources may be needed for paediatric patients with croup in the Omicron era of the COVID-19 pandemic.
  • Further research and policies promoting COVID-19 vaccination may be warranted to prevent COVID-19 and associated complications in children.
 
 
Introduction
Coronavirus disease 2019 (COVID-19) was first detected in Wuhan, China on 31 December 2019.1 Since then, COVID-19 has affected adults and children worldwide. On 31 December 2021, the Centre for Health Protection of Hong Kong announced that the fifth wave of the pandemic, also known as the ‘Omicron surge’, had begun.2 There was evidence that the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicated more rapidly and effectively than other strains in bronchial and nasal epithelial cells, resulting in higher infectivity and transmissibility, along with more severe upper respiratory tract manifestations.3 4
 
Croup, or laryngotracheitis, is an upper airway disease that primarily affects children aged 6 months to 3 years. Causative viruses infect the nasopharyngeal epithelium and spread along the respiratory tract up to the laryngotracheal region, leading to upper airway narrowing, inspiratory stridor, barking cough, and hoarseness.5 6 Thus far, parainfluenza viruses have been the most common causative agents of croup.7
 
Compared with other SARS-CoV-2 variants and other respiratory viruses, the new Omicron variant of SARS-CoV-2 may have a stronger association with croup.3 4 Case reports and case series have been published regarding COVID-19–associated croup8 9 10 11 12; however, few studies in Hong Kong or other countries have focused on possible causative relationships between the Omicron variant and croup.8 12 Analyses of epidemiological data from Hong Kong are needed to guide further management of croup in children during the COVID-19 pandemic.
 
By exploring the incidence, clinical characteristics, treatment options, and outcomes of croup before and after the emergence of COVID-19, as well as after the emergence of the Omicron variant, this study aimed to identify differences among these three groups of patients and provide insights concerning COVID-19&dash;associated croup in Hong Kong.
 
Methods
Study design
This retrospective observational study was conducted in the Department of Paediatrics and Adolescent Medicine at Tuen Mun Hospital, a large public hospital serving a population of >1.1 million (15% of the total Hong Kong population),13 among which >15% are children.14 15 Clinical data and medical records were retrieved from the Clinical Data Analysis and Reporting System of the Hospital Authority.
 
Inclusion and grouping criteria
All hospital admissions with a diagnostic code of ‘Croup’ (J05.0 in the International Classification of Diseases 10th Edition) from 1 January 2018 to 31 March 2022 were included in this study. Patients were grouped into the following three admission periods: (1) non&dash;COVID-19 (1 January 2018 to 31 December 2019); (2) COVID-19&dash;pre-Omicron (1 January 2020 to 31 December 2021); and (3) COVID-19&dash;Omicron (1 January 2022 to 31 March 2022). This grouping approach coincided with the World Health Organization’s announcement of the discovery of a novel coronavirus in Wuhan, China on 31 December 20191 and the Centre for Health Protection’s announcement that the fifth wave of the pandemic (also known as the ‘Omicron surge’) had begun in Hong Kong on 31 December 2021.2 The 2-year cohort from 2018 to 2019 (before the World Health Organization’s announcement) was included for comparisons of characteristics before and after the emergence of SARS-CoV-2.
 
Exclusion criteria
The study population was limited to inpatients at Tuen Mun Hospital, excluding individuals solely managed in the Emergency Department. The study also excluded patients with a final diagnosis (eg, foreign body inhalation) that could mimic the clinical presentation of croup.
 
Clinical data and outcome measurements
Baseline clinical characteristics including age, sex, ethnicity, and significant medical history were retrieved from the medical records of the included patients. Diagnoses of COVID-19 were made by laboratory confirmation of viral infection through real-time polymerase chain reaction (RT-PCR) assays of nasopharyngeal specimens. Diagnoses of specific respiratory viruses were also confirmed by RT-PCR assays of patients’ nasopharyngeal specimens. The incidences of all viruses were analysed.
 
The total numbers of admitted patients with confirmed COVID-19 in the COVID-19–pre-Omicron and COVID-19–Omicron groups were retrieved from the Clinical Data Analysis and Reporting System. Among these patients, individuals with a diagnosis of croup were identified to determine the incidence rate of croup in each group.
 
The Westley Croup Score was calculated on the basis of physical findings documented in the retrieved medical records. It evaluates croup severity using five clinical parameters16: (1) level of consciousness (normal=0, disoriented=5); (2) cyanosis (none=0, with agitation=4, at rest=5); (3) stridor (none=0, with agitation=1, at rest=2); (4) air entry (normal=0, mildly decreased=1, substantially decreased=2); and (5) retraction (none=0, mild=1, moderate=2, severe=3). The raw score ranges from 0 to 17; croup can be categorised as mild (score 0-2), moderate (score 3-5), severe (score 6-11), or impending respiratory failure (score ≥12).
 
The following outcome measurements were also assessed:
  1. Length of hospital stay (days);
  2. Dexamethasone use (number of doses and total amount used);
  3. Use of nebulised adrenaline;
  4. Respiratory support (oxygen therapy and high-flow nasal cannula oxygen therapy);
  5. Paediatric intensive care unit admission;
  6. Other associated medical co-morbidities during the same admission (febrile convulsion, wheezing attacks/acute bronchiolitis, gastrointestinal symptoms, pneumonia, poor feeding/dehydration requiring intravenous fluid therapy, or readmission/abnormal blood test results).
 
Multivariate analysis was performed to examine a range of risk factors. Age, sex, ethnicity, history of croup, history of respiratory diseases, and timing of croup diagnosis were included as possible factors affecting croup severity. The Westley score and number of doses of dexamethasone used were selected as outcome measurements for croup severity.
 
History of croup and history of respiratory diseases were included in multivariate analyses because they are known risk factors for severe or recurrent croup.17 18 Patients in the COVID-19–Omicron group were younger; thus, we regarded age as a possible confounding factor. Considering that croup had a male predominance in previous studies, sex was included as a potential risk factor. Ethnicity was included to determine whether the predominately Chinese population in Hong Kong would influence the outcomes compared with findings in previous studies primarily involving Caucasians or Asians.
 
Statistical analysis
The statistical significance of categorical variables was determined using the Pearson Chi squared test or Fisher’s exact test. The Mann-Whitney U test and Kruskal–Wallis test were utilised to identify any statistically significant differences among groups regarding continuous variables (eg, age and length of stay). Multivariate analysis was performed by logistic regression. SPSS software (Windows version 28.0; IBM Corp, Armonk [NY], United States) was used for statistical analysis.
 
The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist was followed when preparing this article.
 
Results
In total, 423 inpatients were diagnosed with croup during the study periods: 343 were diagnosed in the non–COVID-19 period, 50 were diagnosed in the COVID-19–pre-Omicron period, and 30 were diagnosed in the COVID-19–Omicron period.
 
Baseline characteristics
The baseline characteristics for patients in each time period are shown in Table 1. There were no significant differences (P>0.05) across the three groups in terms of sex ratio, ethnicity, history of prematurity, or significant medical history (including histories of croup and/or respiratory, neurodevelopmental, and cardiac diseases). Male sex predominance was observed across all groups (male-to-female ratio in the non–COVID-19 group=1.77; COVID-19–pre-Omicron group=2.33; COVID-19–Omicron group=5; P=0.079). Most patients were Chinese (non–COVID-19 group: 92.4%, COVID-19–pre-Omicron group: 92.0%, COVID-19–Omicron group: 93.3%; P=0.725), born at term (non–COVID-19 group: 90.1%, COVID-19–pre-Omicron group: 94.4%, COVID-19–Omicron group: 100.0%; P=0.223), and had previous good health (non–COVID-19 group: 66.5%, COVID-19–pre-Omicron group: 72.0%, COVID-19–Omicron group: 70.0%; P=0.143).
 

Table 1. Baseline characteristics of patients with croup in the three time periods in the current study
 
Patients in the COVID-19–Omicron group had a median age of 11.0 months (interquartile range [IQR]=11), which was significantly younger than the median ages of patients in the COVID-19–pre-Omicron group (19.5 months, IQR=22) and the non–COVID-19 group (17.0 months, IQR=13) [P=0.008].
 
Incidence
Among patients diagnosed with croup, one (infection rate=2.6%) and 27 (infection rate=90.0%) were SARS-CoV-2–positive in the COVID-19–pre-Omicron and COVID-19–Omicron groups, respectively (Table 2). Patients diagnosed with croup in the COVID-19–Omicron group were more likely to be SARS-CoV-2–positive than patients with such a diagnosis in the COVID-19–pre-Omicron group (P<0.001) [Table 2].
 

Table 2. Incidences of respiratory viruses in patients with croup across the three time periods in the current study
 
Additionally, 386 and 170 paediatric patients (aged 0-18 years) admitted to Tuen Mun Hospital were SARS-CoV-2–positive in the COVID-19–Omicron and COVID-19–pre-Omicron groups, respectively. Among these patients, 27 were diagnosed with croup in the COVID-19–Omicron group and one was diagnosed with croup in the COVID-19–pre-Omicron group; these values indicated that the incidence of croup among patients with COVID-19 was much higher in the COVID-19–Omicron group (rate=7.0%, 95% confidence interval [CI]=4.61%-10.17%; P=0.0019) than in the COVID-19–pre-Omicron group (rate=0.59%, 95% CI=0.015%-3.28%; P=0.0019). Compared with other SARS-CoV-2 variants, the Omicron variant may be more strongly associated with croup.
 
Respiratory virus infection
Before the emergence of Omicron, among patients with croup, there were no differences in the rates of infection by respiratory viruses such as influenza (non–COVID-19 group: n=50, 19.9% vs COVID-19–pre-Omicron group: n=4, 10.3%; P=0.149), respiratory syncytial virus (non–COVID-19 group: n=27, 10.8% vs COVID-19–pre-Omicron group: n=1, 2.6%; P=0.146), and enterovirus/rhinovirus (non–COVID-19 group: n=40, 15.9% vs COVID-19–pre-Omicron group: n=11, 28.2%; P=0.061). Parainfluenza virus was the main respiratory virus detected in both groups (non–COVID-19 group: n=104, 41.4% vs COVID-19–pre-Omicron group: n=19, 48.7%; P=0.392). There was also no difference in the co-infection rate in the two groups (≥2 other respiratory viruses detected) [non–COVID-19 group: n=32, 12.7% vs COVID-19–pre-Omicron group: n=2, 5.1%; P=0.281] (Table 2).
 
However, after the emergence of Omicron, the SARS-CoV-2 Omicron variant became the main respiratory virus among patients with croup (co-infection in the COVID-19–Omicron group: n=0, vs non–COVID-19 group: n=32, rate=12.7%; P=0.033).
 
Because the respiratory viruses infecting patients with croup were similar between the COVID-19–pre-Omicron and non–COVID-19 groups, a pooled analysis was performed by grouping patients with croup in the two groups and compared with patients in the COVID-19–Omicron group. The results revealed that patients with croup in the COVID-19–Omicron group had significantly lower rates of infection with parainfluenza (COVID-19–Omicron group: n=2, 6.7% vs pre-Omicron group [non–COVID-19 group and COVID-19–pre-Omicron group]: n=123, 42.4%; P<0.001), influenza (COVID-19–Omicron group: n=0 vs pre-Omicron group: n=54, 18.6%; P=0.011), and enterovirus/rhinovirus (COVID-19–Omicron group: n=0 vs pre-Omicron group: n=51, 17.6%; P=0.007). There was no difference in the rate of infection with respiratory syncytial virus (COVID-19–Omicron group: n=1, 3.3% vs pre-Omicron group: n=28, 9.7%; P=0.499) between the time before and after the emergence of Omicron. The rates of infection with individual viruses are shown in Table 2.
 
Westley Croup Score
In the COVID-19–Omicron group, significantly more patients with croup had moderate disease (50.0%) or severe disease (6.7%) according to the Westley score, compared with the non–COVID-19 (moderate disease: 23.9%; severe disease: 0.9%; P<0.001) and COVID-19–pre-Omicron groups (moderate disease: 22.0%; severe disease: 0%; P=0.004). The distribution of severity, according to the Westley score, was similar between the non–COVID-19 and COVID-19–pre-Omicron groups (P=0.780) [Table 3].
 

Table 3. Westley Croup Score in patients with croup across the three time periods in the current study
 
Length of hospital stay
Because causative agents were similar between the non–COVID-19 and COVID-19–pre-Omicron groups, they were grouped together for analysis again and compared with the COVID-19–Omicron group. Patients with croup had a significantly longer hospital stay in the COVID-19–Omicron group (mean=3.63 days, median=3.00, IQR=2) than the pre-Omicron group (mean=2.67 days, median=2.00, IQR=3; P=0.016). This finding indicated that patients with croup who were infected with the Omicron variant of SARS-CoV-2 required longer hospitalisation, implying that such patients had more severe disease than patients infected with other viruses in the pre-Omicron period.
 
Management strategies and outcomes
Table 4 illustrates treatments and management outcomes during the study periods.
 

Table 4. Management strategies in patients with croup across the three time periods in the current study
 
Dexamethasone use
Most patients required zero to one dose of dexamethasone (COVID-19–Omicron group: 66.7%; non–COVID-19 group: 87.5%; COVID-19–pre-Omicron group: 90.0%; P=0.020). Significantly more patients required ≥2 doses in the COVID-19–Omicron group than in the non–COVID-19 (33.3% vs 12.5%; P=0.005) and COVID-19–pre-Omicron groups (33.3% vs 10.0%; P=0.010). A need for repeated doses of dexamethasone indicated more severe disease, considering that guidelines recommend ≥2 doses of dexamethasone for patients with croup who display suboptimal clinical improvement.5 6 19 20 The difference remained statistically significant when the total amount of dexamethasone given was normalised according to the body weight of the patient; patients in the COVID-19–Omicron group required a larger total amount of dexamethasone (mean=0.78 mg/kg) compared with patients in the other two groups (mean of the non–COVID-19 group=0.58 mg/kg, P=0.001; mean of the COVID-19–pre-Omicron group: 0.49 mg/kg, P<0.001).
 
Nebulised adrenaline use
Nebulised adrenaline is often administered to patients with severe croup.5 6 19 20 Most patients in the study did not require nebulised adrenaline. During the non–COVID-19 period, 1.5% of patients (n=5) were given one dose, 0.9% (n=3) were given two doses, and 0.3% (n=1) were given three doses; in the COVID-19–Omicron and COVID-19–pre-Omicron groups, only 6.7% (n=2) and 2.0% (n=1) of the patients, respectively, were given a single dose. No patients in the COVID-19–Omicron and COVID-19–pre-Omicron groups required more than one dose. Overall, there was no significant difference in the need for nebulised adrenaline (P=0.551).
 
Respiratory support
Overall, 6.4% (n=22) of patients admitted in the non–COVID-19 period required oxygen therapy, whereas 2.0% (n=1) required oxygen in the COVID-19–pre-Omicron period and 13.3% (n=4) required oxygen in the COVID-19–Omicron period. Although the oxygen requirement tended to be higher in the COVID-19–Omicron group than in the other two groups, this difference was not statistically significant (P=0.134).
 
Respiratory support also included the use of humidified high-flow oxygen. No patients required intubation or other forms of mechanical ventilation. Humidified high-flow oxygen was required by 1.2% (n=4) of patients in the non–COVID-19 period, 6.7% (n=2) in the COVID-19–Omicron period, and 0% in the COVID-19–pre-Omicron period. There were no differences among the groups concerning humidified high-flow oxygen use (Table 4).
 
Paediatric intensive care unit admissions
In total, 2.9% (n=10), 2.0% (n=1), and 6.7% (n=2) of patients required paediatric intensive care unit admission while hospitalised among the non–COVID-19, COVID-19–pre-Omicron, and COVID-19–Omicron groups, respectively; there was no significant difference across the three groups (P=0.467) [Table 4].
 
Other co-morbidities
Patients with croup had a higher overall incidence of co-morbidities in the COVID-19–Omicron group (46.7%, n=14) than in the non–COVID-19 (25.4%, n=87) and COVID-19–pre-Omicron groups (30.0%, n=15) [Table 5]. Patients with croup had a significantly higher incidence of new co-morbidities in the COVID-19–Omicron group than in the non–COVID-19 group, with an odds ratio (OR) of 2.575 (95% CI=1.207-5.491; P=0.012); this incidence did not differ between the COVID-19–pre-Omicron and non–COVID-19 groups (OR=1.427, 95% CI=0.749-2.718; P=0.278).
 

Table 5. Specific co-morbidities in patients with croup across the three time periods in the current study
 
With respect to specific co-morbidities (Table 5), there were no significant differences in the rates of febrile convulsion, pneumonia, intravenous fluid therapy requirement, readmission, or abnormal blood test results. However, significantly more patients in the COVID-19–Omicron group had gastrointestinal symptoms compared with patients in the other groups. Thus, the Omicron variant was associated with more concomitant gastrointestinal manifestations among patients with croup compared with such patients in the non–COVID-19 (OR=9.250, 95% CI=3.039-28.151; P<0.001) and COVID-19–pre-Omicron groups (OR=3.086, 95% CI=2.217-4.292; P=0.002).
 
Importantly, no patients with croup in the COVID-19–Omicron group had concomitant wheezing attacks or bronchiolitis (n=0), compared with a rate of approximately 1 in 10 during the other two groups (non–COVID-19: n=42, 12.2%; COVID-19–pre-Omicron: n=5, 10.0%). However, the overall difference was not statistically significant (P=0.119) [Table 5].
 
Risk factors
The results in Table 6 indicate that differences in age (P=0.619), sex (P=0.588), ethnicity (P=0.090), history of croup (P=0.501), and history of respiratory diseases (P=0.253) did not affect the risk of greater croup severity. The timing of croup diagnosis was a significant risk factor for greater croup severity. After adjustment for the other factors, the OR for greater croup severity in the COVID-19–Omicron group was 3.94 (95% CI=1.79-8.62; P<0.001) compared with the non–COVID-19 group. Comparison of the COVID-19–Omicron and COVID-19–pre-Omicron groups revealed an OR of 4.46 (95% CI=1.63-12.20; P=0.004) [Table 5].
 

Table 6. Multivariate analysis of factors affecting croup severity by logistic regression
 
The results were consistent when the number of doses of dexamethasone was regarded as the analysis outcome. Patients diagnosed with croup in the COVID-19–Omicron group had an increased risk of greater croup severity. The OR for requiring ≥2 doses of dexamethasone in the COVID-19–Omicron group, compared with the non-COVID group, was 3.02 (95% CI=1.26-7.25; P=0.013). Comparison of the COVID-19–Omicron and COVID-19–pre-Omicron groups showed an OR of 3.66 (95% CI=1.07-12.50; P=0.039) [Table 5].
 
Discussion
Link between the Omicron variant and croup
Our results showed that SARS-CoV-2 became the predominant virus in patients with croup after emergence of the Omicron variant, surpassing parainfluenza virus, which was previously considered the most common viral cause of croup.7 This contrasts with the COVID-19–pre-Omicron group, during which there were no differences in the rates of detected respiratory viruses compared with the non–COVID-19 group. Thus, the Omicron variant was associated with a higher risk of croup, compared with other SARS-CoV-2 variants.
 
Additionally, among patients admitted for treatment of COVID-19, the incidence of croup was significantly higher in the COVID-19–Omicron group than in the COVID-19–pre-Omicron group, indicating that the Omicron variant was associated with a higher risk of croup, compared with other SARS-CoV-2 variants. This finding is consistent with previous reports that the Omicron variant preferentially replicates in the upper respiratory tract,3 4 which differs from observations concerning other variants.
 
The lower co-infection rate during the COVID-19–Omicron period (0%), compared with the non–COVID-19 period (12.7%), could be attributed to the greater replication capacity and infectivity of the Omicron variant of SARS-CoV-2. Another possible explanation for the lower co-infection rate and the shift in predominant respiratory virus from parainfluenza to the Omicron variant of SARS-CoV-2 could have been the implementation of social distancing policies outlined in the Prevention and Control of Disease Ordinance [Cap 599 (F, G, I) of the Laws of Hong Kong]21 22 23 and school suspension24 25 26 27 28 29 in Hong Kong, which may have effectively reduced the transmission of upper respiratory tract infections. These effects were revealed through the reduction in the total number of patients with croup admitted during the 2-year interval since the emergence of COVID-19 in 2020. In the COVID-19–pre-Omicron period, only 50 patients were admitted for croup, compared with 343 during the non–COVID-19 period.
 
Increased croup severity in patients with the Omicron variant
The present study revealed the Omicron variant is causing greater croup severity compared with other variants and respiratory viruses, in terms of a significantly higher Westley score, longer hospitalisation, greater requirement for dexamethasone, and more concomitant gastrointestinal manifestations. Multivariate analysis also showed that patients in the COVID-19–Omicron group, when the Omicron variant of SARS-CoV-2 was the predominant virus, were more likely to develop severe disease.
 
The decrease in the number of patients with concomitant wheezing attacks or bronchiolitis could be attributed to a lower viral load in the lower respiratory tract (relative to the upper respiratory tract), as observed in hamsters,19 30 along with the greater infectivity of the Omicron variant in nasal epithelial cells.3 4 Considering that wheezing attacks and bronchiolitis mainly affect small airways in the lower tract, these findings may explain the lower risks of such co-morbidities in patients with croup who exhibit the Omicron variant of COVID-19.
 
Regarding the length of stay, confounding factors such as quarantine policies, parental anxiety about hospitalisation, and various discharge criteria based on physician preferences could affect the observed correlation with disease severity.
 
During the ‘Omicron surge’, hospital discharge criteria were revised to allow early discharge for clinically stable patients without repeated RT-PCR testing; conversely, in the COVID-19–pre-Omicron group, negative RT-PCR results (or RT-PCR results with certain cycle threshold values) were required prior to discharge.31 32 33 A longer length of stay in patients with croup during the COVID-19–Omicron period despite these relaxed discharge criteria indicates that croup severity was greater in the COVID-19–Omicron period, although other co-morbidities in patients with COVID-19 may also have contributed to the increased length of hospital stay.
 
The potentially greater severity of croup in patients with the Omicron variant of COVID-19 and the diverse range of co-morbidities in such patients had considerable impacts on patient health, caregiver stress, and the public health burden. More healthcare resources, such as in-hospital backup nebulising facilities, may be required during the Omicron-dominant era. The results of the present study will enable paediatricians to be more vigilant and predict a possibly longer disease course, along with the need for repeated dexamethasone administration or enhanced treatment, in patients with COVID-19&dash;Omicron–associated croup.
 
Limitations
There were several limitations in this study. First, it was a single-centre study, limiting its ability to represent the overall population; thus, a more extensive study should be performed in the future.
 
Second, there was no unified treatment protocol for croup in our hospital. Exact medication dosing and timing (eg, concerning addition or repetition) were largely based on clinical decisions by multiple physicians, which may have considerably varied although all administered oral dexamethasone as first-line medication; repeated doses were given as needed, and nebulised adrenaline was reserved for patients with more severe disease.5 6 19 20 These factors could have affected the assessments of severity across study periods by modifying the doses of medication administered.
 
Third, measurement of the Westley score could have been under- or overestimated because it was based on clinical records, where data may have been omitted by attending physicians. These missing data could affect measurements of croup severity across study periods.
 
Finally, patients with croup admitted during the Omicron period (median age=11.0 months) were younger than such patients in previous periods (COVID-19–pre-Omicron group: 19.5 months; non–COVID-19 group: 17.0 months). Possible explanations include the greater transmissibility of the Omicron variant in younger populations compared with other variants34 and the lack of eligibility for SARS-CoV-2 vaccination among patients aged <3 years.35 Thus, overall protection could be compromised in the younger age-group. Other possible confounding factors, such as family history of croup and parental smoking habits, could not be assessed in this study because the data were not available in clinical records.
 
Future directions
This study focusing on croup and its associations with COVID-19 among Hong Kong children provides important insights that can help guide management of the Omicron variant. However, additional population-based studies involving patients from various centres in Hong Kong are needed to achieve a sample size that can facilitate the development of management protocols specifically targeting Omicron-associated croup. In the future, prospective studies could be performed to analyse the long-term outcomes of such patients, thereby facilitating the planning and allocation of healthcare resources in Hong Kong.
 
Conclusion
This retrospective study demonstrated that the Omicron variant of COVID-19 is associated with croup in children; on admission, croup severity was greater compared with past observations of disease.
 
Author contributions
Concept or design: MCY Lam.
Acquisition of data: MCY Lam.
Analysis or interpretation of data: Both authors.
Drafting of the manuscript: MCY Lam.
Critical revision of the manuscript for important intellectual content: DSY Lam.
 
Both authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
Both authors have disclosed no conflicts of interest.
 
Acknowledgement
The authors thank Mr Jaden Lam, Statistical Officer, Quality and Safety Division, New Territories West Cluster for statistical analysis support.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
This research was approved by the New Territories West Cluster Research Ethics Committee of Hospital Authority, Hong Kong (Ref No.: NTWC/REC/22030). Informed patient consent waiver was granted by the Committee due to the retrospective nature of the study.
 
References
1. World Health Organization. Pneumonia of unknown cause—China. 2020 Jan 5. Available form: https://www.who.int/emergencies/disease-outbreak-news/item/2020-DON229. Accessed 29 Jun 2022.
2. The Government of the Hong Kong Special Administrative Region. Archive of statistics on 5th wave of COVID-19. Available from: https://www.coronavirus.gov.hk/eng/5th-wave-statistics.html. Accessed 2 Feb 2024.
3. Hui KP, Ho JC, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 2022;603:715-20. Crossref
4. Peacock TP, Brown JC, Zhou J, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv [pre-print] 2021.12.31.474653. Available from: https://www.biorxiv.org/content/10.1101/2021.12.31.474653v1. Accessed 29 Jun 2022.
5. Cherry JD. Clinical practice. Croup. N Engl J Med 2008;358:384-91. Crossref
6. Sizar O, Carr B. Croup. StatPearls [Internet]. 2023 July Available from: https://www.ncbi.nlm.nih.gov/books/NBK431070/. Accessed 24 July 2023.
7. Rihkanen H, Rönkkö E, Nieminen T, et al. Respiratory viruses in laryngeal croup of young children. J Pediatr 2008;152:661-5. Crossref
8. Murata Y, Tomari K, Matsuoka T. Children with croup and SARS-CoV-2 infection during the large outbreak of Omicron. Pediatr Infect Dis J 2022;41:e249. Crossref
9. Brewster RC, Parsons C, Laird-Gion J, et al. COVID-19–associated croup in children. Pediatrics 2022;149:e2022056492. Crossref
10. Tsoi K, Chan KC, Chan L, Mok G, Li AM, Lam HS. A child with SARS-CoV2–induced croup. Pediatr Pulmonol 2021;56:2377-8. Crossref
11. Venn AM, Schmidt JM, Mullan PC. Pediatric croup with COVID-19. Am J Emerg Med 2021;43:287.e1-3. Crossref
12. Tunç EM, Koid Jia Shin C, Usoro E, et al. Croup during the coronavirus disease 2019 Omicron variant surge. J Pediatr 2022;247:147-9. Crossref
13. Census and Statistics Department, Hong Kong SAR Government. Population and household statistics analysed by District Council District. 2020. Available from: https://www.statistics.gov.hk/pub/B11303012020AN20B0100.pdf. Accessed 29 Jun 2022.
14. Social Welfare Department, Hong Kong SAR Government. Population profile of Tuen Mun District. Available from: https://www.swd.gov.hk/en/pubsvc/district/tuenmun/districtpr/tmpp/ Accessed 18 Jan 2024.
15. Social Welfare Department, Hong Kong SAR Government. Population profile of Yuen Long District. Available from https://www.swd.gov.hk/en/pubsvc/district/yuenlong/districtpr/ylpp/. Accessed 18 Jan 2024.
16. Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978;132:484-7. Crossref
17. Bensoussan N, Nguyen L, Oosenbrug M, He H, Duval M. Characterization and risk factor identification in children with severe croup. Paediatr Child Health 2018;23(suppl 1):e52-3. Crossref
18. Pruikkonen H, Dunder T, Renko M, Pokka T, Uhari M. Risk factors for croup in children with recurrent respiratory infections: a case-control study. Pediatr Perinat Epidemiol 2009;23:153-9. Crossref
19. Smith DK, McDermott AJ, Sullivan JF. Croup: diagnosis and management. Am Fam Physician 2018;97:575-80.
20. Bjornson CL, Johnson DW. Croup in children. CMAJ 2013;185:1317-23. Crossref
21. Hong Kong SAR Government. Prevention and Control of Disease (Requirements and Directions) (Business and Premises) Regulation (Cap 599 sub. leg. F). Available from: https://www.elegislation.gov.hk/hk/cap599F. Accessed 29 Jun 2022.
22. Hong Kong SAR Government. Prevention and Control of Disease (Prohibition on Gathering) Regulation (Cap 599 sub. leg. G). Available from: https://www.elegislation.gov.hk/hk/cap599G. Accessed 29 Jun 2022.
23. Hong Kong SAR Government. Prevention and Control of Disease (Wearing of Mask) Regulation (Cap 599 sub. leg. I). Available from: https://www.elegislation.gov.hk/hk/cap599I. Accessed 29 Jun 2022.
24. Education Bureau, Hong Kong SAR Government. Arrangements on deferral of class resumption for all schools. 2020 Jan 31. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20200131_eng.pdf. Accessed 29 Jun 2022.
25. Education Bureau, Hong Kong SAR Government. Arrangements of early commencement of summer holiday for all schools. 2020 Jul 10. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20200710_eng.pdf. Accessed 29 Jun 2022.
26. Education Bureau, Hong Kong SAR Government. Continuation of suspension of face-to-face classes for schools in Hong Kong: the arrangements. 2021 Jan 4. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20210104_eng.pdf. Accessed 29 Jun 2022.
27. Education Bureau, Hong Kong SAR Government. Face-to-face class arrangements for schools in Hong Kong in the 2021/22 school year. 2021 Aug 2. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20210802_eng.pdf. Accessed 29 Jun 2022.
28. Education Bureau, Hong Kong SAR Government. Suspension of face-to-face classes of primary schools, kindergartens and kindergarten-cum-child care centres until Chinese New Year. 2022 Jan 11. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20220111_eng.pdf. Accessed 29 Jun 2022.
29. Education Bureau, Hong Kong SAR Government. Arrangement of special vacation in 2021/22 school year. 2022 Feb 28. Available from: https://www.edb.gov.hk/attachment/en/sch-admin/admin/about-sch/diseases-prevention/edb_20220228_eng.pdf. Accessed 29 Jun 2022
30. McMahan K, Giffin V, Tostanoski LH, et al. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. Med 2022;3:262-8.e4. Crossref
31. Hong Kong SAR Government. Government announces latest criteria for discharge from isolation and home quarantine. Available from: https://www.info.gov.hk/gia/general/202202/26/P2022022600750.htm. Accessed 26 Feb 2022.
32. Centre for Health Protection, Hong Kong SAR Government. Updated consensus recommendations on criteria for releasing confirmed COVID-19 patients from isolation (as of 4 August 2021). 2021. Available from: https://www.chp.gov.hk/files/pdf/updated_consensus_recommendations_on_criteria_for_releasing_confirmed_covid19_patients_from_isolation_4_august2021r.pdf. Accessed 4 Aug 2021.
33. Centre for Health Protection, Hong Kong SAR Government. Updated consensus recommendations on criteria for releasing confirmed COVID-19 patients from isolation (July 29, 2020). 2020. Available from: https://www.chp.gov.hk/files/pdf/updated_consensus_recommendations_on_criteria_for_releasing_confirmed_covid19_patients_from_isolation29july2020.pdf. Accessed 29 Jul 2020.
34. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US. JAMA Pediatr 2022;176:811-3. Crossref
35. Centre for Health Protection, Hong Kong SAR Government. COVID-19 Vaccine Programme. Available from: https://www.chp.gov.hk/en/features/106934.html. Accessed 18 Jan 2024.

Dietary habits and physical activity during the third wave of the COVID-19 pandemic: associated factors, composite outcomes in a cross-sectional telephone survey of a Chinese population, and trend analysis

Hong Kong Med J 2024 Feb;30(1):33–43 | Epub 19 Feb 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Dietary habits and physical activity during the third wave of the COVID-19 pandemic: associated factors, composite outcomes in a cross-sectional telephone survey of a Chinese population, and trend analysis
Winnie YY Lin, MS, RDN1,2; Martin CS Wong, MD, MPH3; Junjie Huang, MD, MSc3; Yijun Bai, MPH3; Siew C Ng, MB, BS, PhD1,2,4; Francis KL Chan, DSc, MD2,5
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China
2 Microbiota Innovation Center, Hong Kong SAR, China
3 The Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
4 State Key Laboratory of Digestive Disease and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China
5 Centre for Gut Microbiota Research, The Chinese University of Hong Kong, Hong Kong SAR, China
 
Corresponding author: Ms Winnie YY Lin (winnielin@cuhk.edu.hk)
 
 Full paper in PDF
 
Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic created many challenges for Hong Kong residents attempting to maintain healthy lifestyle habits. This study aimed to measure the prevalences of unhealthy dietary habits and physical inactivity levels in Hong Kong Chinese, identify associated factors, and conduct a time trend analysis during the third wave of the COVID-19 pandemic.
 
Methods: A cross-sectional telephone survey was conducted in Hong Kong by simple random sampling. The survey comprised socio-demographic characteristics, clinical information, the Hong Kong Diet Score (HKDS), smoking and alcohol consumption, and a Chinese version of the International Physical Activity Questionnaire Short Form. The composite outcome was low HKDS, physical inactivity, smoking, and alcohol consumption. We used 14 Health Behaviour Survey reports from 2003 to 2019 to establish a trend analysis regarding fruit and vegetable consumption, physical activity level, smoking, and alcohol consumption.
 
Results: We performed 1500 complete telephone surveys with a response rate of 58.8%. Most participants were older adults (≥65 years, 66.7%), women (65.6%), and married (77.9%). The HKDS was significantly lower in men, single individuals, low-income participants, alcohol drinkers, and patients with diabetes mellitus or renal disease. Participants who were single, undergoing long-term management of medical diseases, or had diabetes or renal diseases exhibited greater likelihood of physical inactivity.
 
Conclusion: Prevalences of unhealthy lifestyle habits were high among men, single individuals, and chronic disease patients during the third wave of the COVID-19 pandemic in Hong Kong. The adoption of physical activity habits tended to decrease in the past two decades.
 
 
New knowledge added by this study
  • This population-based survey indicated that a larger proportion of Hong Kong residents, compared with pre-pandemic years, had a non-healthy lifestyle during the third wave of the coronavirus disease 2019 pandemic.
  • Majority of participants had a low Hong Kond Diet Score, suggesting minimal adherence to the traditional Chinese eating pattern; these participants were mainly younger individuals and men.
Implications for clinical practice or policy
  • There is an urgent need to formulate and implement effective public health strategies at both individual and organisational levels. The encouragement of healthy lifestyles through evidence-based health promotion programmes is essential, which could be conveyed to communities through organised and concerted efforts by the government and relevant stakeholders.
  • Future studies should evaluate the effectiveness of various interventions and approaches to achieve these important goals.
 
 
Introduction
The coronavirus disease 2019 (COVID-19) pandemic has affected >770 million people worldwide, causing >7 million deaths as of 31 December 2023.1 The period between July and September 2020 constituted the third wave of the pandemic in Hong Kong, resulted in >1.2 million reported cases between 23 January 2020 and 29 January 2023.2 The containment strategies implemented during the third wave included mandatory mask wear in public places, even when exercising in public outdoor areas; suspensions of public leisure facilities and private gyms; and the initiation of work-from-home arrangements.3 These strategies led to reductions in physical activity and daily movement, with the goal of viral containment. Furthermore, compulsory social distancing and suspension of dine-in services were included among the policies that could affect various dietary and lifestyle habits, although these methods were less stringent than approaches in cities under lockdown. Overall, the unprecedented public health crisis created many challenges for Hong Kong residents attempting to maintain healthy lifestyle habits. Nevertheless, few studies have examined dietary and physical activity habits in the general population during the COVID-19 pandemic.4 5 6
 
Considering that individuals with chronic diseases are more likely to develop severe cases of COVID-19, this study aimed to measure the prevalences of unhealthy dietary habits and physical inactivity levels in an adult Chinese population, to identify factors associated with their adoption of these dietary and physical activity habits, and to perform a time trend analysis comparing the proportions of the population that adopted healthy dietary habits, physical activity levels, and avoidance of smoking and alcohol consumption during the third wave of the COVID-19 pandemic.
 
Methods
Sampling
We utilised a methodology similar to a previous population-based, random telephone survey conducted in Hong Kong.7 Two-stage sampling was performed, in which participants were recruited by trained interviewers through a telephone interview system based on telephone calls to landlines identified by random digit dialling. The sample population was randomly selected by the Centre for Health Behaviours Research at The Chinese University of Hong Kong. Calls were made during typical office hours, 9 am to 5 pm, Monday through Saturday between 7 and 31 October 2020. Three attempts were made if the call initially was not answered. Territory-wide, any Chinese adults aged ≥18 years who could communicate in Chinese via telephone were eligible to participate. Assuming an outcome variable rate of 35%, at least 1456 participants were required to achieve a precision level of 2.5% from the following formula:
 
where ‘p’ stands for proportion and ‘N’ stands for sample size.
 
The interviews were performed using a fieldwork manual highlighting standard operating procedures by a team of trained interviewers and supervised by an experienced project coordinator throughout the study. The characteristics of survey participants are shown in Table 1.
 

Table 1. Participant characteristics (n=1500)
 
Survey instrument
The survey consisted of five sections: (1) socio-demographic details (age, sex, marital status, education level, job status, household income, and receipt of comprehensive social security assistance); (2) clinical information (eg, presence of chronic diseases); (3) smoking (current daily amount/ex-/non-smoker) and alcohol consumption habits (daily amount in the preceding 7 days); (4) dietary screening via the Hong Kong Diet Score (HKDS), using a validated scale that contained nine items assessing the participant’s daily consumption of nine food groups in the preceding 7 days; and (5) level of physical activity in the preceding 7 days, as determined by a Chinese version of the 7-item International Physical Activity Questionnaire Short Form (IPAQ-C).
 
Scoring of the Hong Kong Diet Score, International Physical Activity Questionnaire, and unhealthy lifestyle score
The traditional Mediterranean diet is well-defined and has been positively associated with favourable health outcomes.8 9 10 The Mediterranean diet score is used to measure compliance with a traditional Mediterranean diet. This scoring system has been widely utilised in studies that measure Mediterranean diet adherence or adaptation as an indicator of healthy dietary choices. In this study, we developed the HKDS, a dietary screener that contained nine items assessing dietary intake of nine food groups (alcohol, legumes, grains, fruits, vegetables, meats, dairy, red/orange vegetables, and fatty fish) in the preceding 7 days. The screener incorporated key traditional Greek diet characteristics, known as the Mediterranean diet score of de Groot et al,8 which were also used in a study of Hong Kong Chinese by Woo et al (Table 2).11 The original 8-item survey was modified by removing the ratio of monounsaturated fatty acids to saturated fatty acids and replacing ethanol with alcohol. Dietary fatty acids and ethanol are widely distributed among various food groups; they are typically assessed through weighted foods, which are unlikely to be accurately determined using a single question in a telephone interview. Two additional items were included regarding carotenoid-rich and omega-3–rich food intake based on the Hong Kong Centre for Food Safety Recommended Nutrient Intake for vitamin A12 and the World Health Organization recommendation for omega-3. Both nutrients are inversely associated with incidence of non-communicable diseases (NCDs). For each item, consumption at or above the recommended amount was scored as 1 point and 0 points otherwise; however, for ethanol, consumption below the specified amount was scored as 1 point and 0 points otherwise. Each participant received a total score of 0 to 9; a score of ≥5 was considered high. A pilot survey was conducted with a convenience sample of 23 participants. Intraclass correlation coefficient estimates and 95% confidence intervals (CIs) were determined using a two-way mixed-effects model to assess internal consistency regarding the number of serves (ie, serving sizes of the food group consumed) reported. The intraclass correlation coefficient was 0.87, indicating good reliability. Cohen’s κ was calculated to evaluate agreement between test and retest scores. Agreement between the two tests was fair (κ=0.24, 95% CI=-0.15 to 0.63; P=0.239).
 

Table 2. Prevalence of low dietary scores according to participant characteristics
 
The IPAQ-C score was regarded as a categorical variable indicating exercise level based on the frequency and intensity of physical activity: (1) low (total activity <600 metabolic equivalent of task [MET]–minutes/week), (2) moderate (total activity ≥600 MET-minutes/week), or (3) high (total activity >3000 MET-minutes/week).
 
Finally, an unhealthy lifestyle score (0 to 4) was assigned to each participant based on a composite outcome involving low HKDS, physical inactivity, current smoking habit, and alcohol consumption; each unhealthy habit contributed 1 point to the score.
 
Data analysis
We used SPSS software (Windows version 26.0; IBM Corp, Armonk [NY], United States) for data analysis. Descriptive analyses were performed regarding the participants’ socio-demographic details, clinical information (eg, presence of chronic diseases), and the HKDS. The primary outcome variables included: (1) unhealthy dietary habits (low HKDS score); (2) suboptimal physical activity (low IPAQ-C score, indicating low exercise level); and (3) unhealthy lifestyle score (≥2). Univariable logistic regression was performed to examine associations between socio-demographic variables and each of the first two outcome variables. Multivariable logistic regression was modelled by controlling for covariates with P values <0.20 in univariable regression analysis, a cut-off level commonly used in public health research. For example, Torenfält and Dimberg13 utilised this approach when evaluating stroke and death in middle-aged Swedish men. The approach was also used in a French study14 concerning medical features of patients with COVID-19 and influenza. Additionally, linear regression analysis was conducted in the present study to examine associations between socio-demographic variables and the unhealthy lifestyle score. Time trends for various food intake, physical inactivity, current smoking, and alcohol consumption statuses were evaluated; the prevalences of these lifestyle habits were compared with population-wide figures from governmental reports over the past two decades using the Chi squared test for heterogeneity. P values <0.05 were considered statistically significant.
 
Data sources for time trend comparisons
The Centre for Health Protection has been conducting health surveys periodically since 2003 to collect information about health and lifestyle-related behaviours, as well as practices related to the prevention of NCDs among residents aged ≥15 years.15 The resulting reports have presented key findings concerning physical activity, dietary habits, alcohol consumption, and smoking habits, as well as other self-care practices. We gathered relevant findings from 14 governmental reports covering the period from 2003-2004 to 2018-2019 (calendar years with the most updated figures)15 to perform trend analysis of fruit and vegetable consumption, physical activity level, smoking, and alcohol consumption status among Hong Kong residents. These results were compared with the findings of the present study; adjustments were solely performed for sex because the age distribution was limited in all but the most recent reports.
 
Results
In total, 2551 individuals were contacted for a telephone interview and 1500 participated; the response rate was 58.8%. Most interviewed individuals were older adults (≥65 years, 66.7%), women (65.6%), and married (77.9%). Of the participants, 40.1% were engaged in professional and office work; only 16.3% had attained a tertiary education or higher. About 16% of participants reported a household income ≥HK$30 000, whereas 41.1% reported a household income <HK$10 000. Health status was predominately self-reported as average (42.5%) or above average (51.6%). More than half of the participants (54.5%) were undergoing long-term medical management or were taking medications for chronic diseases; the most common chronic conditions were diabetes mellitus (21.0%) and hypertension (42.7%) [Table 1].
 
Prevalence of low dietary score among Hong Kong Chinese
Dietary habits, as measured by the HKDS (score range, 2-9), were classified as high scoring (5-9) or low scoring (0-4). Approximately 51% of participants had a low score (Table 1), suggesting minimal adherence to the traditional Chinese eating pattern; these participants were mainly younger individuals (aged ≤34 years, 66%) and men (58%) [Table 2]. Greater proportions of participants with lower income, current smokers, and current drinkers had low scores according to the HKDS (54%, 69%, and 67%, respectively) [Table 2]. Participants with chronic diseases had various HKDS results; <50% of patients with renal diseases and diabetes had a high score, and this result indicated that they had a poor dietary habits.
 
Dietary habits and physical activity
A greater risk of practising unhealthy dietary habits (low HKDS) was associated with male sex (adjusted odds ratio [aOR]=1.31, 95% CI=1.03-1.67), non-married status (ie, single/divorced/widowed) [aOR=1.56, 95% CI=1.20-2.03], a diagnosis of diabetes (aOR=1.53, 95% CI=1.15-2.03), and alcohol consumption (aOR=1.76, 95% CI=1.17-2.64) [Table 3].
 

Table 3. Factors associated with unhealthy dietary habits (HKDS <5) among telephone-surveyed participants (n=766)
 
Among all participants, 35.5%, 54.0% and 10.5% had low, moderate, and high levels of physical activity, respectively (Table 1). Participants who were non-married (aOR=1.66, 95% CI=1.23-2.22), undergoing long-term management of medical diseases (aOR=1.65, 95% CI=1.08-2.54), had diabetes (aOR=1.39, 95% CI=1.02 to 1.89), and had renal diseases (aOR=9.32, 95% CI=2.06-42.25) exhibited greater likelihood of physical inactivity (Table 4).
 

Table 4. Factors associated with physical inactivity among telephone-surveyed participants (n=532)
 
Other lifestyle habits: smoking and alcohol
Few participants were current daily smokers (2.8%) and alcohol drinkers (8.5%) [Table 1].
 
Factors associated with higher risk of an unhealthy lifestyle score
Factors associated with an unhealthy lifestyle score are presented in Table 5. Male sex (beta coefficient [β]=0.25, 95% CI=0.16-0.34), non-married status (β=0.19, 95% CI=0.08-0.29), manual work (β=0.17, 95% CI=0.07-0.27), self-reported poor or very poor health status (β=0.26, 95% CI=0.07-0.45), a diagnosis of diabetes (β=0.31, 95% CI=0.20-0.41), and a diagnosis of renal disease (β=0.92, 95% CI=0.53-1.31) increased the likelihood of poor lifestyle habits. Housewife or retired status (β=-0.15, 95% CI=-0.25 to -0.04) and a higher household income (≥HK$30 000; β=-0.20, 95% CI=-0.33 to -0.08) decreased the likelihood of poor lifestyle habits.
 

Table 5. Factors associated with higher risk of unhealthy lifestyle score
 
Time trend analysis of fruit and vegetable consumption, physical activity, smoking, and alcohol consumption
The Health Behaviour Survey, with a response rate of 70.8% in the 2018/2019 report, is a population-based fieldwork study conducted by the Centre for Health Protection of the Department of Health.16 In that survey, female participants comprised 52.7% of the sample, compared with 65.6% in the present telephone survey. The age-group with the largest proportion of participants in the Survey was 65 to 74 years (36.7% vs 11.0%), which might have influenced the sex ratio.
 
Time trend analysis showed that the proportion of surveyed Hong Kong residents eating five daily servings of fruits and vegetables declined for both sexes in general (Fig a). Similarly, a significantly smaller proportion of participants reported walking >10 minutes for ≥5 days per week, and this proportion has continued to decline since 2016 (Fig b). There was a gradual decrease in the number of participants with a moderate or high level of physical activity. Despite a notable peak in 2019, there was a decline in 2020 with <60% of participants reportedly engaging in these physical activities. Finally, significantly smaller proportion of the study participants reported not currently smoking or consuming alcohol, compared with the proportions in previous population-based surveys (2010-2019) [Fig c and d].
 

Figure. (a) Fruit and vegetable consumption, (b) physical activity, (c) smoking status, and (d) alcohol consumption status of surveyed Hong Kong residents from 2004 to 2020. The proportions of participants surveyed by the Department of Health since 2004 who reportedly engaged in healthy dietary habits (ie, consumed recommended amounts of fruits and vegetables, grains, and dairy), had a moderate to high level of physical activity, did not smoke, and did not drink, were compared with surveyed participants in 2020
 
Discussion
In this population-based study of 1500 Hong Kong residents during the third wave of the COVID-19 pandemic, we found that the proportion of people with healthy food intake (ie, daily consumption of five servings of fruits and vegetables) has decreased since 2003; although a slight increased was observed in 2020, it was still below the overall average. Additionally, we found that the prevalence of low physical activity has gradually increased. In contrast, the rates of smoking and alcohol consumption were below the rates observed in pre-pandemic population-based surveys. Men and women in various age-groups had dietary habits less adherent to the traditional Chinese eating pattern, as measured by the HKDS, than 20 years prior. Adherence to the traditional eating pattern was significantly lower among male participants, single individuals, low-income participants, alcohol drinkers, individuals with low physical activity, and patients with diabetes mellitus or renal disease. We also found that men, individuals with non-married status, manual workers, individuals with self-perceived poor or very poor health status, and patients with diabetes and renal disease had a greater likelihood of poor lifestyle habits.
 
Worldwide, insufficient intake of fruits and vegetables and inadequate physical activity have been attributed to 34% and ≥20% of NCDs, respectively.17 18 The incidence of chronic diseases (eg, cancers, diabetes, and cardiovascular disease) in Hong Kong has increased by 60% in the past two decades.19 Although processed food intake was not assessed in this study, the HKDS results indicated very low intakes of legumes and red/orange vegetables among Hong Kong residents; a previous study showed that fruit intake in Hong Kong is among the lowest levels worldwide.20 The report of Health Behaviour Survey 2018/2019 revealed that 95.6% of surveyed participants had inadequate daily fruit and vegetable intake, based on World Health Organization recommendations.16 The present study showed further reduction, such that the proportion of Hong Kong residents consuming the recommended (≥5) daily servings of fruits and vegetables declined by 3.9% in the past two decades. Additionally, 10% of the population reported consuming more than one daily serving of processed meat, and the frequency of processed meat consumption increased by 3.1%.16 Another known risk factor for NCDs, overweight or obesity, affected approximately half of the Hong Kong population aged 15 to 84 years in 2015; this value was slightly (2%) below the global average.21
 
Disruptions to usual routines can lead to new dietary behaviours. For example, dine-in restrictions at restaurants and bars during the pandemic led to greater use of food delivery services, and take-away food is often less healthy.22 However, we observed increased fruit and vegetable consumption after the third wave of the COVID-19 outbreak. This finding is supported by the work of Wang et al,23 which showed that fruit and vegetable consumption increased. Collectively, the disease prevention and control policies that prohibited group gatherings and shortened the operating hours of bars and clubs (if such facilities were not entirely closed) could have significantly reduced smoking and alcohol consumption in Hong Kong during the pandemic. Additionally, the lower level of physical activity could be related to the closure of public sports avenues and restricted access to sports facilities.
 
The dietary habits of Hong Kong residents have changed from the traditional Chinese diet to a fast-paced dining experience involving convenient, processed foods with limited diversity. Hong Kong has a population of >7.5 million people, and 90% of its food supply is imported from other countries.24 Woo et al11 concluded that, despite geographical and cultural differences, traditional Chinese dietary habits were conceptually similar to the health-promoting Mediterranean diet. In 2001, high overall adherence to the Mediterranean diet was observed across all age-groups in Hong Kong, except for younger populations and men.11 In contrast, the present study showed that a smaller proportion of participants in all age and sex groups had high overall adherence to the Mediterranean diet. In this study, intriguingly, women consistently exhibited higher Mediterranean diet score (71%) and HKDS (53%; P<0.005) results, compared with their male counterparts. Moreover, the present study revealed lower prevalences of some chronic diseases among women: diabetes, cardiovascular disease, liver disease, and renal disease. The contemporary diets in modern Hong Kong and many developed regions have low fibre content and high processed food content; they also include food additives, refined sugar, and hydrogenated fats.25 The subtle but consistent westernisation of dietary habits appears to be detrimental for residents who consistently consume these food items.
 
A lack of colourful vegetables and fruits may reduce the diversity of beneficial gut microbiota,26 although leafy greens such as pak choy (Chinese cabbage), choy sum (Chinese flowering cabbage), and Chinese kale are staple foods in the Hong Kong diet throughout the year. Moreover, in a review of literature concerning exercise and gut microbial composition, Mitchell et al27 found that exercise alters gut microbiota; however, the direction of apparent change has varied among studies. Increases in butyrate-producing bacteria and faecal butyrate concentrations, with protective anti-inflammatory effects and the potential to enhance anti-infection immunity, have been observed among physically active adults.28 The mechanisms are unclear but the benefits of adopting a lifestyle with a diverse diet and physical activity consistently create an optimal environment for gut microbiota.
 
Limitations
The large sample size and random sampling design of this territory-wide survey were strengths that enhanced the validity of the findings. However, this study had several limitations that should be addressed. First, cause-and-effect relationships between the COVID-19 pandemic and changes in lifestyle habits could not be established because of the cross-sectional approach. Individuals in home quarantine during the third wave of the pandemic might have experienced temporary changes in lifestyle habits; a prospective observational study and longer trend analysis are needed to facilitate long-term comparisons. Factors other than the pandemic (eg, mental wellness) could also have affected lifestyles among the study population. Although the present study utilised a random sampling strategy, non-response and selection biases were possible because younger segments of the Hong Kong population did not use landlines during the study period. Furthermore, response and social desirability biases may have been present in this telephone survey. Nevertheless, the high response rate and anonymous nature of this survey may have minimised these potential biases. Additionally, generalisation of the study findings should be performed with caution because the survey only included a single Chinese population. Considering that the participants’ characteristics differed from the general population, the findings might not be directly applicable to the general public. Moreover, the survey was conducted in 2020, and lifestyle habits in the general population might have changed throughout the pandemic. Finally, the low case numbers of some self-reported diseases, such as renal disease and cancer, may have resulted in type II error.
 
Conclusion
This representative population-based survey revealed that larger proportions of the general population had unhealthy lifestyles, including dietary habits and physical inactivity, during the COVID-19 pandemic than during pre-pandemic years. There is an urgent need to formulate and implement effective public health strategies at both individual and organisational levels. The encouragement of healthy lifestyles through evidence-based health promotion programmes is essential. This encouragement could be conveyed to communities through organised and concerted efforts by the government and relevant stakeholders. Future studies should evaluate the effectiveness of various interventions and approaches to achieve these important goals.
 
Author contributions
Concept or design: WYY Lin, MCS Wong.
Acquisition of data: WYY Lin, J Huang, Y Bai.
Analysis or interpretation of data: WYY Lin, J Huang, Y Bai.
Drafting of the manuscript: WYY Lin, MCS Wong.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
As editors of the journal, MCS Wong and J Huang were not involved in the peer review process. Other authors have disclosed no conflicts of interest.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
This research was approved by the Survey and Behavioural Research Ethics Committee of The Chinese University of Hong Kong (Ref No.: SBRE-20-099). The interviewees provided informed consent after they were briefed on the study purpose and being assured of the confidentiality measures in place.
 
References
1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/. Accessed 19 Jan 2024.
2. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Situation of COVID-19 (23 January 2020 to 29 January 2023). 2023 July 27. Available from: https://www.chp.gov.hk/files/pdf/local_situation_covid19_en.pdf. Accessed 2 Feb 2024.
3. Chief Executive’s Office, Hong Kong SAR Government. Fighting the virus for six months battling another wave of the epidemic together. 2020 Jul 25. Available from: https://www.ceo.gov.hk/archive/5-term/eng/pdf/article20200725.pdf. Accessed 6 Apr 2022.
4. Mattioli AV, Sciomer S, Cocchi C, Maffei S, Gallina S. Quarantine during COVID-19 outbreak: changes in diet and physical activity increase the risk of cardiovascular disease. Nutr Metab Cardiovasc Dis 2020;30:1409-17. Crossref
5. Bin Mahfoz TM, Shaik RA, Ahmad MS, Alzerwi NA, Almutairi R. A nationwide survey to assess COVID-19’s impact on health and lifestyle in Saudi Arabia. Eur Rev Med Pharmacol Sci 2022;26:4092-101. Crossref
6. Mitchell JJ, Bu F, Fancourt D, Steptoe A, Bone JK. Longitudinal associations between physical activity and other health behaviours during the COVID-19 pandemic: a fixed effects analysis. Sci Rep 2022;12:15956. Crossref
7. Wang JX, Huang J, Cheung CS, Wong WN, Cheung NT, Wong MC. Adoption of an electronic patient record sharing pilot project: cross-sectional survey. J Med Internet Res 2020;22:e13761. Crossref
8. de Groot LC, van Staveren WA, Burema J. Survival beyond age 70 in relation to diet. Nutr Rev 1996;54:211-2. Crossref
9. Fung TT, Rexrode KM, Mantzoros CS, Manson JE, Willett WC, Hu FB. Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women. Circulation 2009;119:1093-100. Crossref
10. Bamia C, Lagiou P, Buckland G, et al. Mediterranean diet and colorectal cancer risk: results from a European cohort. Eur J Epidemiol 2013;28:317-28. Crossref
11. Woo J, Woo KS, Leung SS, et al. The Mediterranean score of dietary habits in Chinese populations in four different geographical areas. Eur J Clin Nutr 2001;55:215-20. Crossref
12. Centre for Food Safety, Hong Kong SAR Government. Nutrient and health—maintain optimal nutrient intake. 2008. Available from: https://www.cfs.gov.hk/english/multimedia/multimedia_pub/multimedia_pub_fsf_28_02.html. Accessed 30 Sep 2020. Crossref
13. Torenfält I, Dimberg L. Stroke and death — findings from a 25-year follow-up of a cohort of employed Swedish middle-aged men of the Coeur study. J Public Health 2022;30:1713-24. Crossref
14. Faury H, Courboulès C, Payen M, et al. Medical features of COVID-19 and influenza infection: a comparative study in Paris, France. J Infect 2021;82:e36-9. Crossref
15. Center for Health Protection, Department of Health, Hong Kong SAR Government. Non-communicable Disease Branch. Publications. Available from: https://www.chp.gov.hk/en/resources/29/100057.html. Accessed 31 Jan 2024.
16. Centre for Health Protection, Department of Health, Hong Kong SAR Government. Report of Health Behaviour Survey 2018/19. Available from: https://www.chp.gov.hk/files/pdf/report_of_health_behaviour_survey_2018_en.pdf. Accessed 29 Jan 2021.
17. World Health Organization. Global health risks: mortality and burden of disease attributable to selected major risks. 2009. Available from: https://apps.who.int/iris/handle/10665/44203. Accessed 29 Jan 2021.
18. World Health Organization. Physical activity. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/physical-activity. Accessed 22 Jan 2024.
19. Hospital Authority. Overview of Hong Kong Cancer Statistics of 2018. 2020. Available from: https://www3.ha.org.hk/cancereg/pdf/overview/Overview%20of%20HK%20Cancer%20Stat%202018.pdf. Accessed 30 Sep 2020.
20. Micha R, Khatibzadeh S, Shi P, et al. Global, regional and national consumption of major food groups in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys worldwide. BMJ Open 2015;5:e008705. Crossref
21. World Health Organization. Obesity and overweight. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 23 Jun 2021.
22. Nguyen TH, Vu DC. Food delivery service during social distancing: proactively preventing or potentially spreading coronavirus disease-2019? Disaster Med Public Health Prep 2020;14:e9-10. Crossref
23. Wang J, Yeoh EK, Yung TK, et al. Change in eating habits and physical activities before and during the COVID-19 pandemic in Hong Kong: a cross-sectional study via random telephone survey. J Int Soc Sports Nutr 2021;18:33. Crossref
24. Research Office, Legislative Council Secretariat. Fact sheet: regulation of imported food in Hong Kong. 2016. Available from: https://www.legco.gov.hk/research-publications/english/1516fsc14-regulation-of-imported-food-in-hong-kong-20160226-e.pdf. Accessed 22 Jan 2024.
25. Jew S, AbuMweis SS, Jones PJ. Evolution of the human diet: linking our ancestral diet to modern functional foods as a means of chronic disease prevention. J Med Food 2009;12:925-34. Crossref
26. Garcia-Mantrana I, Selma-Royo M, Alcantara C, Collado MC. Shifts on gut microbiota associated to Mediterranean diet adherence and specific dietary intakes on general adult population. Front Microbiol 2018;9:890. Crossref
27. Mitchell CM, Davy BM, Hulver MW, Neilson AP, Bennett BJ, Davy KP. Does exercise alter gut microbial composition? a systematic review. Med Sci Sports Exerc 2019;51:160-7. Crossref
28. Allen JM, Mailing LJ, Niemiro GM, et al. Exercise alters gut microbiota composition and function in lean and obese humans. Med Sci Sports Exerc 2018;50:747-57. Crossref

Genetic association of COVID-19 severe versus non-severe cases by RNA sequencing in patients hospitalised in Hong Kong

Hong Kong Med J 2024 Feb;30(1):25–31 | Epub 8 Feb 2024
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Genetic association of COVID-19 severe versus non-severe cases by RNA sequencing in patients hospitalised in Hong Kong
Qi Li, PhD1,2 #; Zigui Chen, PhD3 #; Yexian Zhang, PhD2 #; Renee WY Chan, PhD4,5,6,7; Marc KC Chong, PhD1,2; Benny CY Zee, PhD1,2; Lowell Ling, MD8; Grace Lui, MD8; Paul KS Chan, MD3; Maggie H Wang, PhD1,2
1 The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China
2 The Chinese University of Hong Kong Shenzhen Research Institute, Shenzhen, China
3 Department of Microbiology, Stanley Ho Centre for Emerging Infectious Diseases, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
4 Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
5 Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
6 CUHK-UMCU Joint Research Laboratory of Respiratory Virus and Immunobiology, Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
7 Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong, Hong Kong SAR, China
8 Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China
# Equal contribution
 
Corresponding author: Prof MH Wang (maggiew@cuhk.edu.hk)
 
 Full paper in PDF
 
Abstract
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has caused extensive disruption of public health worldwide. There were reports of COVID-19 patients having multiple complications. This study investigated COVID-19 from a genetic perspective.
 
Methods: We conducted RNA sequencing (RNA-Seq) analysis of respiratory tract samples from 24 patients with COVID-19. Eight patients receiving mechanical ventilation or extracorporeal membrane oxygenation were regarded as severe cases; the remaining 16 patients were regarded as non-severe cases. After quality control, statistical analyses were performed by logistic regression and the Kolmogorov–Smirnov test to identify genes associated with disease severity.
 
Results: Six genes were associated with COVID-19 severity in both statistical tests, namely RPL15, BACE1-AS, CEPT1, EIF4G1, TMEM91, and TBCK. Among these genes, RPL15 and EIF4G1 played roles in the regulation of mRNA translation. Gene ontology analysis showed that the differentially expressed genes were mainly involved in nervous system diseases.
 
Conclusion: RNA sequencing analysis showed that severe acute respiratory syndrome coronavirus 2 infection is associated with the overexpression of genes involved in nervous system disorders.
 
 
New knowledge added by this study
  • Differentially expressed genes between patients with severe and non-severe cases of coronavirus disease 2019 (COVID-19) were reported.
  • Overexpression of genes involved in cell proliferation, viral binding and replication, and neurological and lung diseases was observed, suggesting a pathophysiological mechanism by which severe acute respiratory syndrome coronavirus 2 induces lung inflammation and neurological complications.
Implications for clinical practice or policy
  • Future studies that involve gene expression profiling with larger sample sizes, in vitro infection experiments, and animal models can help to elucidate the mechanisms and corresponding therapeutic approaches for neurological complications of COVID-19.
 
 
Introduction
Coronavirus disease 2019 (COVID-19) has spread to >500 million people and caused 6.2 million deaths worldwide as of 22 April 2022.1 Approximately 20% of patients with COVID-19 develop severe symptoms and 5% of patients require intensive care.2 A wide range of complications were reported with COVID-19 infection, including nervous system diseases,3 4 circulatory system diseases,5 6 7 8 9 urinary system diseases,10 and digestive system diseases.11
 
Various genetic associations with COVID-19 outcomes have been explored.12 13 14 15 A whole-genome sequencing study of germline mutations revealed a cluster of six genes (SLC6A20, CCR9, FYCO1, CXCR6, XCR1, and LZTFL1) that increased susceptibility to severe COVID-19 with respiratory failure.16 In a Chinese population, a whole-genome sequencing study of 332 patients with COVID-19 identified loci in the genes TMEM189 and UBE2V1 with potential genome-wide implications through the IL-1 signalling pathway.17 In an intensive care unit cohort of 15 patients with severe COVID-19, analysis of RNA sequencing (RNA-Seq) data from blood samples showed that the immune-modulating genes PD-L1 and PD-L2 were differentially expressed among patients with fatal outcomes.18
 
Thus far, studies of gene expression at initial sites of infection in patients with severe and non-severe COVID-19 remain limited. To investigate COVID-19 from a genetic perspective, we conducted RNA-Seq analysis of respiratory tract samples from patients with COVID-19; we sought to identify genes associated with disease severity.
 
Methods
Patients
Twenty-four patients were recruited from Prince of Wales Hospital in Hong Kong between 7 February and 10 April 2020. All patients had severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, confirmed by two independent real-time reverse transcription–polymerase chain reaction assays targeting the N gene.19 Symptoms on admission were recorded, and medical histories were collected from clinical health records. Among the recruited patients, eight who received mechanical ventilation or extracorporeal membrane oxygenation were regarded as severe cases; the remaining 16 patients showed asymptomatic or mild (no pneumonia) to moderate (pneumonia but not requiring oxygen supplementation) disease and were regarded as non-severe cases. RNA sequencing was performed on upper and lower respiratory swab samples collected within 3 days after hospitalisation.
 
RNA sequencing data
Total RNA was extracted from respiratory swab samples using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), pre-treated with DNase I and depleted of human rRNA and globin genes using the QIAseq FastSelect ribosomal RNA and globin mRNA Removal Kit (Qiagen, Hilden, Germany). Illumina libraries for RNA-Seq next-generation sequencing were prepared using the KAPA HyperPrep Kit (Roche, Pleasanton [CA], US) in accordance with the manufacturer’s instructions, then sequenced on an Illumina NextSeq 500 system (Illumina, San Diego [CA], US) using 150 bp paired-end reads. The raw data consisted of 58 735 Ensembl-annotated20 genes. Quality control was performed to remove patients with low numbers of RNA-Seq reads (three samples) and genes with zero reads in >20% of samples (55 571 genes). Thus, 3164 genes remained available for differential expression analysis. Raw read count data were summarised as fragments per million reads mapped21 and then log2-transformed.
 
Statistical analysis
Logistic regression was utilised to identify genes associated with severity outcomes. Subsequent evaluations by the Kolmogorov–Smirnov (KS) test were performed to test for differences in gene expression between groups. The Bonferroni corrected significance threshold was 1.58 × 10-5.
 
Functional analysis of genes
According to their disease relevance in the GeneCards21 22 and MalaCards23 24 databases, genes were categorised into the following 10 disease groups: nervous system, integumentary system, circulatory system, urinary system, digestive system, respiratory system, musculoskeletal system, endocrine system, reproductive system, and infectious diseases.
 
Results
Demographics and baseline characteristics
The patients’ demographics and baseline characteristics are summarised in Table 1. The mean age of patients in the severe group was 62.13 years (95% confidence interval [CI]=53.34-70.91), which was significantly higher than that in the non-severe group (29.73 years; 95% CI=22.11-37.36). Compared with the non-severe group, the severe group had higher prevalences of complications including cardiovascular, liver, endocrine, and metabolic disorders, as well as higher rates of respiratory, fever, and diarrhoea symptoms. The COVID-19 World Health Organization score25 was significantly higher in the severe group than in the non-severe group. Lopinavir, antibiotics, conventional oxygen therapy, and mechanical ventilation were more commonly used for treatment in the severe group than in the non-severe group (Table 1).
 

Table 1. Demographic and baseline clinical characteristics of patients with severe and non-severe cases of coronavirus disease 2019 (COVID-19)
 
Differentially expressed genes according to RNA sequencing
Six genes, namely RPL15, BACE1-AS, CEPT1, EIF4G1, TMEM91, and TBCK, were differentially expressed between the severe and non-severe groups (all P values <0.05 in both logistic regression and the KS test) [Table 2]. Fold-change and odds ratio results indicated that these genes were consistently highly expressed in the severe group. The complete list of genes with P values <0.05 in KS test is provided in online supplementary Table 1.
 

Table 2. Differentially expressed genes between patients with severe and non-severe cases of coronavirus disease 2019 according to RNA sequencing analysis
 
Gene ontology and enrichment analysis
The functions of the identified genes were summarised through database and literature searches. Two genes, 60S ribosomal protein L15 (RPL15) and eukaryotic translation initiation factor 4 gamma 1 (EIF4G1), play roles in host translation of viral mRNA.26 27 28 Furthermore, the top genes were mainly involved in neurological disorders. RPL15 is involved in the life cycle of human immunodeficiency virus,29 30 and baculovirus infection reportedly disrupts the expression of this gene.31 32 EIF4G1 plays a role in viral binding and affects the pathogenicity and virulence of H5N1 influenza A virus, foot-and-mouth disease virus, and vaccinia virus33 34 35; it also contains multiple mutations among patients with familial Parkinson’s disease.36 TBCK encodes a conserved protein kinase that regulates cell size and proliferation.37 CEPT1 encodes choline/ethanolamine phosphotransferase, which is used in the synthesis of choline- or ethanolamine-containing phospholipids. The function of TMEM91, a transmembrane protein, is unclear; however, the results of genome-wide association studies suggest that loci containing this gene are involved in lung diseases.
 
The non-coding gene BACE1-AS regulates the stability of the BACE1 protein and directly increases the abundance of amyloid beta-peptide (Aβ1-42) in Alzheimer’s disease.38 The implications of this gene in severe COVID-19 are unclear. For the top 15 overexpressed genes (P values in KS test <0.05), disease relevance data were retrieved from GeneCards22; 14 of the 15 genes (93.3%) have been linked to neurological diseases, followed by eye (80.0%) and psychiatric (73.3%) diseases. Thus, all of the top genes were involved in nervous system disorders (Fig).
 

Figure. Frequency of diseases related to the top identified genes (n=15)
 
Discussion
Nervous system disorders such as encephalopathy, impaired consciousness, seizure, ataxia, neuropathies, neurodegenerative diseases, and anosmia have been extensively documented in patients with COVID-19.39 40 41 The two major potential pathogenesis pathways are direct viral invasion and immune-mediated injury. Direct viral entry to the central nervous system can travel through hematogenous or olfactory routes, or by transneuronal spread from the lungs.42 Post-mortem analysis of brain tissue from patients with COVID-19 encephalitis reportedly contained SARS-CoV-2 viral particles.43 44 Furthermore, a series of autopsy studies showed that localised inflammation of the brainstem nuclei, as well as the cytokine storm associated with SARS-CoV-2 infection, could disrupt the blood–brain barrier and cause necrosis in the brains of patients with severe COVID-19.45 46 In patients with COVID-19, anosmia may be caused by an inflammation-mediated decrease in odorant receptor expression.47 Several studies have utilised RNA-Seq to characterise the transcriptomic profiles of patients with COVID-19.48 49 Significant downregulation of genes related to the hypoxia-inducible factor system was observed during periods of infection and oxygen deprivation.50 Additionally, transcriptomic profiles of peripheral blood mononuclear cells revealed that patients with COVID-19 shared several dysregulated genes with individuals who had bipolar illness, post-traumatic stress disorder, or schizophrenia.51 The present findings suggest that SARS-CoV-2 infection is associated with differential expression of genes involved in nervous system disorders. Future studies that involve gene expression profiling with larger sample sizes, in vitro infection experiments, and animal models can help to elucidate the mechanisms and corresponding therapeutic approaches for neurological complications of COVID-19.
 
Limitations
A major limitation of this study was its small sample size. Patient age distributions considerably differed between groups. However, age-stratified analysis showed effects consistent with the directions reported in Table 2, although the statistical significance was hindered by the small sample size (online supplementary Table 2 and online supplementary Fig). Further sequencing of samples collected from respiratory tract sites may provide stronger evidence of protein expression abnormalities at the initial site of SARS-CoV-2 infection.
 
Conclusion
In this study, we conducted RNA-Seq analysis to identify differentially expressed genes between patients with severe and non-severe cases of COVID-19. We observed overexpression of genes involved in cell proliferation, viral binding and replication, and neurological and lung diseases, suggesting a pathophysiological mechanism by which SARS-CoV-2 induces lung inflammation and neurological complications.
 
Author contributions
Concept or design: BCY Zee, PKS Chan, MH Wang.
Acquisition of data: Z Chen, PKS Chan.
Analysis or interpretation of data: Q Li, Z Chen, Y Zhang, RWY Chan, MKC Chong, PKS Chan, G Lui, L Ling.
Drafting of the manuscript: Q Li, MH Wang.
Critical revision of the manuscript for important intellectual content: Q Li, Y Zhang, MH Wang.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
BCY Zee is a shareholder of Health View Bioanalytic Limited. As a statistical adviser of the journal, MKC Chong was not involved in the peer review process. MH Wang is a shareholder of Beth Bioinformatics Co, Ltd. Other authors have disclosed no conflicts of interest.
 
Funding/support
This research was partially supported by the Health and Medical Research Fund of the former Food and Health Bureau, Hong Kong SAR Government (Ref Nos.: COVID190103, COVID190112 and INF-CUHK-1), The Chinese University of Hong Kong (CUHK) Project Impact Enhancement Fund (Ref No.: CUPIEF/Ph2/COVID/06) and CUHK Direct Grant (Ref No.: 2020.025). The funders had no role in study design, data collection/analysis/interpretation, or manuscript preparation.
 
Ethics approval
The study protocol of this research was approved by the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (Ref No.: 2020.076). All patients provided written informed consent for participation in this research.
 
Supplementary material
The supplementary material was provided by the authors and some information may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by the Hong Kong Academy of Medicine and the Hong Kong Medical Association. The Hong Kong Academy of Medicine and the Hong Kong Medical Association disclaim all liability and responsibility arising from any reliance placed on the content.
 
References
1. World Health Organization. COVID-19 global data. Available from: https://covid19.who.int/WHO-COVID-19-global-data.csv. Accessed 22 Apr 2022.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239-42. Crossref
3. Gusev EI, Martynov MY, Boyko AN, et al. The novel coronavirus infection (COVID-19) and nervous system involvement: mechanisms of neurological disorders, clinical manifestations, and the organization of neurological care. Neurosci Behav Physiol 2021;51:147-54. Crossref
4. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg 2021;200:106349. Crossref
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. Crossref
6. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8. Crossref
7. Chen R, Liang W, Jiang M, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest 2020;158:97-105. Crossref
8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985. Crossref
9. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052-9. Crossref
10. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829-38. Crossref
11. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:667-78. Crossref
12. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in COVID-19. Nature 2021;591:92-8. Crossref
13. COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020;28:715-8. Crossref
14. Anastassopoulou C, Gkizarioti Z, Patrinos GP, Tsakris A. Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity. Human Genomics 2020;14:40. Crossref
15. Kousathanas A, Pairo-Castineira E, Rawlik K, et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 2022;607:97-103. Crossref
16. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med 2020;383:1522-34. Crossref
17. Wang F, Huang S, Gao R, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov 2020;6:83. Crossref
18. Fredericks AM, Jentzsch MS, Cioffi WG, et al. Deep RNA sequencing of intensive care unit patients with COVID-19. Sci Rep 2022;12:15755. Crossref
19. Lui G, Ling L, Lai CK, et al. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19. J Infect 2020;81:318-56. Crossref
20. Howe KL, Achuthan P, Allen J, et al. Ensembl 2021. Nucleic Acids Res 2021;49:D884-91. Crossref
21. Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016;54:1.30.1-33. Crossref
22. GeneCards. Available from: www.genecards.org. Accessed 15 Jan 2024.
23. Rappaport N, Twik M, Plaschkes I, et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res 2017;45:D877-87. Crossref
24. MalaCards. Available from: www.malacards.org. Accessed 15 Jan 2024.
25. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020;20:e192-7. Crossref
26. Ulyanova V, Shah Mahmud R, Laikov A, et al. Anti-influenza activity of the ribonuclease binase: cellular targets detected by quantitative proteomics. Int J Mol Sci 2020;21:8294. Crossref
27. Hanson P, Zhang HM, Hemida MG, Ye X, Qiu Y, Yang D. IRES-dependent translational control during virus-induced endoplasmic reticulum stress and apoptosis. Front Microbiol 2012;3:92. Crossref
28. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997;71:5382-90. Crossref
29. Frankel AD, Young JA. HIV-1: fifteen proteins and an RNA. Annu Rev Biochem 1998;67:1-25. Crossref
30. Kash JC, Goodman AG, Korth MJ, Katze MG. Hijacking of the host-cell response and translational control during influenza virus infection. Virus Res 2006;119:111-20. Crossref
31. van Oers MM, Doitsidou M, Thomas AA, de Maagd RA, Vlak JM. Translation of both 5’ TOP and non-TOP host mRNAs continues into the late phase of Baculovirus infection. Insect Mol Biol 2003;12:75-84. Crossref
32. Zhou H, Zhu J, Tu J, et al. Effect on virulence and pathogenicity of H5N1 influenza A virus through truncations of NS1 eIF4GI binding domain. J Infect Dis 2010;202:1338-46. Crossref
33. Foeger N, Kuehnel E, Cencic R, Skern T. The binding of foot-and-mouth disease virus leader proteinase to eIF4GI involves conserved ionic interactions. FEBS J 2005;272:2602-11. Crossref
34. Zaborowska I, Kellner K, Henry M, Meleady P, Walsh D. Recruitment of host translation initiation factor eIF4G by the Vaccinia Virus ssDNA-binding protein I3. Virology 2012;425:11-22. Crossref
35. Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011;89:398-406. Crossref
36. Bhoj EJ, Li D, Harr M, et al. Mutations in TBCK, encoding TBC1-domain-containing kinase, lead to a recognizable syndrome of intellectual disability and hypotonia. Am J Hum Genet 2016;98:782-8. Crossref
37. Chong JX, Caputo V, Phelps IG, et al. Recessive inactivating mutations in TBCK, encoding a Rab GTPase-activating protein, cause severe infantile syndromic encephalopathy. Am J Hum Genet 2016;98:772-81. Crossref
38. Khatoon F, Prasad K, Kumar V. COVID-19 associated nervous system manifestations. Sleep Med 2022;91:231-6. Crossref
39. Butowt R, von Bartheld CS. Anosmia in COVID-19: underlying mechanisms and assessment of an olfactory route to brain infection. Neuroscientist 2021;27:582-603. Crossref
40. Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun 2020;88:945-6. Crossref
41. Johansson A, Mohamed MS, Moulin TC, Schiöth HB. Neurological manifestations of COVID-19: a comprehensive literature review and discussion of mechanisms. J Neuroimmunol 2021;358:577658. Crossref
42. Paniz-Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020;92:699-702. Crossref
43. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis 2020;94:55-8. Crossref
44. von Weyhern CH, Kaufmann I, Neff F, Kremer M. Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. Lancet 2020;395:e109. Crossref
45. Virhammar J, Kumlien E, Fällmar D, et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology 2020;95:445-9. Crossref
46. Radmanesh A, Derman A, Ishida K. COVID-19–associated delayed posthypoxic necrotizing leukoencephalopathy. J Neurol Sci 2020;415:116945. Crossref
47. Daamen AR, Bachali P, Owen KA, et al. Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. Sci Rep 2021;11:7052. Crossref
48. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020;9:761-70. Crossref
49. Gagliardi S, Poloni ET, Pandini C, et al. Detection of SARS-CoV-2 genome and whole transcriptome sequencing in frontal cortex of COVID-19 patients. Brain Behav Immun 2021;97:13-21. Crossref
50. Moni MA, Lin PI, Quinn JM, Eapen V. COVID-19 patient transcriptomic and genomic profiling reveals comorbidity interactions with psychiatric disorders. Transl Psychiatry 2021;11:160. Crossref
51. MAQC Consortium; Shi L, Reid LH, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61. Crossref

COVID-19 vaccination and transmission patterns among pregnant and postnatal women during the fifth wave of COVID-19 in a tertiary hospital in Hong Kong

Hong Kong Med J 2024 Feb;30(1):16–24 | Epub 16 Jan 2024
https://doi.org/10.12809/hkmj2210249
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE  CME
COVID-19 vaccination and transmission patterns among pregnant and postnatal women during the fifth wave of COVID-19 in a tertiary hospital in Hong Kong
PW Hui, MD, FRCOG; LM Yeung, BNur, MPH; Jennifer KY Ko, MB, BS, MRCOG; Theodora HT Lai, MB, BS, MRCOG; Diana MK Chan, MB, BS, MRCOG; Dorothy TY Chan, MB, BS; Sophia YK Mok, MB, BS, MRCOG; Kitty KW Ma, MB, BS; Pamela SY Kwok, BNur, MSM, Polly WC Pang, BN; Mimi TY Seto, MB, BS, MRCOG
Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong SAR, China
 
Corresponding author: Dr PW Hui (apwhui@hku.hk)
 
 Full paper in PDF
 
Abstract
Introduction: Vaccination is a key strategy to control the coronavirus disease 2019 (COVID-19) pandemic. Safety concerns strongly influence vaccine hesitancy. Disease transmission during pregnancy could exacerbate risks of preterm birth and perinatal mortality. This study examined patterns of vaccination and transmission among pregnant and postnatal women during the fifth wave of COVID-19 in Hong Kong.
 
Methods: The Antenatal Record System and Clinical Management System of the Hospital Authority was used to retrieve information concerning the demographic characteristics, vaccination history, COVID-19 status, and obstetric outcomes of women who were booked for delivery at Queen Mary Hospital in Hong Kong and had attended the booking antenatal visit from 1 July 2021 to 30 June 2022.
 
Results: Among 2396 women in the cohort, 2006 (83.7%), 1843 (76.9%), and 831 (34.7%) had received the first, second, and third doses of COVID-19 vaccine, respectively. Among 1012 women who had received the second dose, 684 (67.6%) women were overdue for their third dose. There were 265 (11.1%) reported COVID-19 cases. Women aged 20 to 29 years had a low vaccination rate but the highest disease rate (19.1%). The disease rate was more than tenfold higher in women who had no (20.3%) or incomplete (18.8%) vaccination, compared with women who had complete vaccination (2.1%; P<0.001).
 
Conclusion: Acceptance of COVID-19 vaccination was low in pregnant women. Urgent measures are needed to promote vaccination among pregnant women before the next wave of COVID-19.
 
 
New knowledge added by this study
  • As of 30 June 2022, only 34.7% of women in Hong Kong had received three doses of coronavirus disease 2019 (COVID-19) vaccine.
  • Two-thirds women scheduled for a third dose of COVID-19 vaccine did not receive the booster dose during pregnancy.
  • The disease rate was almost ten times higher in women who had no or incomplete vaccination, compared with women who had complete vaccination.
  • Women aged 20 to 29 years had a low vaccination rate but the highest disease rate.
Implications for clinical practice or policy
  • Pregnant women should receive education concerning the importance and safety of COVID-19 vaccination during pregnancy and breastfeeding.
  • Delayed receipt of booster doses increase susceptibility to COVID-19 during future waves.
  • A comprehensive programme incorporating pertussis and COVID-19 vaccination for pregnant women should be considered.
 
 
Introduction
Vaccination is an effective tool to combat the coronavirus disease 2019 (COVID-19) pandemic. Two types of COVID-19 vaccines are used in Hong Kong: the Sinovac-CoronaVac inactivated severe acute respiratory syndrome coronavirus 2 vaccine (Sinovac Biotech Ltd, Beijing, China) and Pfizer BioNTech BNT162b2 (Pfizer Inc, Philadelphia [PA], United States) messenger RNA vaccine began distribution on 26 February 2021 and 10 March 2021, respectively.
 
According to the World Health Organization, vaccine hesitancy is defined as delaying or refusing vaccination despite the availability of vaccination services.1 In a study conducted during the third wave of COVID-19 in Hong Kong, the overall vaccine acceptance rate was approximately 37%.2 Although the subsequent acceptance rate has varied with pandemic progression, confidence in COVID-19 vaccines has remained a key factor in reducing vaccine hesitancy.3
 
Pregnant women were generally excluded from clinical trials focusing on the development, safety, and efficacy of COVID-19 vaccines.4 When COVID-19 vaccines were introduced in Hong Kong, routine vaccination was not recommended for women who were pregnant or breastfeeding, except when there was a high risk of exposure or complications.5 The relative lack of data may have contributed to vaccine hesitancy among pregnant women.6 7 8 Based on data concerning the efficacy and safety of COVID-19 vaccination in preventing serious illness,9 COVID-19 vaccination is recommended for people who are pregnant, breastfeeding, planning to become pregnant, or may become pregnant in the future.10 11
 
On 23 April 2021, the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) issued an interim recommendation that pregnant women receive the BioNTech COVID-19 vaccine at the same time as the general population.12 On 18 February 2022, the Sinovac vaccine was also recommended for use in pregnant women.12 Furthermore, the recommended interval between the second and third doses of COVID-19 vaccine was shortened from 180 days to 90 days, beginning on 4 March 2022. The vaccine pass policy for entry to specific premises was tightened on 31 May 2022.13 For persons who were over 18 years old and had no history of infection, a minimal of two doses of vaccination was required. A third dose was required if the second dose was taken over 6 months ago. Starting from 13 June 2022, women attending obstetric clinics were required to provide a negative result proof of a polymerase chain reaction–based nucleic acid test conducted with specimen collected within 48 hours before the visit if they did not fulfil the vaccine pass requirement.14
 
The fifth wave of COVID-19 in Hong Kong has resulted in an overwhelming number of COVID-19 cases. Pregnant women are not automatically protected from COVID-19; indeed, their vaccine hesitancy and low vaccination rate may lead to greater susceptibility. Information concerning the patterns of COVID-19 vaccination and disease transmission among pregnant women in Hong Kong is unavailable. This study examined patterns of vaccination and transmission among pregnant women who were booked for delivery at a tertiary hospital in Hong Kong, with the goal of providing insights into maternal disease characteristics.
 
Methods
This retrospective review included women who were booked for delivery at Queen Mary Hospital in Hong Kong and had attended the booking antenatal visit from 1 July 2021 to 31 March 2022. Information concerning COVID-19 vaccination history was retrieved from the Clinical Management System of the Hospital Authority, which captured COVID-19 vaccination data from the Department of Health.
 
Pregnant women were diagnosed with COVID-19 because of symptoms or (in the absence of symptoms) during admission screening. Women diagnosed with COVID-19 through other channels were able to reschedule their appointments. Phone consultations were provided by the obstetric team at Queen Mary Hospital. The clinical details of COVID-19 cases were documented in the computerised Antenatal Record System. Additionally, antenatal progress notes were updated if a pregnant woman reported a history of COVID-19 during a follow-up visit. Data regarding demographic characteristics, COVID-19 status, and obstetric outcomes were retrieved from the Antenatal Record System.
 
The vaccinated group comprised women who received at least one dose of any type of COVID-19 vaccine. Vaccination periods were classified as pre-pregnancy, antenatal, and postnatal for women with a known date of delivery, miscarriage, or termination of pregnancy as of 30 June 2022. For women with ongoing pregnancies and unknown obstetric outcomes, the vaccination period was estimated according to the expected date of delivery. Antenatal status was regarded as known ongoing pregnancy before 42 weeks of gestation. A vaccination episode was defined as any episode of COVID-19 vaccination including the first, second, and third doses. The number of days elapsed since vaccination was defined as the interval between the last dose of COVID-19 vaccine and 30 June 2022 for women who had received one or two doses of vaccine. Complete vaccination was regarded as the period between 15 and 90 days after the second dose of COVID-19 vaccine, or 14 days after the third dose of COVID-19 vaccine for women who had never been diagnosed with COVID-19. For women with COVID-19, the date of diagnosis was regarded as the reference point when determining vaccination status.
 
Descriptive statistics were reported. Vaccination rates were calculated according to age-group. Background demographic characteristics were compared between vaccinated and unvaccinated groups. Student’s t test, analysis of variance, and the Chi squared test were used as appropriate. Regression analyses were conducted to identify factors affecting vaccine acceptance. P values <0.05 were considered statistically significant. Statistical analyses were performed using SPSS software (Windows version 26; IBM Corp, Armonk [NY], United States).
 
Results
Table 1 shows the demographic characteristics of 2396 pregnant women who had attended the booking antenatal visit between 1 July 2021 and 31 March 2022. As of 30 June 2022, 2006 (83.7%), 1843 (76.9%), and 831 (34.7%) women had received the first, second, and third doses of COVID-19 vaccine, respectively. Among the 1843 women who had received two doses of vaccine, 1056 (57.3%) underwent vaccination before pregnancy (Fig 1). Of these 1843 women, 831 received a third dose; the median interval between the second and third doses was 280 days (interquartile range, 239-308). Of the remaining 1012 women who had received only two doses of vaccine, 684 (67.6%) and 504 (49.8%) had already passed the 90-day and 180-day intervals, respectively. Their median number of days elapsed since the last vaccine was 315 (interquartile range, 145-368), which considerably exceeded the recommended 90-day interval.
 

Table 1. Background characteristics of women who received antenatal care between 1 July 2021 and 31 March 2022
 

Figure 1. Pattern of coronavirus disease 2019 vaccination episodes according to timing of vaccination
 
Only 26.6% (1243/4680) of vaccination episodes occurred during pregnancy. Among women who underwent antenatal vaccination, 65.7% (817/1243) had it during the fifth wave of COVID-19 between January 2022 and June 2022; 65.7% (537/817) of these women received the third dose. The two peaks of vaccination for third dose were observed in early March 2022 and late May 2022 (Fig 2).
 

Figure 2. Vaccination episodes during the fifth wave of coronavirus disease 2019 (COVID-19)
 
The vaccination rate was the lowest among Chinese women (81.4%), but the highest among Caucasian women (96.4%) [Fig 3]. Multivariate analysis showed that active working status (odds ratio [OR]=1.94; 95% confidence interval [CI]=1.47-2.56) was significantly associated with a higher COVID-19 vaccination rate, whereas Chinese ethnicity (OR=0.21; 95% CI=0.13-0.33) and women with obstetric complications (OR=0.72; 95% CI=0.55-0.94) were significantly associated with a lower COVID-19 vaccination rate.
 

Figure 3. Percentages of coronavirus disease 2019 (COVID-19) vaccination and disease transmission among pregnant women by ethnicity
 
In total, there were 265 (11.1%) COVID-19 cases in this cohort; the earliest diagnosis was made on 1 January 2022 during the fifth wave of COVID-19 in Hong Kong (Table 2). The disease rate was more than tenfold higher in women who had no (20.3%) or incomplete (18.8%) vaccination, compared with women who had complete vaccination (2.1%; P<0.001). After exclusion of pregnancies among women aged ≤19 years, there was an insignificant trend of lower vaccination among young women (ie, aged 20-29 years), but their disease rate was the highest (19.1%) [Fig 4].
 

Table 2. Vaccination background and pregnancy outcome among pregnant women with coronavirus disease 2019 (COVID-19)
 

Figure 4. Percentages of coronavirus disease 2019 (COVID-19) vaccination and disease transmission among pregnant women by age
 
Among 237 (89.4%) women who had an antenatal diagnosis of COVID-19, 42 (17.7%) required admission for monitoring and 26 (11.0%) delivered in an isolation facility. No women required intensive care or oxygen support. There were no adverse maternal outcomes or cases of vertical transmission.
 
Discussion
Coronavirus disease 2019 vaccination
To our knowledge, this is the first report of the low COVID-19 vaccination rate (83.7%) among pregnant women in Hong Kong. This rate is considerably lower than the single-dose rate among the general public (92.7%) that was reported on the government’s vaccination dashboard on the final day of the study period (ie, 30 June 2022).15 Furthermore, the disease rate was more than threefold higher in women who had no or incomplete vaccination, compared with women who had complete vaccination.
 
Pregnant women are considered a vulnerable group. The substantial increase in the disease rate, combined with a lower vaccination rate, among women aged 20 to 29 years is particularly concerning. A case of COVID-19 during pregnancy can lead to adverse obstetric outcomes, including increased risks of preterm delivery, growth restriction, and stillbirth.16 In addition to the effectiveness of vaccination in terms of reducing severe complications, the transplacental transfer of immunoglobulins after maternal vaccination might provide infants with protection against COVID-19.10 16 17 18
 
Vaccine hesitancy
Vaccine hesitancy is a potential public health problem.19 The five psychological antecedents of vaccination are confidence, complacency, constraints, calculation, and collective responsibility.20 21 Acceptance of COVID-19 vaccination has varied among countries, with the highest rates reported in India, the Philippines, and Latin America.22 In the present study, Chinese women had a lower vaccination rate, compared with their non-Chinese counterparts.
 
The COVID-19 pandemic has contributed to a decrease in vaccine hesitancy.23 In May 2021, a systemic review showed that an estimated 47% of pregnant women worldwide intended to undergo COVID-19 vaccination.24
 
Communities generally become more complacent when the number of disease cases is low, suggesting that the perceived risk of disease transmission is minimal. This phenomenon was evident in Hong Kong across several waves of COVID-19 transmission.15 The vaccination rate increased during the fifth wave of COVID-19 when there was an exponential surge in the number of disease cases. A similar pattern was observed in the present study, such that two-thirds of the antenatal vaccination episodes occurred during the fifth wave of COVID-19 in Hong Kong.
 
Despite this relative surge in vaccination, around two-thirds of women eligible for the third dose did not receive it during pregnancy. This delay poses a major threat because the protective effect of the previous two doses may have dissipated. Importantly, although the rate of vaccination was higher in the antenatal group than the postnatal group, most women in the antenatal group had undergone vaccination before pregnancy. Thus, they may have a higher risk of serious adverse effects from COVID-19 if they become ill in the peripartum period. After exclusion of the small number of pregnant women aged ≤19 years, vaccination rates were consistently low among pregnant women of all ages. Pregnant women may have a higher risk of disease transmission in future waves of COVID-19; at the end of the present study, only one-third of pregnant women in this cohort had received three doses of vaccine.
 
Lack of confidence has been identified as the main factor consistently associated with lower COVID-19 vaccine hesitancy.3 The implementation of the stringent vaccine pass policy had driven another peak of vaccination in late May 2022. However, nearly half of the women who had received two doses of vaccine were indeed overdue for the third dose, and hence did not fulfil the vaccine pass for entrance to specific premises or could not attend obstetric clinics without undergoing nucleic acid testing. This group of vaccine had received COVID-19 vaccine before but had it mostly before pregnancy. Pregnancy could represent the key hindrance for their vaccination in the antenatal period. Government policy might not be adequate enough for promoting vaccination in pregnant women. Concern about possible harmful side-effects was the top reason for reluctance; confidence in COVID-19 vaccine safety and efficacy was the main predictor of acceptance, particularly in the pregnant population.8 22 In a Japanese cohort, concerns about potential effects on the fetus and breastfeeding were the main reasons for low COVID-19 vaccination acceptance.25 These findings highlight the need to distribute correct information and provide sufficient education to address concerns among women of reproductive age. In particular, antenatal women should receive additional information concerning vaccine safety during pregnancy.
 
Vaccination promotion
A study in Hong Kong showed that recommendations from the government constituted the strongest factor driving COVID-19 vaccine acceptance.2 Education about the safety and benefit of vaccination is also important.7 Webinars would be useful in efforts to educate the general public. Within the hospital setting, vaccination teams comprising obstetricians and midwives could allay concerns and dispel myths about vaccination among working staff at all levels; this approach could provide useful information for pregnant and breastfeeding women. There is also a need to combat physician hesitancy in recommending COVID-19 vaccination for pregnant women.26 To address this need, the HKCOG revised its recommendations on 3 March 2022 to indicate that women who are planning to become pregnant, are pregnant, or are breastfeeding should undergo COVID-19 vaccination along with the general population.12 A corresponding educational video to promote COVID-19 vaccination was made available on 5 March 2022.12
 
Possible interventions to promote vaccination in Hong Kong include the provision of vaccines at convenient venues and the involvement of healthcare professionals in information dissemination.27 During the fifth wave of COVID-19, pregnant women were proactively asked to consider COVID-19 vaccination when they attended obstetric clinics. Leaflets were distributed with information about the HKCOG recommendations, as well as community vaccination sites. The establishment of a pathway specifically for pregnant women, which reduced their waiting time in vaccine clinics, also helped to increase the vaccination rate. Moreover, vaccination was provided to women in the maternity wards of some hospitals and women attending antenatal clinics in Maternal and Child Health Centres. All of these measures helped reduce vaccine hesitancy in pregnant women.28
 
In Hong Kong, a pertussis vaccination programme for pregnant women was launched on 2 July 2020.29 The programme was incorporated into antenatal care, such that all pregnant women received counselling concerning the rationale for vaccination; the vaccine was administered during obstetric follow-up. To facilitate vaccine availability in our hospital, all women were asked to indicate their preference concerning pertussis vaccination during the first antenatal visit. It may be useful to incorporate COVID-19 vaccination into the maternal immunisation programme.
 
Strengths
This study had some notable strengths. The results of the present large cohort study provide clinicians and policymakers with key insights concerning the COVID-19 vaccination rate among pregnant women in Hong Kong. The study period was designed to include both antenatal and postnatal periods for a better understanding of vaccination behaviour among women in each period. A real-time collection method was adopted to capture COVID-19 vaccination records from the Clinical Management System, thereby ensuring data reliability.
 
Limitations
Nevertheless, this study had some limitations. A small number of women who underwent COVID-19 vaccination outside Hong Kong were not automatically identified in the system; however, they were included in the cohort if their vaccination history had been documented in antenatal records. Because rapid antigen self-tests were acceptable for diagnosis in Hong Kong beginning on 26 February 2022, the number of recorded COVID-19 cases in our cohort might have been lower than the actual number of cases if patients did not report positive COVID-19 test results to our department. Finally, this study did not explore whether the generally more cautious approach of pregnant women, in terms of avoiding all types of diseases, might contribute to a lower disease rate compared with the general public.
 
Conclusion
The rate of COVID-19 vaccination was low among pregnant and postnatal women in Hong Kong in early 2022. Pregnant women had a high risk of disease transmission because many of them had not received the third dose of COVID-19 vaccine. Urgent measures are needed to promote vaccination among pregnant women before future waves of COVID-19. In particular, women should receive information concerning vaccine safety to avoid unnecessary delays related to pregnancy.
 
Author contributions
Concept or design: PW Hui, DTY Chan.
Acquisition of data: All authors.
Analysis or interpretation of data: PW Hui.
Drafting of the manuscript: PW Hui, LM Yeung, JKY Ko, THT Lai, MTY Seto.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Acknowledgement
The authors thank Dr TW Chay, Dr YF Chiu, Ms WK Choi, Dr TY Hui, Dr KH Lam, Dr KS Lee, Dr YH Luk, Dr SK Ma, Dr HS Wang, Dr CCY Wong, Dr CL Wong, Dr LC Wong, and Dr CWK Yan of Department of Obstetrics and Gynaecology, Queen Mary Hospital for their contributions to research data retrieval and entry.
 
Declaration
The abstract has been presented online in the Royal College of Obstetricians and Gynaecologists World Congress 2023 (14 June 2013, London, United Kingdom).
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
Ethics approval was obtained from the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (Ref No.: UW 22-205). Informed patient consent has been waived by the Board due to the retrospective nature of the research.
 
References
1. MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine 2015;33:4161-4. Crossref
2. Wong MC, Wong EL, Huang J, et al. Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine 2021;39:1148-56. Crossref
3. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in factors associated with COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: serial cross-sectional surveys. Lancet Reg Health West Pac 2022;23:100441. Crossref
4. Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion of pregnant women in COVID-19 vaccine trials. Vaccine 2021;39:868-70. Crossref
5. Scientific Committee on Emerging and Zoonotic Disease and Scientific Committee on Vaccine Preventable Diseases, Centre for Health Protection, Hong Kong SAR Government. Consensus interim recommendations on the use of COVID-19 vaccines in Hong Kong (as of Jan 7, 2021). Available from: https://www.chp.gov.hk/files/pdf/consensus_interim_recommendations_on_the_use_of_covid19_vaccines_inhk.pdf. Accessed 30 Mar 2022.
6. Tao L, Wang R, Han N, et al. Acceptance of a COVID-19 vaccine and associated factors among pregnant women in China: a multi-center cross-sectional study based on health belief model. Hum Vaccin Immunother 2021;17:2378-88. Crossref
7. Sznajder KK, Kjerulff KH, Wang M, Hwang W, Ramirez SI, Gandhi CK. COVID-19 vaccine acceptance and associated factors among pregnant women in Pennsylvania 2020. Prev Med Rep 2022;26:101713. Crossref
8. Sutton D, D’Alton M, Zhang Y, et al. COVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged women. Am J Obstet Gynecol MFM 2021;3:100403. Crossref
9. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. N Engl J Med 2021;384:2273-82. Crossref
10. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of maternal vaccination with mRNA COVID-19 vaccine during pregnancy against COVID-19–associated hospitalization in infants aged <6 months—17 states, July 2021–January 2022. MMWR Morb Mortal Wkly Rep 2022;71:264-70. Crossref
11. Girardi G, Bremer AA. Scientific evidence supporting coronavirus disease 2019 (COVID-19) vaccine efficacy and safety in people planning to conceive or who are pregnant or lactating. Obstet Gynecol 2022;139:3-8. Crossref
12. The Hong Kong College of Obstetricians and Gynaecologists. The Hong Kong College of Obstetricians and Gynaecologists advice on COVID-19 vaccination in pregnant and lactating women (interim; updated on 3rd March 2022). 2022. Available from: http://www.hkcog.org.hk/hkcog/Upload/EditorImage/20220304/20220304134806_9035.pdf. Accessed 30 Mar 2022.
13. Hong Kong SAR Government. FEHD reminds catering premises operators and customers to observe requirements on third stage of Vaccine Pass. 2022. Available from: https://www.info.gov.hk/gia/general/202205/30/P2022053000726.htm?fontSize=1. Accessed 30 May 2022.
14. Hong Kong SAR Government. Government to implement Vaccine Pass arrangement in designated healthcare premises. 2022. Available from: https://www.info.gov.hk/gia/general/202205/21/P2022052100421.htm. Accessed 21 May 2022.
15. Together, We Fight the Virus. The Government of the Hong Kong Special Administrative Region. Available from: https://www.coronavirus.gov.hk/eng/index.html. Accessed 30 Jun 2022.
16. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320. Crossref
17. Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nat Rev Immunol 2022;22:277-82. Crossref
18. Nir O, Schwartz A, Toussia-Cohen S, et al. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy. Am J Obstet Gynecol MFM 2022;4:100492. Crossref
19. Shook LL, Kishkovich TP, Edlow AG. Countering COVID-19 vaccine hesitancy in pregnancy: the “4 Cs”. Am J Perinatol 2022;39:1048-54. Crossref
20. Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R. Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. PLoS One 2018;13:e0208601. Crossref
21. Chau CY. COVID-19 vaccination hesitancy and challenges to mass vaccination. Hong Kong Med J 2021;27:377-9. Crossref
22. Skjefte M, Ngirbabul M, Akeju O, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol 2021;36:197-211. Crossref
23. Gencer H, Özkan S, Vardar O, Serçekuş P. The effects of the COVID-19 pandemic on vaccine decisions in pregnant women. Women Birth 2022;35:317-23. Crossref
24. Shamshirsaz AA, Hessami K, Morain S, et al. Intention to receive COVID-19 vaccine during pregnancy: a systematic review and meta-analysis. Am J Perinatol 2022;39:492-500. Crossref
25. Hosokawa Y, Okawa S, Hori A, et al. The prevalence of COVID-19 vaccination and vaccine hesitancy in pregnant women: an internet-based cross-sectional study in Japan. J Epidemiol 2022;32:188-94. Crossref
26. Chervenak FA, McCullough LB, Grünebaum A. Reversing physician hesitancy to recommend COVID-19 vaccination for pregnant patients. Am J Obstet Gynecol 2022;226:805-12. Crossref
27. Wang K, Wong EL, Cheung AW, et al. Influence of vaccination characteristics on COVID-19 vaccine acceptance among working-age people in Hong Kong, China: a discrete choice experiment. Front Public Health 2021;9:793533. Crossref
28. Iacobucci G. COVID-19 and pregnancy: vaccine hesitancy and how to overcome it. BMJ 2021;375:n2862. Crossref
29. Hospital Authority. Public hospital pertussis vaccination programme for pregnant women. Jun 28, 2020. Available from: https://www.ha.org.hk/haho/ho/cc/pertussis_press_release_en.pdf. Accessed 29 Jun 2023.

Non–vitamin K oral anticoagulants versus warfarin for the treatment of left ventricular thrombus

Hong Kong Med J 2024 Feb;30(1):10–5 | Epub 8 Feb 2024
https://doi.org/10.12809/hkmj2210034
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE  CME
Non–vitamin K oral anticoagulants versus warfarin for the treatment of left ventricular thrombus
Kevin KH Kam, MB, ChB, MRCP1; Jeffrey SK Chan, MB, ChB1; Alex PW Lee, MD, FRCP1,2
1 Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong SAR, China
2 Laboratory of Cardiac Imaging and 3D Printing, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China
 
Corresponding author: Prof Alex PW Lee (alexpwlee@cuhk.edu.hk)
 
 Full paper in PDF
 
Abstract
Introduction: Left ventricular thrombus (LVT) is associated with significant morbidity and mortality. Conventional treatment comprises warfarin-mediated anticoagulation; it is unclear whether non–vitamin K oral anticoagulants (NOACs) exhibit comparable efficacy and safety. Limited data are available for Asian patients. This study compared NOACs with warfarin in terms of clinical efficacy and safety for managing LVT.
 
Methods: Clinical and echocardiographic records were retrieved for all adult patients with echocardiography-confirmed LVT at a major regional centre in Hong Kong from January 2011 to January 2020. Discontinuation of anticoagulation by 1 year was recorded. Outcomes were compared between patients receiving NOACs and those receiving warfarin. Primary outcomes were cumulative mortality and net adverse clinical events (NACEs). Secondary outcomes were complete LVT resolution and percentage reduction in LVT size at 3 months.
 
Results: Forty-three patients were included; 28 received warfarin and 15 received NOACs, with follow-up periods (mean ± standard deviation) of 20 ± 12 months and 22 ± 9 months, respectively (P=0.522). Use of NOACs was associated with significantly lower NACE risk (hazard ratio [HR]=0.111, 95% confidence interval [CI]=0.012-0.994; P=0.049) and a tendency towards lower cumulative mortality (HR=0.184, 95% CI=0.032-1.059; P=0.058). There were no significant differences in secondary outcomes. Considering LVT resolution, discontinuation of anticoagulation by 1 year was not significantly associated with different outcomes.
 
Conclusion: Non–vitamin K oral anticoagulants may be an efficacious and safe alternative to warfarin for LVT management. Future studies should explore the safety and efficacy of anticoagulation discontinuation by 1 year as an overall strategy.
 
 
New knowledge added by this study
  • In a Hong Kong cohort, non–vitamin K oral anticoagulant users had fewer net adverse clinical events and tended to exhibit lower mortality, compared with warfarin users.
  • Considering left ventricular thrombus (LVT) resolution, discontinuation of anticoagulation by 1 year may be a safe overall strategy.
Implications for clinical practice or policy
  • Non–vitamin K oral anticoagulants may be an efficacious and safe alternative to warfarin for LVT management.
  • Further studies are needed to explore the safety and efficacy of anticoagulant discontinuation by 1 year as an overall strategy for patients with LVT resolution.
 
 
Introduction
Left ventricular thrombus (LVT) primarily occurs in patients who exhibit heart failure with reduced ejection fraction, particularly when these conditions are secondary to dilated cardiomyopathy or myocardial infarction. Recent advances in the treatment of myocardial ischaemia and heart failure have reduced the estimated incidence to 7 cases per 10 000 patients.1 However, this lower incidence does not reduce the importance of identifying and treating LVT; one study has shown very high risks of major cardiovascular or cerebrovascular events and mortality in patients with LVT.2
 
Although LVT has conventionally been managed with warfarin, multiple guidelines suggest different treatment algorithms based on expert opinion and small-scale studies, reflecting the lack of evidence that underlies such recommendations.3 4 This lack of evidence is partly related to the low incidence of LVT, which hinders adequately powered research with high evidence quality. Considering the growing popularity of non–vitamin K oral anticoagulants (NOACs), there has been increasing interest in the use of NOACs as an alternative to warfarin for LVT management.5 A systematic review in 2020, which involved only relevant case series and case reports, concluded that NOACs constitute a ‘reasonable alternative’ to warfarin for LVT management.6 However, another 2020 study of >500 patients showed that NOACs increased the incidence of stroke or systematic embolism compared with warfarin.7 Nonetheless, only thromboembolic events were compared in that study; safety outcomes, specifically bleeding events, were not investigated. Thus, it remains unclear whether NOACs exhibit efficacy and safety similar to warfarin for LVT management. This retrospective cohort study aimed to evaluate the efficacy and safety of NOACs versus warfarin for the treatment of LVT.
 
Methods
Patient population
This retrospective cohort study included all patients with LVT diagnosed by echocardiography from January 2011 to January 2020 at our institution, a major tertiary university hospital in Hong Kong. Only patients aged ≥18 years were included. Patients were excluded if baseline echocardiography, pharmacotherapy regimen or clinical records were non-retrievable, or if the type of anticoagulation therapy (warfarin or NOACs) was switched within the first 2 years after LVT diagnosis.
 
At our institution, all patients began anticoagulation therapy upon echocardiography-based diagnosis of LVT. Patients either received warfarin with titration and maintenance of a therapeutic international normalised ratio of 2-3, or they received NOAC therapy. Because there are no specific treatment recommendations in current guidelines, anticoagulant selection was performed at the treating physicians’ discretion, generally considering patient-specific factors such as renal function, presence of other indications, and drug compliance. Follow-up echocardiography was performed 3 months after diagnosis of LVT, and further follow-up echocardiography was performed as clinically indicated. Anticoagulation was only discontinued if LVT had been resolved; this step required a shared, informed decision between the patient and the physician. Anticoagulation discontinuation was not considered for patients with persistent LVT.
 
Outcomes and measurements
All patients were followed up for ≤3 years. Echocardiographic images of all included patients at baseline and the 3-month follow-up were reviewed. The left ventricular ejection fraction, baseline size of LVT, and any resolution of LVT by the 3-month follow-up or the size of residual LVT at the 3-month follow-up were recorded. Clinical records of all patients were reviewed using the Clinical Management System of the Hong Kong Hospital Authority; important pre-morbid conditions, types of anticoagulants used, and pre-specified clinical outcomes were recorded. Any discontinuation of anticoagulation by 1 year was recorded.
 
The primary outcomes were cumulative mortality and net adverse clinical events (NACEs), defined as any of the following: ischaemic stroke, intracranial haemorrhage, systemic thromboembolism other than cerebral embolism, fatal bleeding (Bleeding Academic Research Consortium class 58), and major non-fatal bleeding (Bleeding Academic Research Consortium class 38). Secondary outcomes were complete resolution of LVT and percentage reduction of LVT size at the 3-month follow-up. Outcomes were also compared between patients who had discontinued anticoagulation by 1 year and those who continued anticoagulation for >1 year.
 
Statistical analysis
Unless otherwise specified, all continuous variables are expressed as mean ± standard deviation. Pre-morbid conditions and clinical outcomes in the two anticoagulation therapy groups were compared using Fisher’s exact test (for dichotomous variables) or Mann-Whitney U test (for continuous variables); the Mann-Whitney U test was chosen over parametric tests because the sample sizes were unlikely to support an assumption of data normality. Kaplan-Meier survival curves were used to visualise survival status and freedom from NACEs throughout the study period; Cox regression was used to compare mortality and NACE use between the two groups. Cases with missing values were excluded from analysis of the respective variables; no imputation was performed. All P values were two-sided, and P<0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (Windows version 25.0; IBM Corp, Armonk [NY], United States).
 
Results
In total, 43 patients (37 men) with LVT were included in this study: 28 received warfarin and 15 received NOACs. No patients were excluded for switching anticoagulant therapy during the first 2 years after LVT diagnosis. Of the patients treated with NOACs, 10 received apixaban, four received dabigatran, and one received rivaroxaban. Their baseline characteristics are summarised in Table 1; the two cohorts were generally comparable, except the NOAC cohort included more patients with diabetes mellitus (P=0.001) and atrial fibrillation or flutter (P=0.043). Eleven patients in the warfarin cohort and three patients in the NOAC cohort had non-ischaemic cardiomyopathy (P=0.308), including one patient with non-compaction cardiomyopathy and another patient (lost to follow-up after 6 months) with myocarditis. Both of these patients were in the warfarin cohort.
 

Table 1. Baseline characteristics of included patients
 
Three patients (all in the warfarin group) were lost to follow-up: one after 6 months (as noted above), one after 22 months, and one after 26 months. One of these patients had discontinued anticoagulation therapy by 1 year. The warfarin and NOAC cohorts were followed up for mean intervals of 20 ± 12 months (median, 20; interquartile range, 7-33) and 22 ± 9 months (median, 19; interquartile range, 15-31), respectively (P=0.522). All patients were examined by follow-up echocardiography at 3 months after initiation of anticoagulation therapy, except one patient in the warfarin cohort who died 1 month after diagnosis of LVT. In total, 14 deaths were observed in the NOAC (n=2; 13.3%) and warfarin (n=12; 42.9%) cohorts during the study period. Causes of death in the NOAC cohort were cardiovascular (sudden death; n=2); in the warfarin cohort, the causes of death were cardiovascular (n=8), intracerebral haemorrhage (n=3), gastrointestinal haemorrhage (n=1), and malignancy (n=2). Of the 34 patients who completed 1 year of follow-up, nine had discontinued anticoagulation therapy.
 
All primary and secondary outcomes are summarised in Table 2. We observed a significantly lower risk of NACEs in the NOAC cohort (n=1 [6.7%] in the NOAC cohort vs n=13 [46.4%] in the warfarin cohort; hazard ratio [HR]=0.124, 95% confidence interval [CI]=0.016-0.952; P=0.045), which remained statistically significant after adjustment for the clinical statuses of diabetes mellitus and atrial fibrillation or flutter (HR=0.111, 95% CI=0.012-0.994; P=0.049) [Fig 1]. There was a tendency towards lower mortality in the NOAC cohort (n=2 [13.3%] in the NOAC cohort vs n=12 [42.9%] in the warfarin cohort; HR=0.285, 95% CI=0.064-1.275; P=0.101 [before adjustment of clinical statuses]), which remained similar after adjustment for the clinical statuses of diabetes mellitus and atrial fibrillation or flutter (HR=0.184, 95% CI=0.032-1.059; P=0.058) [Fig 2]. Numerically lower rates of ischaemic stroke (n=0 [0%] in the NOAC cohort vs n=5 [17.9%] in the warfarin cohort), major non-fatal bleeding (n=0 [0%] in the NOAC cohort vs n=4 [14.3%] in the warfarin cohort), and fatal bleeding (n=1 [6.7%] in the NOAC cohort vs n=4 [14.3%] in the warfarin cohort) were observed among patients receiving NOACs.
 

Table 2. Comparison of outcomes between warfarin and non–vitamin K oral anticoagulant cohorts
 

Fig 1. Kaplan-Meier curve of cumulative freedom from net adverse clinical events (NACEs) during the study period. The hazard ratio was calculated by Cox regression with adjustment for clinical statuses of diabetes mellitus and atrial fibrillation or flutter
 

Fig 2. Kaplan-Meier curve of cumulative survival during the study period. The hazard ratio was calculated by Cox regression with adjustment for clinical statuses of diabetes mellitus and atrial fibrillation or flutter
 
Concerning secondary outcomes, there were no significant differences between the two cohorts in LVT resolution (P=0.451) or percentage reduction in LVT size (P=0.390) at the 3-month follow-up.
 
The outcomes of patients whose had or had not discontinued anticoagulation therapy by 1 year are summarised in Table 3. There were no significant differences between the two cohorts.
 

Table 3. Comparison of outcomes between patients with or without anticoagulation discontinuation at 1 year
 
Discussion
In this retrospective cohort study, we explored the use of NOACs as an alternative to warfarin for LVT management in a Hong Kong hospital. Although the sample size was limited, we found that NOAC use was associated with significantly fewer NACEs, with a tendency towards differences in cumulative survival. Additionally, anticoagulation discontinuation by 1-year post-diagnosis was not associated with significantly different clinical outcomes.
 
Our results confirm and extend previous findings concerning similar rates of LVT regression between NOAC and warfarin therapies; moreover, it has been reported that NOAC use is at least non-inferior to warfarin in terms of cumulative survival.2 Importantly, we demonstrated significantly lower rates of NACEs in NOAC users, a key finding that was likely driven by tendencies towards reductions in ischaemic stroke and major non-fatal bleeding. The numerically lower rate of major non-fatal bleeding in NOAC users was consistent with previous findings of lower bleeding risk among patients receiving NOACs compared with patients receiving warfarin.9 10 11 This reduction in bleeding risk is more prominent among Asian individuals than among non-Asian individuals.12 Therefore, it is possible that clinical practice recommendations for Asian individuals should be different from that for non-Asian individuals.
 
A recent study by Abdelnabi et al13 demonstrated significantly more effective resolution of LVT with rivaroxaban. We did not observe such difference, consistent with recent findings by Iqbal et al.14 These discrepancies may be related to differences in imaging intervals: we repeated echocardiography at 3 months and Iqbal et al14 repeated imaging at a mean interval of 233 days, whereas Abdelnabi et al13 repeated imaging at 1 month. Importantly, Abdelnabi et al13 observed converging rates of thrombus resolution by 3 and 6 months after initiation of anticoagulation, when they performed additional imaging. It is thus possible that frequent imaging intervals (more frequent than that recommended by societal guidelines3 4) are required to demonstrate differences in the rate of thrombus resolution. Although the clinical benefits of NOACs in our cohort were mainly driven by a reduction in bleeding events, more rapid thrombus resolution may be relevant in other populations. Further investigation in this area may be warranted.
 
Another recent study by Robinson et al7 revealed significantly higher rates of systemic thromboembolism among patients receiving NOACs, compared with those receiving warfarin. In the present study, systemic embolism was rare, and there were no pronounced numerical differences in the rates of systemic embolism between cohorts. Although this finding may be partly related to our small sample size, ethnic differences in thromboembolic tendencies could also play important roles. It has been observed that Asian individuals are generally less susceptible to thromboembolism than Caucasian and Hispanic individuals,15 consistent with the rarity of systemic thromboembolism in our cohort. These findings may imply that any increase in systemic thromboembolism associated with NOAC use, as detected by Robinson et al,7 is less relevant for Asian patients. Considering this lack of relevance and the reduction in NACEs observed in the present study, NOAC use may be preferrable to warfarin in Asian patients. Further studies with larger cohorts should be conducted to confirm these findings.
 
Additionally, we observed that considering the resolution of LVT, anticoagulation discontinuation by 1 year probably did not lead to significantly different rates of adverse outcomes, despite the numerically higher rate of cerebrovascular accidents. Although Lattuca et al2 showed that anticoagulation for ≥3 months reduced the incidence of major adverse cardiovascular events, it has been unclear whether anticoagulation can be discontinued after resolution of LVT. Our results, derived from a small cohort, warrant further investigation in larger cohorts.
 
Limitations
There were several limitations in this study. First, the sample size was limited, primarily due to the rarity of LVT—although the study was conducted in a large tertiary hospital, only 43 patients could be included over a 9-year period. Second, various NOACs were used. Nonetheless, subgroup analysis was precluded by the small sample size; the present study design remains valid as a general comparison of vitamin K versus non–vitamin K anticoagulants, especially because all included NOACs are commonly prescribed. Third, more patients in the NOAC cohort had diabetes mellitus and atrial fibrillation or flutter. Despite these co-morbidities, we found that NOACs remained statistically superior to warfarin for NACEs; we also found a tendency for better cumulative mortality among patients receiving NOACs after adjustment for these two co-morbidities. Thus, our results remain valid in terms of demonstrating the probable superiority of NOACs over warfarin for LVT management in Asian patients.
 
Conclusion
The use of NOACs to treat patients with LVT was associated with significantly fewer NACEs, with a tendency towards lower cumulative mortality. Additionally, anticoagulation discontinuation by 1 year might be safe for patients with LVT resolution. Overall, NOACs may be superior to warfarin for LVT management. Further studies are required to confirm our findings and determine the optimal duration of anticoagulation therapy for LVT management.
 
Author contributions
Concept or design: KKH Kam, JSK Chan.
Acquisition of data: KKH Kam.
Analysis or interpretation of data: JSK Chan.
Drafting of the manuscript: JSK Chan.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
KKH Kam and JSK Chan have disclosed no conflicts of interest. APW Lee received grants, consulting fees/honoraria, and research support from Boehringer Ingelheim, Bayer, and Pfizer.
 
Declaration
This research was presented as a poster at the European Society of Cardiology Congress 2021 (27-30 August 2021, online).
 
Funding/support
This research was supported by the Hong Kong Special Administrative Region Government Health and Medical Research Fund (Grant No.: 05160976). The funder had no role in study design, data collection/analysis/interpretation or manuscript preparation.
 
Ethics approval
This research was approved by The Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (Ref No.: 2020.425). The need for individual patient consent was waived by the Committee due to the retrospective nature of the study.
 
References
1. Lee JM, Park JJ, Jung HW, et al. Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb. 2013;20:73-93. Crossref
2. Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol 2020;75:1676-85. Crossref
3. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119-77. Crossref
4. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236. Crossref
5. McCarthy CP, Murphy S, Venkateswaran RV, et al. Left ventricular thrombus: contemporary etiologies, treatment strategies, and outcomes. J Am Coll Cardiol 2019;73:2007-9. Crossref
6. Kajy M, Shokr M, Ramappa P. Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature. Am J Ther 2020;27:e584-90. Crossref
7. Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 2020;5:685-92. Crossref
8. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 2011;123:2736-47. Crossref
9. Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2017;23:968-78. Crossref
10. Chan YH, See LC, Tu HT, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc 2018;7:e008150.Crossref
11. Patel P, Pandya J, Goldberg M. NOACs vs. warfarin for stroke prevention in nonvalvular atrial fibrillation. Cureus 2017;9:e1395. Crossref
12. Yamashita Y, Morimoto T, Toyota T, et al. Asian patients versus non-Asian patients in the efficacy and safety of direct oral anticoagulants relative to vitamin K antagonist for venous thromboembolism: a systemic review and meta-analysis. Thromb Res 2018;166:37-42. Crossref
13. Abdelnabi M, Saleh Y, Fareed A, et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT trial). J Am Coll Cardiol 2021;77:1590-2. Crossref
14. Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Hear Fail 2020;7:2032-41. Crossref
15. Zakai NA, McClure LA. Racial differences in venous thromboembolism. J Thromb Haemost 2011;9:1877-82. Crossref

Long-term trends in the incidence and management of shoulder dystocia in a tertiary obstetric unit in Hong Kong

Hong Kong Med J 2023 Dec;29(6):524–31 | Epub 14 Sep 2023
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Long-term trends in the incidence and management of shoulder dystocia in a tertiary obstetric unit in Hong Kong
Eric HL Chan, MB, ChB, MRCOG; SL Lau, MB, ChB, MRCOG; TY Leung, MD, FRCOG
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China
 
Corresponding author: Prof TY Leung (tyleung@cuhk.edu.hk)
 
 Full paper in PDF
 
Abstract
Introduction: Because there have been changes in the management of macrosomic pregnancies and shoulder dystocia in the past decade, this study was conducted to compare the incidences of shoulder dystocia and perinatal outcomes between the periods of 2000-2009 and 2010-2019.
 
Methods: This retrospective study was conducted in a tertiary obstetric unit. All cases of shoulder dystocia were identified using the hospital’s electronic database. The incidences, maternal and fetal characteristics, obstetric management methods, and perinatal outcomes were compared between the two study periods.
 
Results: The overall incidence of shoulder dystocia decreased from 0.23% (134/58 326) in 2000-2009 to 0.16% (108/65 683) in 2010-2019 (P=0.009), mainly because of the overall decline in the proportion of babies with macrosomia (from 3.3% to 2.3%; P<0.001). The improved success rates of the McRoberts’ manoeuvre (from 31.3% to 47.2%; P=0.012) and posterior arm extraction (from 52.9% to 92.3%; P=0.042) allowed a greater proportion of affected babies to be delivered within 2 minutes (from 59.0% to 79.6%; P=0.003). These changes led to a significant reduction in the proportion of fetuses with low Apgar scores: <5 at 1 minute of life (from 13.4% to 5.6%; P=0.042) and <7 at 5 minutes of life (from 11.9% to 4.6%; P=0.045).
 
Conclusion: More proactive management of macrosomic pregnancies and enhanced training in the acute management of shoulder dystocia led to significant improvements in shoulder dystocia incidence and perinatal outcomes from 2000-2009 to 2010-2019.
 
 
New knowledge added by this study
  • The incidence of shoulder dystocia decreased from 2000-2009 to 2010-2019, mainly because of a reduction in the proportion of babies with macrosomia.
  • Perinatal outcomes in cases of shoulder dystocia were improved because of enhanced dystocia relief skills and an overall decline in birth weight.
Implications for clinical practice or policy
  • Proactive management in cases of suspected macrosomia (eg, early induction of labour) effectively reduced the incidence of shoulder dystocia.
  • The incidence of shoulder dystocia was significantly greater among cases with birth weight ≥4200 g, which may be a reasonable threshold for considering elective caesarean section.
  • Appropriate training (eg, using SOPHIE course) led to improvements in shoulder dystocia relief skills and better perinatal outcomes.
 
 
Introduction
Shoulder dystocia is an uncommon obstetric emergency with an incidence that reportedly ranging from 0.58% to 0.7%.1 2 3 It can result in severe perinatal morbidities, including brachial plexus palsies, clavicular fractures, humeral fractures, hypoxic-ischaemic encephalopathy, cerebral palsy, and even mortality soon after birth.1 2 3 4 5 6 Considering the unpredictable and complex nature of shoulder dystocia, many professional bodies have established systematic approaches with routine training simulations and algorithms to improve fetal outcomes in such cases.1 2 7 8 9 The most common approach is represented by the HELPERR mnemonic, which consists of a sequence of manoeuvres including the McRoberts’ manoeuvre, suprapubic pressure, rotational methods, posterior arm delivery, all-fours position, and clavicular fracture.7 Although the McRoberts’ manoeuvre and suprapubic pressure are often the preferred initial manoeuvres, their success rates (56.0%) are lower than that of the rotational methods (62.4%) and posterior arm delivery (86.1%).5 6 10 The Royal College of Obstetricians and Gynaecologists (RCOG) in 20121 and the American College of Obstetricians and Gynecologists in 20172 revised their guidelines to indicate that either posterior arm delivery or rotational methods can be used after an unsuccessful attempt of the McRoberts’ manoeuvre. Furthermore, a randomised controlled trial published in 2015 demonstrated that the induction of labour at 38 weeks in macrosomic pregnancies could reduce the risk of shoulder dystocia, compared with expectant management.11 The overall caesarean rate did not increase when using this approach. Accordingly, early induction of labour has become an option in cases of suspected fetal macrosomia.
 
Considering changes in the management of macrosomic pregnancies and shoulder dystocia in the past decade, this study compared the incidences of shoulder dystocia, the maternal and fetal characteristics in such cases, and their obstetric management methods and perinatal outcomes between the periods of 2000-2009 and 2010-2019.
 
Methods
Study design
This retrospective study was conducted in a university tertiary obstetric unit that provided obstetric services in the New Territories East Cluster of Hong Kong. All consecutive cases of shoulder dystocia reported from 2000 to 2019 inclusive were identified using the hospital’s electronic database.12 Shoulder dystocia was objectively defined as the requirement of an ancillary obstetric manoeuvre following failed delivery of the anterior shoulder after downward fetal neck traction or head-to-body delivery interval (HBDI) >1 minute, as described in previous reports.4 5 13 Multiple pregnancies, vaginal breech deliveries, and known stillbirths before labour were excluded. Our unit protocol for the management of shoulder dystocia followed the RCOG Green-top Guidelines for shoulder dystocia that was published in 2005 and updated in 2012.1 Beginning in 2002, hands-on training in shoulder dystocia relief was routinely conducted using the ALSO (Advanced Life Support in Obstetrics) program7; the PROMPT (Practical Obstetric Multi-Professional Training)8 and the SOPHIE (Safe Obstetric Practice for High risk and Emergency)9 training methods were added in 2011, after the publication of our articles regarding shoulder dystocia.4 5 The McRoberts’ manoeuvre with or without suprapubic pressure was usually the first manoeuvre performed, followed by a rotational manoeuvre or posterior arm delivery if the McRoberts’ manoeuvre was unsuccessful. A midwife was designated to document each event, including the personnel involved, usage and duration of manoeuvres, and delivery times of the fetal head and fetal body. Umbilical cord blood was collected immediately after delivery for blood gas analysis using a Bayer Rapidpoint 400 Blood Gas Analyzer (Bayer HealthCare, Seattle [WA], United States), as described in our previous reports.14 15 Delivery data, including birth weight and perinatal complications, were recorded immediately after delivery by the attending staff, then crosschecked by another staff member. Two to 3 months later, fetal outcomes were subjected to further review and confirmation during postnatal follow-up and monthly audit meetings. All midwives and obstetricians attended annual training sessions regarding the management of shoulder dystocia.
 
Identified cases and corresponding medical records were reviewed to collect maternal, fetal, and obstetric characteristics. Advanced maternal age was defined as ≥35 years at the estimated date of delivery. Short stature was defined as maternal height <150 cm. Maternal body weights at booking and delivery were recorded to calculate the body mass index (BMI) at each time point. Obesity was defined as BMI >30 kg/m2, in accordance with World Health Organization guidelines.16 17 Parity and diabetes mellitus/gestational diabetes mellitus statuses were noted. Obstetric and neonatal characteristics were recorded, including delivery mode, fetal distress, birth weight, HBDI duration, and the use and sequence of manoeuvres. Macrosomia was defined as birth weight ≥4000 g. Neonatal outcomes were also recorded, including the Apgar scores at 1 minute and 5 minutes of life, cord arterial pH, and neonatal complications (eg, subgaleal haemorrhage, hypoxic-ischaemic encephalopathy, brachial plexus injury, clavicular fracture, and humeral fracture).
 
Statistical analysis
The incidences of shoulder dystocia were calculated for three groups: all singleton live pregnancies (excluding multiple pregnancies and stillbirths), all singleton live cephalic-presenting pregnancies with spontaneous onset of labour (excluding cases of fetal malpresentation and elective caesarean deliveries), and all singleton live cephalic-presenting pregnancies with successful vaginal delivery (excluding emergency caesarean deliveries).12 The incidences of shoulder dystocia were also calculated for various birth weight ranges.
 
The incidences of shoulder dystocia, maternal and fetal characteristics in each case, and perinatal outcomes were compared between 2000-2009 and 2010-2019. Analyses were performed using SPSS (Windows version 26.0; IBM Corp, Armonk [NY], United States). The incidences of shoulder dystocia; maternal, obstetric, and fetal characteristics; and neonatal complications related to shoulder dystocia during 2000-2009 and 2010-2019 were analysed using the Chi squared test and Fisher’s exact test for categorical variables, t test for parametric continuous variables, and Mann-Whitney U test for non-parametric continuous variables. The threshold for statistical significance was set at P<0.05.
 
Results
In total, this study included 242 cases of shoulder dystocia in the study unit. Table 1 shows the incidences of shoulder dystocia in each decade according to type of birth and range of birth weight. The overall incidence of shoulder dystocia among all singleton live pregnancies decreased from 0.23% (134/58 326) during 2000-2009 to 0.16% (108/65 683) during 2010-2019 (P=0.009). Similarly, the incidence of shoulder dystocia among singleton cephalic-presenting pregnancies with spontaneous onset of labour decreased from 0.25% to 0.19% (P=0.031), and the incidence of shoulder dystocia among singleton cephalic-presenting pregnancies with vaginal delivery decreased from 0.29% to 0.21% (P=0.017). The incidences of shoulder dystocia were generally similar across birth weight categories, but the incidence considerably decreased in the 4200-4399 g group.
 

Table 1. Incidences of shoulder dystocia according to birth weight category among all singleton pregnancies, singleton cephalic-presenting pregnancies with spontaneous onset of labour, and singleton live cephalic-presenting pregnancies delivered vaginally during the periods of 2000-2009 and 2010-2019
 
Table 2 shows the birth weight distribution for all singleton cephalic live pregnancies. The mean birth weight decreased from 3180 ± 472 g during 2000-2009 to 3132 ± 463 g during 2010-2019 (P<0.001). The proportion of babies weighing ≥4000 g was 3.3% during 2000-2009, whereas it was 2.3% during 2010-2019.
 

Table 2. Birth weight distribution among all singleton cephalic live pregnancies during the periods of 2000-2009 and 2010-2019
 
Table 3 illustrates the maternal and obstetric characteristics in cases of shoulder dystocia during each decade. There were no statistically significant differences between the two decades in terms of advanced maternal age, maternal age, maternal height, maternal weight at booking and delivery, BMI at booking and delivery, obesity at delivery, or nulliparity. However, the proportion of shoulder dystocia cases involving maternal diabetes increased from 9.0% during 2000-2009 to 19.4% during 2010-2019 (P=0.018). Additionally, the proportion of shoulder dystocia cases involving instrumental delivery decreased from 65.7% to 47.2% (P=0.004), but there was no statistically significant difference in the proportion of deliveries involving fetal distress. Although there was no significant change in birth weight, the proportion of babies with macrosomia among shoulder dystocia cases tended to decrease over time (from 27.6% to 18.5%; P=0.097).
 

Table 3. Maternal and obstetric characteristics in cases of shoulder dystocia during the periods of 2000-2009 and 2010-2019
 
Table 4 shows the success rates of various manoeuvres in terms of alleviating shoulder dystocia. During 2010-2019, 79.6% of babies in cases of shoulder dystocia had HBDI ≤2 minutes; 14.8% and 5.6% of such babies had HBDI of 3-4 minutes and ≥5 minutes, respectively. These proportions were significantly better than the proportions during 2000-2009 (59.0%, 31.3%, and 9.7%, respectively; P=0.003). The success rate of the McRoberts’ manoeuvre in terms of alleviating shoulder dystocia increased from 31.3% to 47.2% (P=0.012) among all vaginal deliveries, which was partially attributed to the increased success rate among instrumental deliveries (from 20.5% to 39.2%; P=0.017). Although the rotational manoeuvre continued to be preferred over posterior arm extraction (77.6% vs. 22.4%) after failure of the McRoberts’ manoeuvre and suprapubic pressure, the success rate of posterior arm extraction increased from 52.9% in 2000-2009 to 92.3% in 2010-2019 (P=0.042). Table 5 shows the neonatal outcomes of shoulder dystocia. There were significant reductions in the rates of low Apgar scores: for an Apgar score <5 at 1 minute of life, the rate decreased from 13.4% to 5.6% (P=0.042); for an Apgar score <7 at 5 minutes of life, the rate decreased from 11.9% to 4.6% (P=0.045). There were no statistically significant changes in the rates of other neonatal complications.
 

Table 4. Performances of various manoeuvres in terms of alleviating shoulder dystocia during the periods of 2000-2009 and 2010-2019
 

Table 5. Neonatal outcomes of shoulder dystocia during the periods of 2000-2009 and 2010-2019
 
Discussion
Trend in the incidence of shoulder dystocia
This study revealed a significant reduction in the overall incidence of shoulder dystocia over the past two decades in a tertiary obstetric unit in Hong Kong. One possible reason is the increased use of caesarean delivery, in both elective and emergency settings, in cases of suspected macrosomia. This hypothesis is supported by the decrease in the incidences of shoulder dystocia among all births and among all pregnancies with onset of labour in the 4200-4399 g subgroup during 2010-2019 (Table 1). However, such decreases were not observed in other subgroups with babies weighing ≥4000 g (4000-4199 g, 4400-4599 g, and ≥4600 g) [Table 1]. These findings suggest that caesarean delivery in cases of suspected macrosomia is not a major factor contributing to shoulder dystocia prevention. Furthermore, the absence of any change in shoulder dystocia incidence among subgroups with babies weighing <4200 g was consistent with our departmental practice of using 4200 g, rather than 4000 g, as a threshold for offering caesarean delivery to non-diabetic women. The use of a lower fetal weight threshold (eg, 4000 g) in pregnant Chinese women could lead to an unnecessary increase in the rate of caesarean delivery.18 The practice of early induction of labour in cases of suspected macrosomia may be the main factor contributing to the decrease in shoulder dystocia incidence.11 Since 2011, women with a fetal abdominal circumference or estimated fetal weight above the 97th percentile (but <4200 g) have been counselled about the risk of difficult labour, along with the benefits and risks of inducing labour to prevent further macrosomia. These approaches are consistent with the decreases in overall mean birth weight and proportion of babies ≥4000 g from 2000-2009 to 2010-2019 (Table 2).
 
Improvements in the acute management of shoulder dystocia
Additionally, our study revealed improvements in the acute management of shoulder dystocia. In particular, the overall success rate of the McRoberts’ manoeuvre in terms of alleviating shoulder dystocia improved from 31.3% during 2000-2009 to 47.2% during 2010-2019; these results were consistent with rates in published reports, which have considerably varied from 23% to 70%.5 6 19 20 21 Our improved success rate was mainly attributed to the increased success rate among instrumental deliveries (from 20.5% to 39.2%) [Table 4]. We previously speculated that instrumental delivery increased the risk of shoulder dystocia while reducing the likelihood of McRoberts’ manoeuvre success, presumably related to delayed descent of the shoulders during instrumental delivery.22 The SOPHIE training emphasises that proper performance of the McRoberts’ manoeuvre should result in cephaloid rotation of the mother’s pelvis, manifested by elevation of the mother’s buttocks from the bed. To achieve this goal, the best method for hyperflexion of the mother’s hips involves grasping the back of the mother’s distal thigh and pushing it in the direction of the mother’s head. By leaning in the same direction, the clinician can use their own weight to facilitate hip hyperflexion. A common mistake is holding the mother’s knee and pushing at the foot. The resulting force is reduced and the mother may experience discomfort at the ankle joint (Fig a and b).9
 

Figure. McRoberts’ manoeuvre. (a) A common mistake involves holding the mother’s knee and pushing at the foot (blue arrow), which makes the manoeuvre less effective. (b) Hyperflexion of the mother’s hips is achieved by grasping the back of the mother’s distal thigh and pushing it in the direction of the mother’s head (blue arrow). By leaning in the same direction (red arrow), the clinician can use their own weight to facilitate hip hyperflexion. An effective McRoberts’ manoeuvre should result in cephaloid rotation of the mother’s pelvis (curved yellow arrow), manifested by elevation of the mother’s buttocks from the bed (black arrow). (c and d) Posterior arm delivery. The fetal left posterior forearm is grasped by the clinician’s left hand. The direction of the extraction is outward and upward (blue straight arrow), enabling rotation of the posterior shoulder (curved red arrows; clockwise direction in this scenario)
 
Importantly, this study showed an increasing trend in the utilisation of posterior arm delivery during 2010-2019, which is consistent with the updated practice guidelines from the RCOG and the American College of Obstetricians and Gynecologists during the same period.1 2 The success rate of posterior arm delivery also substantially increased (from 52.9% to 92.3%) [Table 4] and humeral fracture (a complication associated with posterior arm delivery) did not occur in any case during 2010-2019. The improvement in the success and safety may be related to the enhanced training through the SOPHIE course, which emphasises that the clinician should use the correct hand (ie, right hand for a fetus facing the mother’s left side, and vice versa); this hand should be inserted into the vagina with sufficient depth to reach the fetal posterior forearm, and extraction should be conducted by grasping the forearm (rather than the elbow or upper arm). The direction of the extraction should be outward and upward to generate a rotational effect on the shoulders (Fig c and d).9 10
 
In addition to enhanced clinician skills, improved management of shoulder dystocia may have resulted from a decline in birth weight from 2000-2009 to 2010-2019, although the difference was not statistically significant. Improvements in the success rates of the McRoberts’ manoeuvre and posterior arm delivery led to improved management of shoulder dystocia, represented by a shorter HBDI (Table 4). Among cases of shoulder dystocia, the proportion of babies with an HBDI of ≤2 minutes increased from 59.0% during 2000-2009 to 79.6% during 2010-2019; conversely, the proportion of such babies with HBDI ≥5 minutes decreased from 9.7% to 5.6% (Table 4). Along with the improvement in HBDI, fewer babies had a low Apgar score. However, such improvements did not lead to significant reductions in the incidences of severe fetal acidosis and hypoxic-ischaemic encephalopathy, possibly because of the small sample size. The management of prenatally missed macrosomia with severe shoulder dystocia remains a substantial challenge. Our group recently reported a severe case of shoulder dystocia in which the posterior shoulder was also lodged in the middle of the pelvic cavity. The situation was resolved by our modified posterior axillary sling traction technique, which involved using a ribbon gauze to form a sling, in combination with long and slim right-angle forceps to facilitate sling placement.23 In our report as well as in our recent review, we emphasised that the sling primarily functions by facilitating shoulder rotation to enable delivery through the wider diagonal diameter of the outlet of the birth canal.10
 
Strengths and limitations
The strengths of this study include its analysis of a relatively large number of women over two decades, the use of complete and audited outcomes data, and the uniform management of pregnancy complications in accordance with standard guidelines and department protocols.12 However, because this was a retrospective study, causal factors underlying the findings could not be fully elucidated; possible confounding factors included changes in the management of pregnancy complications, management of babies with macrosomia, and management of shoulder dystocia, as well as changes in the levels of skills and experience among clinical personnel during the study period.
 
Conclusion
More proactive management of macrosomic pregnancies led to decreases in the overall proportion of babies with macrosomia and incidence of shoulder dystocia from 2000-2009 to 2010-2019. Improvements in shoulder dystocia relief skills were demonstrated by increases in the success rates of manoeuvres (eg, the McRoberts’ manoeuvre and posterior arm delivery), as well as decreases in HBDI and Apgar scores.
 
Author contributions
All authors contributed to the concept or design of the study, acquisition of the data, analysis or interpretation of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
The corresponding author is the programme director for the Safe Obstetric Practice for High risk and Emergency (SOPHIE) course. Other authors have disclosed no conflicts of interest.
 
Acknowledgement
The authors thank the creators of the SOPHIE course (https://www.obg.cuhk.edu.hk/training-education/sophie-course/) and Ms Catherine Chan at the Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong for contributing to the illustrations.
 
Funding/support
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
 
Ethics approval
Ethical approval was obtained from the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (Ref No.: CRE 2017.442). Informed patient consent was waived by the Committee due to the retrospective nature of the study.
 
References
1. Royal College of Obstetricians and Gynaecologists. Shoulder Dystocia. Green-Top Guideline No. 42. 2nd Edition. London: Royal College of Obstetricians and Gynaecologists. 2012. Available from: https://www.rcog.org.uk/media/ewgpnmio/gtg_42.pdf. Accessed 14 Aug 2023.
2. Practice Bulletin No 178: Shoulder Dystocia [editorial]. Obstet Gynecol 2017;129:e123-33. Crossref
3. Leung TY, Chung TK. Severe chronic morbidity of childbirth. Best Pract Clin Res Obstet Gynaecol 2009;23:401-23. Crossref
4. Leung TY, Stuart O, Sahota DS, Suen SS, Lau TK, Lao TT. Head-to-body delivery interval and risk of fetal acidosis and hypoxic ischaemic encephalopathy in shoulder dystocia: a retrospective review. BJOG 2011;118:474-9. Crossref
5. Leung TY, Stuart O, Suen SS, Sahota DS, Lau TK, Lao TT. Comparison of perinatal outcomes of shoulder dystocia alleviated by different type and sequence of manoeuvres: a retrospective review. BJOG 2011;118:985-90. Crossref
6. Hoffman MK, Bailit JL, Branch DW, et al. A comparison of obstetric maneuvers for the acute management of shoulder dystocia. Obstet Gynecol 2011;117:1272-8. Crossref
7. American Academy of Family Physicians. Advanced Life Support in Obstetrics (ALSO®). Available from: https://www.aafp.org/cme/programs/also.html. Accessed 7 Jan 2022.
8. PROMPT Maternity Foundation. Practical Obstetric Multi-Professional Training. Available from: https://www.promptmaternity.org. Accessed 7 Jan 2022.
9. Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong & Prince of Wales Hospital. SOPHIE Course–Safe Obstetric Practice for High risk and Emergency Course. Available from: https://www.obg.cuhk.edu.hk/training-education/sophie-course/. Accessed 14 Aug 2023.
10. Lau SL, Sin WT, Wong L, Lee NM, Hui SY, Leung TY. A critical evaluation of the external and internal maneuvers for resolution of shoulder dystocia. Am J Obstet Gynecol. In press. Crossref
11. Boulvain M, Senat MV, Perrotin F, et al. Induction of labour versus expectant management for large-for-date fetuses: a randomised controlled trial. Lancet 2015;385:2600-5. Crossref
12. Wong ST, Tse WT, Lau SL, Sahota DS, Leung TY. Stillbirth rate in singleton pregnancies: a 20-year retrospective study from a public obstetric unit in Hong Kong. Hong Kong Med J 2022;28:285-93. Crossref
13. Spong CY, Beall M, Rodrigues D, Ross MG. An objective definition of shoulder dystocia: prolonged head-to-body delivery intervals and/or the use of ancillary obstetric maneuvers. Obstet Gynecol 1995;86:433-6. Crossref
14. Leung TY, Lok IH, Tam WH, Leung TN, Lau TK. Deterioration in cord blood gas status during the second stage of labour is more rapid in the second twin than in the first twin. BJOG 2004;111:546-9. Crossref
15. Leung TY, Tam WH, Leung TN, Lok IH, Lau TK. Effect of twin-to-twin delivery interval on umbilical cord blood gas in the second twins. BJOG 2002;109:63-7. Crossref
16. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63. Crossref
17. Leung TY, Leung TN, Sahota DS, et al. Trends in maternal obesity and associated risks of adverse pregnancy outcomes in a population of Chinese women. BJOG 2008;115:1529-37. Crossref
18. Cheng YK, Lao TT, Sahota DS, Leung VK, Leung TY. Use of birth weight threshold for macrosomia to identify fetuses at risk of shoulder dystocia among Chinese populations. Int J Gynaecol Obstet 2013;120:249-53. Crossref
19. McFarland MB, Langer O, Piper JM, Berkus MD. Perinatal outcome and the type and number of maneuvers in shoulder dystocia. Int J Gynaecol Obstet 1996;55:219-24. Crossref
20. Gherman RB, Goodwin TM, Souter I, Neumann K, Ouzounian JG, Paul RH. The McRoberts’ maneuver for the alleviation of shoulder dystocia: how successful is it? Am J Obstet Gynecol 1997;176:656-61. Crossref
21. Spain JE, Frey HA, Tuuli MG, Colvin R, Macones GA, Cahill AG. Neonatal morbidity associated with shoulder dystocia maneuvers. Am J Obstet Gynecol 2015;212:353.e1-5. Crossref
22. Lok ZL, Cheng YK, Leung TY. Predictive factors for the success of McRoberts’ manoeuvre and suprapubic pressure in relieving shoulder dystocia: a cross-sectional study. BMC Pregnancy Childbirth 2016;16:334. Crossref
23. Kwan AH, Hui AS, Lee JH, Leung TY. Intrauterine fetal death followed by shoulder dystocia and birth by modified posterior axillary sling method: a case report. BMC Pregnancy Childbirth 2021;21:672. Crossref

Ten-year territory-wide trends in the utilisation and clinical outcomes of extracorporeal membrane oxygenation in Hong Kong

Hong Kong Med J 2023 Dec;29(6):514–23 | Epub 16 Nov 2023
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE  CME
Ten-year territory-wide trends in the utilisation and clinical outcomes of extracorporeal membrane oxygenation in Hong Kong
Pauline Y Ng, MB, BS, FHKCP1,2; Vindy WS Chan1; April Ip, MPH1; Lowell Ling, MB, BS, FHKCA3; KM Chan, MB, ChB, FCICM3; Anne KH Leung, MB, ChB, FHKCA4; Kenny KC Chan, MB, ChB, MStat5; Dominic So, MB, BS, HKCA6; HP Shum, MB, BS, MD7; CW Ngai, MB, ChB, FHKCP2; WM Chan, MB, ChB, FHKCP2; WC Sin, MB, ChB, FHKCP2,8
1 Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 Department of Adult Intensive Care, Queen Mary Hospital, Hong Kong SAR, China
3 Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China
4 Department of Intensive Care, Queen Elizabeth Hospital, Hong Kong SAR, China
5 Department of Intensive Care, Tuen Mun Hospital, Hong Kong SAR, China
6 Department of Intensive Care, Princess Margaret Hospital, Hong Kong SAR, China
7 Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China
8 Department of Anaesthesiology, The University of Hong Kong, Hong Kong SAR, China
 
Corresponding author: Dr PY Ng (pyeungng@hku.hk)
 
 Full paper in PDF
 
Abstract
Introduction: The utilisation of extracorporeal membrane oxygenation (ECMO) has been rapidly increasing in Hong Kong. This study examined 10-year trends in the utilisation and clinical outcomes of ECMO in Hong Kong.
 
Methods: We retrospectively reviewed the records of all adult patients receiving ECMO who were admitted to the intensive care units (ICUs) of public hospitals in Hong Kong between 2010 and 2019. Temporal trends across years were assessed using the Mann–Kendall test. Observed hospital mortality was compared with the Acute Physiology and Chronic Health Evaluation (APACHE) IV–predicted mortality.
 
Results: The annual number of patients receiving ECMO increased from 18 to 171 over 10 years. In total, 911 patients received ECMO during the study period: 297 (32.6%) received veno-arterial ECMO, 450 (49.4%) received veno-venous ECMO, and 164 (18.0%) received extracorporeal cardiopulmonary resuscitation. The annual number of patients aged ≥65 years increased from 0 to 47 (27.5%) [P for trend=0.001]. The median (interquartile range) Charlson Comorbidity Index increased from 1 (0-1) to 2 (1-3) [P for trend<0.001] while the median (interquartile range) APACHE IV score increased from 90 (57-112) to 105 (77-137) [P for trend=0.003]. The overall standardised mortality ratio comparing hospital mortality with APACHE IV–predicted mortality was 1.11 (95% confidence interval=1.01-1.22). Hospital and ICU length of stay both significantly decreased (P for trend=0.011 and <0.001, respectively).
 
Conclusions: As ECMO utilisation increased in Hong Kong, patients put on ECMO were older, more critically ill, and had more co-morbidities. It is important to combine service expansion with adequate resource allocation and training to maintain quality of care.
 
 
New knowledge added by this study
  • During the 10-year study period, there was increasing utilisation of extracorporeal membrane oxygenation (ECMO) in older patients, patients with more co-morbidities, and patients with greater disease severity.
  • Patients receiving ECMO require significant resources for out-of-hours services, inter-hospital transfers, and major operations.
  • Although the observed hospital mortality was comparable with the Acute Physiology and Chronic Health Evaluation IV–predicted mortality, efforts should be made to systematically collect physiological data for computation of Survival after Veno-Arterial ECMO and Respiratory ECMO Survival Prediction scores in the future.
Implications for clinical practice or policy
  • Among patients receiving ECMO in Hong Kong, clinical outcomes can be improved by revising patient selection criteria, enhancing therapy for bridge to transplantation and promoting organ transplantation, and consolidating ECMO services in specialised centres.
 
 
Introduction
Extracorporeal membrane oxygenation (ECMO) offers life-sustaining support by supplementing heart and lung functions in patients with circulatory or respiratory failure. There is increasing utilisation of ECMO in intensive care units (ICUs) worldwide; for example, the Extracorporeal Life Support Organization (ELSO) registry reported a 10-fold increase in ECMO runs from 1643 in 1990 to 18 260 in 2020.1 Hong Kong is a Special Administrative Region of the People’s Republic of China, with a population of 7.4 million and an independent healthcare system.2 In Hong Kong, various assessments of ICU performance have been performed for other disease entities,3 but there have been few reports of ECMO-specific data and patient outcomes.4 In particular, Hong Kong has a higher ECMO centre–to-population ratio compared with international guidelines.5 6 A retrospective study examined the risk score–mortality association in patients receiving ECMO, but it only included data from a single tertiary ICU and was not fully representative of territory-wide practices.7 Because ECMO is a high-cost, labour-intensive ICU treatment modality, it is important to understand how ECMO is utilised in Hong Kong, its associated resource implications, and review patient outcomes for future planning efforts.
 
In this study, using a territory-wide administrative registry of all patients receiving ECMO in the ICUs of public hospitals in Hong Kong, we examined trends in ECMO utilisation and clinical outcomes. Our primary objective was to summarise the status of ECMO services in Hong Kong over the past decade.
 
Methods
Study population
This retrospective observational study covered the period from 1 January 2010 to 31 December 2019. All adult patients aged ≥18 years with an ECMO episode and admission to the ICU of a public hospital under the Hospital Authority were identified using an administrative ECMO patient registry managed by a centralised ICU committee. An episode of ECMO was defined on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code for ECMO.8 The need for ICU admission was determined using the Acute Physiology and Chronic Health Evaluation IV (APACHE IV) evaluation form.9 10 Patients with missing ECMO details (eg, ECMO duration and configuration) and patients managed in non-mixed disciplinary ICUs were excluded from the study.
 
Data collection
Extracorporeal membrane oxygenation data were extracted from the administrative patient registry, which contained information about ECMO configuration, time of initiation, and time of discontinuation that had been entered by qualified nurses at the corresponding ECMO centre. The Clinical Data Analysis and Reporting System (CDARS), a central de-identified data repository comprising electronic health records from all public hospitals in Hong Kong, was accessed to collect patient baseline characteristics and components of the following disease severity scores: Sequential Organ Failure Assessment (SOFA),11 Survival after Veno-Arterial ECMO (SAVE),12 Respiratory ECMO Survival Prediction (RESP),13 Charlson Comorbidity Index (CCI), and APACHE IV14 (online supplementary Table 1). For patients with multiple ICU admissions during a single hospital stay, the APACHE IV score for the first ICU admission was used. Clinical outcomes including length of stay (LOS) and mortality were retrieved from the CDARS.
 
Study outcomes and definitions
The primary outcomes were trends in ECMO utilisation over 10 years, including number of patients receiving ECMO, illness severity (as measured by disease severity scores), and numbers of tertiary and quaternary inter-hospital transfers. Secondary outcomes were mortality, hospital and ICU LOS, transplantation procedures, ventricular assistive device (VAD) implantation, and complications. For patients who were transferred between hospitals, hospital mortality was defined as death during the final hospitalisation. Four common complications of ECMO, namely haemorrhagic, neurological, renal and cardiovascular complications, were identified using ICD-9-CM diagnostic and procedural codes (online supplementary Table 2).8 Major non-cranial bleeding was identified as the diagnosis of gastrointestinal, major internal, and/or postoperative bleeding; alternatively, it was identified by the need for haemostatic procedures, transfusion of >2 units of packed red blood cells over 24 hours, and/or use of recombinant factor VII. Stroke was subdivided into haemorrhagic and ischaemic types. Patients with acute ischaemic limbs were identified by the diagnosis of acute limb ischaemia or compartment syndrome or by the performance of limb-saving procedures (eg, fasciotomy and amputation). Brain death was identified by the appropriate diagnostic code or by a procedure code indicating organ collection from a deceased donor.
 
For the purposes of subsequent analyses, ECMO centres referred to designated ICUs under the governance of the Hospital Authority Central Organising Committee in ICU Services. An emergency admission was defined as an admission in which the patient had emergency room attendance records within the preceding 12 hours. Extracorporeal membrane oxygenation initiation in the emergency room was defined as an ECMO episode in which the patient had emergency room attendance records within the preceding 24 hours. An inter-hospital transfer was defined when ECMO was started at another institution before patient transferal with ECMO in situ to one of six ECMO centres. A transfer to a quaternary cardiothoracic unit was defined as an instance of intra- or inter-hospital transfer from a mixed ICU to cardiothoracic care in one of three centres, either during ECMO care or within 12 hours after stopping ECMO.
 
Statistical analysis
Frequencies and percentages were used to describe categorical variables. The Shapiro–Wilk test was used to assess data normality; data were expressed as means with standard deviations or medians with interquartile ranges, as appropriate. Categorical variables were compared between groups using the Chi squared test; continuous variables were compared by the t test or Mann-Whitney U test, as appropriate. The Mann–Kendall test was used to assess temporal trends in patient characteristics and outcomes across years, in sequential order from 2010 to 2019. Model discrimination and model calibration of risk scores in predicting hospital mortality were examined using the area under the receiver operating characteristic (AUROC) curve and the Hosmer–Lemeshow test. The observed hospital mortality was compared with that predicted from risk scores using standardised mortality ratios (SMRs). Patients with missing APACHE IV scores were excluded from this analysis.
 
All statistical analysis and data visualisation procedures were performed in Stata 16 (StataCorp; College Station [TX], United States). Tests were considered statistically significant when two-tailed P values were <0.05.
 
Results
Patient characteristics and co-morbidities
From January 2010 to December 2019, among 125 101 ICU admissions overall in Hong Kong, 911 (0.73%) involved patients receiving ECMO as follows: 297 (32.6%) veno-arterial (V-A) ECMO, 450 (49.4%) veno-venous (V-V) ECMO, and 164 (18.0%) extracorporeal cardiopulmonary resuscitation (ECPR) [Fig 1]. There was a steady increase in the annual number of patients receiving ECMO, with a 9.5-fold increase from 18 episodes in 2010 to 171 episodes in 2019 (Fig 2). The annual number of V-A ECMO episodes significantly increased from 3 (16.7%) to 67 (39.2%) over 10 years (P for trend=0.001) [Table 1]. The total number of ECMO patient-days increased from 109 in 2010 to 1565 in 2019 (online supplementary Fig 1).
 

Figure 1. Study cohort
 

Figure 2. Numbers and types of extracorporeal membrane oxygenation (ECMO) episodes from 2010 to 2019
 

Table 1. Demographic characteristics of patients receiving extracorporeal membrane oxygenation (ECMO) from 2010 to 2019 in Hong Kong (n=911)
 
A total of 583 (64.0%) patients were male, with a median age at admission of 54 years (interquartile range, 42-62), and 185 (20.3%) patients of ≥65 years. There was increasing utilisation of ECMO among patients aged ≥65 years (P for trend=0.001). The median CCI was 1 (0-2), and an increasing number of patients had a CCI ≥2 (P for trend=0.002) [Table 1].
 
Among the 889 (97.6%) patients with complete APACHE IV data, the median APACHE IV score was 100 (73-132), with an increase from 90 (57-112) in 2010 to 105 (77-137) in 2019 (P for trend=0.003); the median APACHE IV–estimated risk of death was 0.5 (0.2-0.8). Complete demographic details are shown in Table 1; trends in co-morbidities and disease severity scores are shown in online supplementary Figure 2.
 
Extracorporeal membrane oxygenation resources and inter-hospital transfers
Within the publicly funded hospital system, the number of ECMO centres under centralised ICU governance increased from three in 2010 to five in 2015, and then seven in 2019. The total number of available ECMO consoles paralleled the increase: from three in 2010 to nine in 2015, and then 11 in 2019 (online supplementary Table 3).
 
Among the 911 patients receiving ECMO, 469 (51.5%) were initiated outside of the regular 9 am to 5 pm period, including 247 (52.7%) patients receiving V-V ECMO, 137 (29.2%) patients receiving V-A ECMO, and 85 (18.1%) patients receiving ECPR. In total, 710 (77.9%) emergency admissions were identified. These patients were younger, had fewer co-morbidities, and were more likely to receive V-V ECMO [371/710 (52.3%) vs 79/201 (39.3%); P=0.001]. In total, 370 (40.6%) patients had ECMO initiated within 24 hours of emergency admission; these patients were more likely to receive ECPR [113/370 (30.5%) vs 51/541 (9.4%); P<0.001] and have higher APACHE IV scores [118 (86-146) vs 91 (69-118); P<0.001].
 
Overall, there were 222 (24.4%) episodes of inter-hospital transfer from non-ECMO centres to ECMO centres; the annual number of episodes increased from one (1/18 [5.6%]) in 2010 to 22 (22/171 [12.9%]) in 2019 (P for trend<0.001) [online supplementary Fig 3]. In total, 173 (77.9%) patients were transferred from ICUs in other hospitals; the remaining 49 patients were transferred from non-ICU settings. Most transferred patients (66.2%) received V-V ECMO (online supplementary Fig 4a); their principal diagnoses are shown in online supplementary Figure 4b and 4c. Transferred patients had worse RESP scores [-2 (-4 to 0) vs -1 (-3 to 2); P<0.001], better SAVE scores (-6 ± 5 vs -8 ± 5; P=0.012), and lower APACHE IV scores [89 (69-117) vs 104 (75-136); P<0.001]. Among the patients transferred to ECMO centres, 54 (24.3%) underwent a major operation within 7 days of transfer, and 32 (59.3%) of these surgeries involved the cardiovascular system. Other procedural details are shown in online supplementary Figure 4d and 4e.
 
There were 52 (5.7%) episodes of inter-hospital transfer to quaternary cardiothoracic ICUs; the annual number remained relatively consistent throughout the 10-year study period (P for trend=0.121) [online supplementary Fig 3]. Patients in these transfers were younger (P=0.048); they were more likely to receive V-A ECMO [31/52 (59.6%) vs 266/859 (31.0%); P<0.001] and ECPR [15/52 (28.8%) vs 149/859 (17.3%); P=0.036] (online supplementary Fig 5a). The primary diagnoses are shown in online supplementary Figure 5b and 5c. Among the patients involved in quaternary transfers, 22 (42.3%) underwent a major operation within 28 days of transfer, and 18 (81.8%) of these surgeries involved the cardiovascular system. Other procedural details are shown in online supplementary Figure 5d and 5e.
 
Patient outcomes
The overall numbers of hospital mortalities and ICU mortalities were 456 (50.1%) and 382 (41.9%), respectively. The numbers of hospital mortalities among patients receiving V-V ECMO, V-A ECMO, and ECPR were 152 (33.9%), 178 (59.9%), and 126 (76.8%), respectively (online supplementary Table 4). The median hospital LOS was 26.8 (interquartile range, 10.7-55.6) days, and the median ICU LOS was 10.2 (interquartile range, 4.8-20.1) days [Table 2]. Throughout the 10-year study period, the annual number of hospital mortalities increased from one (5.6%) in 2010 to 90 (52.6%) in 2019 (P for trend<0.001). The hospital LOS decreased from 36.6 (interquartile range, 26.8-57.2) to 25.2 (7.6-50.2) days [P for trend=0.011], and ICU LOS decreased from 15.5 (10.8-18.2) days in 2010 to 7.9 (3.9-19.8) days in 2019 (P for trend<0.001).
 
After adjustments for age, sex, APACHE IV score, and type of ECMO, the odds of hospital mortality were significantly lower in patients with ECMO initiated within 24 hours of emergency admission (adjusted odds ratio [OR]=0.56, 95% confidence interval [CI]=0.40-0.78; P=0.001). There were no significant associations with hospital mortality among patients who had emergency admission (adjusted OR=0.78, 95% CI=0.54- 1.12; P=0.17), patients who were transferred to ECMO centres (adjusted OR=0.74, 95% CI=0.52- 1.05; P=0.09), or patients who were transferred to quaternary cardiothoracic ICUs (adjusted OR=0.58, 95% CI=0.30-1.13; P=0.11). Patients transferred to quaternary cardiothoracic ICUs had significantly lower ICU mortality [4 (7.7%) vs 378 (44.0%); P<0.001] and significantly longer hospital LOS [38.3 (22.1-111.0) vs 25.6 (9.4-53.1) days, P<0.001]. The unadjusted and adjusted outcomes in various patient subgroups are presented in online supplementary Table 5.
 
In total, 41 (4.5%) patients were successfully bridged to VAD or transplantation. Among 461 patients who were receiving V-A ECMO and ECPR, 31 (6.7%) patients underwent VAD implantation and eight (1.7%) patients underwent heart transplantation. Among 450 patients who were receiving V-V ECMO, one (0.2%) patient underwent lung transplantation.
 
In terms of complications, there were 466 (51.2%) cases of major bleeding, 28 (3.1%) ischaemic limb complications, and nine (1.0%) patients who were declared brain-dead. Among 76 (8.3%) patients with stroke, 54 (5.9%) had haemorrhagic stroke (Table 2).
 

Table 2. Clinical outcomes among patients receiving extracorporeal membrane oxygenation (ECMO) from 2010 to 2019 in Hong Kong (n=911)
 
Prediction of hospital mortality
The ability of risk scores to predict post-ECMO hospital mortality was examined. There was a significant increase in the annual median APACHE IV score from 90 (57-112) in 2010 to 105 (77-137) in 2019 (P for trend=0.003). The SOFA score on the first day of ICU admission and the SAVE score in patients receiving V-A ECMO also showed significant trends (P for trend<0.001). No significant trends were observed regarding the SOFA score on the first day of ECMO (P for trend=0.58) or the RESP score in patients receiving V-V ECMO (P for trend=0.46) [Table 1].
 
The APACHE IV score showed good discriminatory power and was well calibrated for the prediction of hospital mortality (AUROC=0.727; Hosmer–Lemeshow test P=0.356); as was SOFA score on the first day of ECMO (AUROC=0.670; Hosmer–Lemeshow test P=0.322) [Fig 3]. The overall SMR for hospital mortality compared with APACHE IV–predicted mortality was 1.11 (95% CI=1.01-1.22) and there was no significant trend over the 10-year study period (P for trend=0.135) [Fig 4]. The SAVE and RESP scores, estimated using data from electronic health records, displayed limited discriminatory power for the prediction of hospital mortality in patients receiving V-A and V-V ECMO (AUROC=0.604 and 0.527, respectively). The ROC curves for various risk prediction models are shown in Fig 3.
 

Figure 3. Receiver operating characteristic (ROC) curves for various risk prediction models
 

Figure 4. Standardised mortality ratio (SMR) for hospital mortality
 
Discussion
To our knowledge, this is the first 10-year longitudinal study of the majority of patients receiving ECMO in Hong Kong; the results showed that the numbers of patients and complexities of medical conditions increased throughout the study period. Although patients receiving ECMO represent a small proportion of ICU patients overall, they require significant resource utilisation including out-of-hours services, inter-hospital transfers, and major operations. Comparisons with standardised risk scores suggested satisfactory performance based on the APACHE IV model, but the lack of complete and granular patient data precluded meaningful conclusions with respect to ECMO-specific risk scores.
 
Trends in patient characteristics
In addition to the observation of a 9.5-fold increase in ECMO utilisation in Hong Kong over the 10-year study period, including greater use of V-A ECMO after 2012 and rapid uptake of ECPR after 2015, this study revealed that patients receiving ECMO were increasingly older, had an increasing co-morbidity burden, and displayed greater disease severity upon ICU admission. This is not only attributable to the overall advances in ECMO,15 but also encouraged by the multiple studies showing indistinguishable survival after ECMO in older adult patients compared with the younger ones.16 17 18 The increased utilisation of ECMO in ECPR is supported by clinical trials demonstrating the efficacy of this approach. In the CHEER trial (mechanical CPR, Hypothermia, ECMO and Early Reperfusion), treatment with mechanical cardiopulmonary resuscitation, hypothermia, ECMO, and early reperfusion led to increased survival among patients with refractory cardiac arrest.19 The ARREST trial (Advanced Reperfusion Strategies for Refractory Cardiac Arrest) showed a similar increase in survival upon initiation of early ECPR among patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation.20 The increasing numbers of patients receiving ECMO have also resulted from greater utilisation of V-A ECMO to manage conditions such as acute myocardial infarction complicated by refractory cardiogenic shock,21 as well as efforts to transition to therapies including VAD and heart transplantation.22 The overall growth of ECMO utilisation in Hong Kong is similar to global patterns evident in the ELSO registry.1
 
Patient mortality
The observed overall SMR for post-ECMO hospital mortality was slightly worse than the predicted overall SMR, possibly because ECMO services were in early phases of development at various centres throughout the study period. The decrease in SMR in the later portion of the study period, when ECMO services had matured at most centres, may be an indication of progress. When the results were stratified according to the type of ECMO, we found that the rate of hospital mortality among patients receiving V-V ECMO was better in Hong Kong than in the global ELSO registry (33.9% vs 40.8%), whereas the rates of hospital mortality among patients receiving V-A ECMO and ECPR were worse (V-A ECMO: 59.8% in Hong Kong vs 55.4% globally; ECPR: 76.8% in Hong Kong vs 69.8% globally). The sharp increase in ECPR utilisation may have contributed to an artificially elevated SMR, considering that ECPR is associated with worse survival relative to V-V ECMO and V-A ECMO19; notably, in a pilot cohort of patients receiving ECPR in Hong Kong, ICU survival was 32.4%.23 The low rate of ECMO bridging to transplantation in Hong Kong—nine (1.0%) patients over 10 years—also reduces overall cohort survival. Among developed countries/regions, Hong Kong has a very low rate of registration in the Centralised Organ Donation Register (3.8%) and limited motivation to participate in organ donation.24 Nevertheless, it remains important to actively explore methods to lower the SMR. One possibility involves consolidating ECMO services to a few specialised centres, based on evidence of a volume-outcome relationship repeatedly identified in other observational cohorts across various geographical regions and healthcare settings.25 26 Furthermore, a study in the United States showed that multidisciplinary interventions—including coordination among surgeons, cardiologists, and ECMO specialists, as well as the implementation of standardised ECMO admission and weaning protocols—were associated with lower mortality in patients receiving ECMO,27 indicating a need to strengthen interdisciplinary communication or expand collaborations with allied health services to maintain standards of care.
 
Risk prediction
The comparative utility of various risk scores for outcome prediction in Hong Kong merits attention. In terms of predicting hospital mortality among patients receiving ECMO in the present study, the APACHE IV score performed best, followed by the SOFA score on the first day of ECMO; the SAVE and RESP scores had moderate discriminatory power. The satisfactory performance of the APACHE IV score in Hong Kong was previously demonstrated in a large retrospective cohort study of ICU patients (c-statistic=0.889).28 Importantly, most data were available for APACHE IV scores in the present study, and the corresponding accuracy was high. However, the main limitation of APACHE IV scores is the lack of definite correlation with the time and patient condition upon ECMO initiation,29 which likely leads to a systemic under-representation of disease severity. The SOFA score, which can be calculated on a daily basis, has the theoretical advantage of more closely reflecting disease severity and clinical progression30; the SOFA score on the date of ECMO initiation demonstrated good performance in predicting hospital mortality among patients in our cohort. We note that the limited predictive performances of ECMO-specific SAVE and RESP scores are mainly related to the difficulty of retrieving accurate physiological data from the CDARS; various components of the scores were determined by a combination of diagnostic codes, procedural codes, and laboratory parameters. Although these scores have been validated in international cohorts,12 13 their systematic adoption as benchmarks for ECMO service performance in Hong Kong is hindered by the lack of available patient data. Among the six ECMO centres included in the present study, only four routinely collect patient and ECMO data for submission to the international ELSO registry; none of the centres compute SAVE and RESP scores. Within the community of ECMO providers in Hong Kong, we strongly encourage collaborative efforts to routinely document ECMO-specific severity scores and improve coding practices within electronic health records and the CDARS; these approaches will facilitate outcome monitoring and resource allocation. Moreover, validation of these scores in Hong Kong will be informative because Asians were substantially underrepresented in the original scoredevelopment cohorts established using the ELSO international registry.12 13
 
Limitations
There were some limitations in this study. First, the retrospective observational design utilised data that were not recorded in a manner intended for research purposes; systematic biases in missing data may be present. Inaccurate diagnoses and procedural coding practices may have led to insufficient collection of relevant clinical data and information regarding ECMO circuit complications. However, the clinical outcomes of hospital mortality and LOS were captured from administrative data with a low risk of error. Second, the presence of between-centre heterogeneity related to non-uniform clinical practices may have contributed to outcome differences that were not reflected in the overall cohort. Third, patients receiving ECMO in non-mixed disciplinary ICUs or coronary care units were excluded from the study; outcomes and resource utilisation may have been considerably different among these patients. Finally, the collected data did not allow examination of ECMO cost-effectiveness, an important metric for service and resource planning.
 
Conclusion
In this territory-wide study, we observed increasing trends in ECMO utilisation in Hong Kong that were similar to global patterns. The overall observed mortality was reasonably close to the APACHE IV–predicted mortality. Systematic documentation of ECMO-specific risk scores is needed to ensure high-quality data for ECMO service benchmarking and development efforts.
 
Author contributions
Concept or design: PY Ng, A Ip.
Acquisition of data: VWS Chan, A Ip.
Analysis or interpretation of data: PY Ng, VWS Chan.
Drafting of the manuscript: PY Ng, VWS Chan.
Critical revision of the manuscript for important intellectual content: All authors.
 
All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.
 
Conflicts of interest
All authors have disclosed no conflicts of interest.
 
Funding/support
This research was supported by an unrestricted philanthropic donation from Mr and Mrs Laurence Tse. The funder had no role in study design, data collection, analysis and interpretation of the data, or manuscript preparation.
 
Ethics approval
This research was approved by the Institutional Review Board of The University of Hong Kong/Hospital Authority Hong Kong West Cluster (Ref No.: UW 20-573). The research was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived by the Board due to the retrospective nature of the research.
 
References
1. Extracorporeal Life Support Organization. ECLS Registry Report. International Summary. October 2021. Report data through 2020. Available from: https://www.elso.org/Portals/0/Files/Reports/2021_October/International%20Report%20October_page1.pdf. Accessed 20 Dec 2021.
2. Department of Health, Hong Kong SAR Government. Health Facts of Hong Kong. 2021 Edition. Available from: https://www.dh.gov.hk/english/statistics/statistics_hs/files/2021.pdf. Accessed 20 Dec 2021
3. Lam KW, Lai KY. Evaluation of outcome and performance of an intensive care unit in Hong Kong by APACHE IV model: 2007-2014. J Emerg Crit Care Med 2017;1:16. Crossref
4. Sin SW, Young K. Development of extracorporeal membrane oxygenation in Hong Kong: current challenges and future development. Hong Kong Med J 2017;23:216-7. Crossref
5. Combes A, Brodie D, Bartlett R, et al. Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am J Respir Crit Care Med 2014;190:488-96. Crossref
6. Ng PY, Ip A, Fang S, et al. Effect of hospital case volume on clinical outcomes of patients requiring extracorporeal membrane oxygenation: a territory-wide longitudinal observational study. J Thorac Dis 2022;14:1802-14. Crossref
7. Ng WT, Ling L, Joynt GM, Chan KM. An audit of mortality by using ECMO specific scores and APACHE II scoring system in patients receiving extracorporeal membrane oxygenation in a tertiary intensive care unit in Hong Kong. J Thorac Dis 2019;11:445-55. Crossref
8. National Center for Health Statistics, Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm. Accessed 10 Oct 2023.
9. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34:1297-310. Crossref
10. Zimmerman JE, Kramer AA, McNair DS, Malila FM, Shaffer VL. Intensive care unit length of stay: benchmarking based on Acute Physiology and Chronic Health Evaluation (APACHE) IV. Crit Care Med 2006;34:2517-29. Crossref
11. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10. Crossref
12. Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)–score. Eur Heart J 2015;36:2246-56. Crossref
13. Schmidt M, Bailey M, Sheldrake J, et al. Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score. Am J Respir Crit Care Med 2014;189:1374-82. Crossref
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. Crossref
15. Mosier JM, Kelsey M, Raz Y, et al. Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions. Crit Care 2015;19:431. Crossref
16. Lee SN, Jo MS, Yoo KD. Impact of age on extracorporeal membrane oxygenation survival of patients with cardiac failure. Clin Interv Aging 2017;12:1347-53. Crossref
17. Narotsky DL, Mosca MS, Mochari-Greenberger H, et al. Short-term and longer-term survival after veno-arterial extracorporeal membrane oxygenation in an adult patient population: does older age matter? Perfusion 2016;31:366-75. Crossref
18. Saito S, Nakatani T, Kobayashi J, et al. Is extracorporeal life support contraindicated in elderly patients? Ann Thorac Surg 2007;83:140-5. Crossref
19. Stub D, Bernard S, Pellegrino V, et al. Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the CHEER trial). Resuscitation 2015;86:88-94. Crossref
20. Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet 2020;396:1807-16. Crossref
21. Tsao NW, Shih CM, Yeh JS, et al. Extracorporeal membrane oxygenation–assisted primary percutaneous coronary intervention may improve survival of patients with acute myocardial infarction complicated by profound cardiogenic shock. J Crit Care 2012;27:530.e1-11. Crossref
22. Brugts JJ, Caliskan K. Short-term mechanical circulatory support by veno-arterial extracorporeal membrane oxygenation in the management of cardiogenic shock and end-stage heart failure. Expert Rev Cardiovasc Ther 2014;12:145-53. Crossref
23. Ng PY, Li AC, Fang S, et al. Predictors of favorable neurologic outcomes in a territory-first extracorporeal cardiopulmonary resuscitation program. ASAIO J 2022;68:1158-64. Crossref
24. Tsai NW, Leung YM, Ng PY, et al. Attitudes of visitors at adult intensive care unit toward organ donation and organ support. Chin Med J (Engl) 2019;132:373-6. Crossref
25. Muguruma K, Kunisawa S, Fushimi K, Imanaka Y. Epidemiology and volume-outcome relationship of extracorporeal membrane oxygenation for respiratory failure in Japan: a retrospective observational study using a national administrative database. Acute Med Surg 2020;7:e486. Crossref
26. Barbaro RP, Odetola FO, Kidwell KM, et al. Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med 2015;191:894-901. Crossref
27. Ratnani I, Tuazon D, Zainab A, Uddin F. The role and impact of extracorporeal membrane oxygenation in critical care. Methodist Debakey Cardiovasc J 2018;14:110-9. Crossref
28. Ling L, Ho CM, Ng PY, et al. Characteristics and outcomes of patients admitted to adult intensive care units in Hong Kong: a population retrospective cohort study from 2008 to 2018. J Intensive Care 2021;9:2. Crossref
29. Ko M, Shim M, Lee SM, Kim Y, Yoon S. Performance of APACHE IV in medical intensive care unit patients: comparisons with APACHE II, SAPS 3, and MPM0 III. Acute Crit Care 2018;33:216-21. Crossref
30. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score–development, utility and challenges of accurate assessment in clinical trials. Crit Care 2019;23:374. Crossref

Pages